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ABSTRACT 
Tumour-associated neutrophils (TAN) can have a significant impact on the tumour 
microenvironment via release of potent growth and angiogenic factors, chemokines and 
proteinases that can profoundly influence tumour progression. Moreover, several studies have 
shown that increased neutrophil numbers systematically or within the tumour correlate with an 
unfavourable prognosis in head and neck squamous cell cancer (HNSCC) patients. The aims of this 
study were to identify which factors are responsible for neutrophil recruitment into HNSCC and if 
TAN affect tumour growth in an in vivo model. 
The number of TAN within human HNSCC tissue was evaluated by immunohistochemical staining 
for the neutrophil marker myeloperoxidase (MPO). The factors secreted by FaDu HNSCC multi-
cellular tumour spheroids (MCTS) were analysed by cytokine array and ELISA.  Neutrophils 
isolated from the peripheral blood of healthy volunteers were used to measure neutrophil 
migration to factors identified from the array, then the recruitment of neutrophils to MCTS was 
assessed overtime by flow cytometry in the absence and presence of small molecule inhibitors. 
FaDu xenograft mouse models were used to confirm the effect of these inhibitors on neutrophil 
recruitment in vivo and also on tumour growth. 
MPO staining confirmed the presence of marked numbers of TAN in HNSCC compared to normal 
oral epithelium. HNSCC MCTS resemble in vivo tumours, displaying areas of hypoxia, necrosis and 
cell proliferation. Neutrophils migrated to recombinant CXCL8, CXCL1 and MIF and these 
chemoattractants were found in the conditioned medium of FaDu MCTS.  The recruitment of 
neutrophils into FaDu MCTS was significantly inhibited when neutrophils were pre-treated with 
antagonists for CXCR2 and CXCR4, the receptors for CXCL8, CXCL1 and MIF respectively. Moreover, 
use of the MIF inhibitor, ISO-1 caused a dramatic reduction in the number of neutrophils recruited 
into FaDu MCTS. In addition, in vivo, ISO-1 significantly reduced the number of TAN by up to 80% 
in xenograft FaDu tumours. Collectively, these data suggest that CXCL8, CXCL1 and MIF in 
particular are important in the recruitment of TAN into HNSCC.   
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Chapter 1: Introduction  
1.1.  Head and Neck Cancer  
Head and neck cancers (HNCs) are a group of heterogeneous malignancies arising from many 
distinct anatomical sites of the head and neck region including the oral cavity, oropharynx, 
nasopharynx, hypopharynx, nasal cavity and para-nasal sinuses, ear, salivary glands and larynx. 
The majority (approximately 90%) of HNCs arise from the squamous epithelium and therefore, 
the term head and neck squamous cell carcinoma (HNSCC) is frequently used to describe 
these cancers.    
1.1.1. Epidemiology of Head and Neck Cancer  
According to the World Health Organization (WHO) approximately 600,000 new cases and 
300,000 deaths of HNSCC are reported annually, making it the sixth most common cancer 
(Warnakulasuriya, 2009) and the eighth leading cause of cancer mortality worldwide (Ragin 
et al., 2007). These cancers also have a higher male to female ratio of approximately 4:1 
(Ferlay et al., 2010). Although, there is a large variation in HNSCC incidence by both sex and 
geographic region, the highest incidences are found in the Indian subcontinent, Eastern 
Europe, Australia, Brazil, Southern Africa and parts of the Pacific region (Warnakulasuriya, 
2009). In UK, there were a total of 7495 cases reported in 2015 with 54% of cases reported in 
people above 65 years of age (Globocan, 2012) (Fig. 1.1). Despite surgical and therapeutic 
advances, individuals with HNSCC have a poor 5-year survival rate that is a result of various 
factors including late stage of diagnosis (primarily due to the lack of pain at early stage of 
disease), high probability of recurrence and secondary metastasis (Ragin and Taioli, 2007, 
Ragin et al., 2007). 
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( A )  
( B ) 
( C ) 
Figure 1.1 Incidence, prevalence and mortality rates for lip, oral cavity and pharynx in 
the UK and globally. (A) Bar chart shows the estimated age-standardized incidence of 
HNC in UK in 2015. (B) 5-year prevalence and (C) mortality rates of lip and oral cavity 
cancer worldwide in 2012. Data is shown as rates per 100, 000 of the global population 
in both sex (Data obtained from GLOBOCAN 2012).    
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1.1.2. Risk Factors  
1.1.2.1. Smoking and alcohol consumption 
The major risk factors identified for HNSCC are tobacco use and alcohol consumption. The 
increased risk is due to the genotoxic effects produced by carcinogen metabolites found in 
tobacco smoke including nitrosamines and polycyclic hydrocarbons, and acetaldehyde 
present in alcohol (Pai and Westra, 2009). Over a prolonged period of time these carcinogens 
irreversibly damage the DNA of key genes that regulate the cell cycle leading to altered gene 
expression and ultimately dysregulated mitosis.  A study of the effect of possible risk factors 
for death from cancer in low and middle income countries showed that smoking accounts for 
42% of deaths of people diagnosed with cancer of the oral cavity while heavy alcohol 
consumption accounts for 16% of deaths globally. In contrast, in high income countries deaths 
due to these risk factors are much higher with smoking accounting for 71% of deaths and 33% 
for alcohol consumption (Danaei et al., 2005). 
1.1.2.2 Human Papillomavirus  
 Approximately, 20-25% of individuals with HNC contain DNA for the oncogenic Human 
Papillomavirus (HPV).  HPV is a DNA virus known as the main causative agent of cervical cancer 
and it is increasingly being associated as a risk factor in the development of HNSCC, 
particularly in younger patients. HPV types 16 and 18 have been recognized as the 
predominant virus responsible for up to 70% of oropharyngeal cancers (Pai and Westra, 2009). 
Increasing evidence shows that HPV-associated HNSCCs strongly correlate with viral infection 
and sexual activity (Smith et al., 2004).  In contrast to cancers arising from smoking and 
alcohol, HPV-positive HNSCC have been associated with better outcomes and a reduced risk 
of recurrence than HPV-negative HNSCC (Ragin and Taioli, 2007). Immune profiling of HPV-
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positive and –negative tumours demonstrated an increased expression of immune-related 
genes such as the antigen presenting ligand (CD83), co-stimulatory molecules (GITRL), 
adhesion molecule (CD62L), chemokine receptor (CXCR3) and the NK cell marker (NKG2D) in 
HPV-positive compared to HPV-negative samples. This immune activation pattern was 
associated with accumulation of CD20+B and FoxP3+T-reg cells and was a predictor for 
improved survival (Russell et al., 2013), suggesting that differences between the aetiology of 
HPV-positive and –negative HNSCC leads to altered immune responses that ultimately affect 
patient outcome.  
1.1.2.3 Other HNSCC aetiological factors  
There is strong evidence to suggest that dietary factors also play an important role in the 
development of HNSCC. For example, there is an association between high intake of red meat 
and increased risk of oral cancer, while other studies show a protective effect of foods that 
contain vitamin C, E, and vegetable and fruit consumption (Saman, 2012). The precise 
mechanism of how these foods affect carcinogenesis is unknown and is a topic of much 
debate. However, several studies have now associated low folate status with cancer risk 
(George et al., 2009, Pelucchi et al., 2003). Folate is an essential dietary component required 
for production of nucleotides and therefore essential for DNA synthesis and repair. Low folate 
status has been shown to cause uracil mis-incorporation (Blount et al., 1997) and impaired 
DNA repair (Duthie et al, 2008) all of which increase the risk of cancer. Other exogenous risk 
factors include ultra-violet DNA damage upon exposure to sunlight (Weller et al., 2010), a 
particular risk for lip cancers, occupational exposure to carcinogens (Gustavsson et al., 1998) 
and poor oral hygiene (Orbak et al., 2005), although the latter may be associated with tumour 
progression rather than carcinogenesis. 
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1.1.3. Mechanisms of tumorigenesis  
Mounting evidence accumulating over several decades indicates that HNSCC tumour 
development is a multistep process involving a number of genetic alterations over a long 
period of time. The route that normal cells take on their way to transformation into a 
neoplastic cell is highly diverse, but during this complex process impairment in function of 
critical genes, including oncogenes and tumour suppressor genes play a critical role in tumour 
initiation and progression (Kopnin, 2000). A prominent example is mutation in the p53 gene 
that occurs commonly in HNSCC and well as in many human cancers. This accounts for 
dysregulated function of the p53 tumour suppressor protein that results in inefficiency of DNA 
repair mechanisms and loss in apoptotic machinery (Levine, 1997). Mutation of p53 has been 
reported in 40%-60% of patients with HNSCC and is linked with progression from pre-
malignancy to invasive disease (Shin et al., 2001, Cruz et al., 1998). Overexpression of 
Epidermal Growth Factor Receptor (EGFR) has been detected in 90% of HNSCC (Kalyankrishna 
and Grandis, 2006) and binding of receptor to any of its ligands initiates multiple layers of 
growth signalling and amplification that mediate uncontrolled cell growth. Other important 
signalling mechanism in HNSCC is the inhibitory transforming growth factor-ß (TGF-ß) 
pathway.  TGF-ß binding to its receptors initiates phosphorylation of intracellular SMAD2, 
SMAD3 and SMAD 4 (Huntley et al., 2004), which governs target gene transcription and thus 
inhibits proliferation and induces apoptosis. Inactivation of TGF-ß has been detected in 
various cancers, including HNSCC (Wang et al., 1997). Oral squamous cell carcinoma (OSCC) 
cells have been shown to avoid apoptosis by the PI3K–PTEN–AKT pathway, and mutations of 
PIK3CA have been defined in 10-20% of patients (Kozaki et al., 2006).   
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As a result of this genetic instability and uncontrolled cell growth, tumours increase in size 
but cannot exceed 1-2 mm3 in an avascular state. In order to maintain an adequate supply of 
oxygen and nutrients and diffusion of waste products the tumour requires the formation of 
new blood vessels – the process of angiogenesis (Folkman, 2002). Under normal physiological 
conditions, like wound healing, this process is tightly regulated, while during tumour 
progression the angiogenic switch, which controls the balance between pro- and anti-
angiogenic molecules, is skewed to a pro-angiogenic state. This leads to multiple defects in 
tumour vascular shape, branching pattern, size and lack of normal arrangement of arterioles, 
capillaries and venules (Baluk et al., 2005). A tumour with a high tendency of forming a 
network of microvessels will mostly transfer from microscopic lesion to a rapidly expanding 
mass with metastatic spread (Zetter, 1998).  For example, increased expression of the pro-
angiogenic factor VEGF in HNSCC was associated with increased tumour vascularity and poor 
prognosis (Kyzas et al., 2005).  
1.1.4. Clinical and histological pathogenesis of oral cancer  
Most of the tumours that occur in the head and neck region are squamous cell in origin and 
the overwhelming majority of these are in the oral cavity (oral squamous cell carcinoma; 
OSCC). Clinically, the appearance of the normal oral mucosa is pink/red with smooth mucosal 
surfaces. Histologically, the tissue is typically comprised of a dense connective tissue 
containing fibroblasts, blood vessels and neuronal tissue. Stratified layers of epithelial cells 
are attached to the connective tissue via interactions between the basal cells and the 
basement membrane by hemi-desmosome contacts. The epithelial basal cells act as stem cells 
and are the only cells that have the ability to replicate (these are also cells that become 
malignant). As the cells divide they differentiate towards the apical surface of the epithelium, 
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firstly becoming spinous cells and then finally differentiating into the stratum corneum before 
desquamating into the oral cavity (Fig. 1.2). Some parts of the oral mucosa are highly 
keratinised (hard palate) whereas others are non-keratinised (buccal mucosa) depending on 
their function.   
 
 
At initial stages, lesions present clinically in the form of pre-malignant lesions such as 
leukoplakia (white plaque), erythroplakia (red plaque) or combination of both 
(erythroleukoplakia). Leukoplakia is the most frequently observed although erythroplakia 
tend to be more aggressive and these lesions are the ones most likely to progress to cancer. 
Lesions at that stage are usually small in size and mostly asymptomatic (Mashberg et al., 1989) 
Figure 1.2 Histology of the oral mucosa. Histological micrograph showing the connective 
tissue and epithelium of the oral mucosa. The epithelium is further divided into distinct 
regions and can be keratinised or non-keratinised depending on location in the oral cavity. 
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with little or no pain commonly experienced. Histological examination of leukoplakias can 
demonstrate thickening of the entire epithelium (acanthosis) and/or thickening of the surface, 
keratinised layers of the epithelium (hyperkeratosis) (Fig. 1.3). Not all leukoplakias continue 
to form tumours. In fact, the development of cancer is uncommon with only 8%-18% of 
patients going on to develop SCC within 8 years after the diagnosis of a pre-malignant lesion 
(Jr et al., 1984). Most pre-malignant lesions regress and the epithelium returns to a normal 
clinical appearance. Most people presenting at oral medicine clinics have high risk factors 
such as smoking and alcohol consumption and so the aetiology of many of the pre-malignant 
lesions that return to normal are unknown, likewise, there is currently no way to discriminate 
between those lesions that progress to cancer from those that do not. At the histological level 
these changes include drop-shaped rete ridges, nuclear enlargement, keratin pearls and 
irregular epithelial stratification and mitotic cells in the spinous (upper) layer of the 
epithelium (Fig. 1.3). Based on the severity of the cellular abnormalities, dysplasia is graded 
from mild dysplasia (abnormalities limited to the lower one-third of the epithelium), 
expanding of dysplastic lesion to the lower two-thirds in moderate dysplasia, and involvement 
of full thickness of the epithelium in severe dysplasia/carcinoma in situ.  Once a pre-malignant 
lesion has progressed to cancer the characteristic clinical features include ulceration and 
sever pain of the lesion, and formation of a lump which is often hard on palpation (Bagan et 
al., 2010) (Fig. 1.3).  As the tumour grows, it invades the connective tissue and it is at this 
stage that the tumour is considered as an invasive carcinoma.  Histologically, this is 
characterized by increased cell nuclear to cytoplasmic ratio, varying degrees of keratinization 
intercellular bridges, increased atypical mitotic figures; hyperchromasia, basement 
membrane invasion, and an associated inflammatory response (Fig. 1.3) (Rivera and Venegas, 
2014).  
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1.1.5. Insight into the HNSCC tumour microenvironment  
For decades most cancers, including HNSCC, have been thought of and treated as if they are 
composed of a heterogeneous population of epithelial cells, but this concept has shifted 
because of the recognition of the active role that the stroma plays in cancer progression 
(Shekhar et al., 2001). The tumour stroma is comprised of endothelial cells (EC), neuronal cells, 
immune cells, cancer-associated fibroblasts (CAF) and their surrounding matrix. Collectively, 
these elements along with cancerous cells are commonly referred to as the tumour 
microenvironment (TME).  The presence of most of these cellular components has been 
Clinical   Histology   
Figure 1.3 Clinical and histological images represent the change in oral mucosa in oral cancer 
progression  
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reported in HNSCC and their contribution in the process required for tumour progression will 
be discussed briefly here.   
The major cellular elements of TME are CAFs and these have been reported in HNSCC with an 
active myofibroblastic (MF)-like phenotype (Vered et al., 2010). Accumulating evidence has 
demonstrated that cross-talk between CAF and HNSCC cells enhance the neoplastic 
progression by facilitating connective tissue invasion (Daly et al., 2008), aiding epithelial cell 
proliferation (Lin et al., 2011), initiating the epithelial-to-mesenchymal transition (EMT) 
(Dudas et al., 2011a), producing angiogenic factors for tumour angiogenesis, regulating 
immune escaping processes (Dudas et al., 2011b, Alcolea et al., 2012) and promoting 
metastasis (Vered et al., 2010). Not surprisingly, the presence of myofibroblast CAFs have 
been associated with poor prognosis and mortality in OSCC (Marsh et al., 2011).  
Along with CAF there has been much interest in the role that tumour-associated leukocytes 
play in cancer progression. Many different types of tumours have been shown to contain 
leukocytes populations such as lymphocytes, granulocytes and macrophages. In recent years 
tumour-associated macrophages (TAM) have received much attention and in some tumours 
these cells can make up to 50% of a cell population of the tumour mass (Van Overmeire et al., 
2014). Infiltration of macrophages has been observed in numerous human cancers and their 
density has been correlated positively with poor prognosis (Takeya and Komohara, 2016), 
including in OSCC (Mori et al., 2011). TAM have been associated with increased secretion of 
factors that can affect tumour growth directly (Condeelis and Pollard, 2006), but their main 
influence seems to be on tumour angiogenesis (Murdoch et al., 2008). TAM have been shown 
to accumulate in hypoxic/necrotic areas of some tumours, most likely due to their role as 
scavenger phagocytes, where they secrete a number of factors that dramatically influence 
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vascularisation such as vascular endothelial growth factor (VEGF), matrix metalloproteinase 
7 and MMP9 (Granata et al., 2010, Huang et al., 2002). TAM can also secrete 
immunomodulatory cytokines such as IL-10 that dampen down any T-cell response directed 
against tumour cells (Sica et al., 2000). The role that innate immune cells play in cancer 
progression has led to an increased interest in neutrophils. These are also phagocytic cells 
that are traditionally recognised as key players in the innate immunity to pathogens. This 
thesis examines the role that neutrophils play in HNSCC and so the following sections discuss 
this leukocyte in more detail.  
1.2. Neutrophils 
1.2.1. Origin and life cycle 
Neutrophils are key players of the human innate immune system. They are derived from 
hematopoietic pluripotent stem cells in the bone marrow in a process known as myelopoiesis, 
which is a term used to describe the production of granulocytes and monocytes from 
progenitor cells.  During granulopoiesis (production of granulocytes), the appearance of 
cytoplasmic granules marks the transition from myeloblasts to promyelocytes, myelocytes to 
metamyelocyte and continues until these cells differentiate into mature, segmented 
neutrophils also known as polymorphonuclear cells (PMN). Neutrophil granules have been 
classified based on their content and differentiation stage at which granule synthesis takes 
place. They are segregated as primary granules (azurophillic), secondary granules (specific) 
and tertiary granules (gelatinase). These granules house an array of toxic weaponry such as 
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antimicrobial agents, proteinases and reactive oxygen species (ROS), which can have a 
profound effect on host tissues (Fig. 1.4)   
 
The bone marrow acts as a reservoir to hold the extensive high production rate of neutrophils 
(approximately 1011 cells per day) that is essential to meet the increased need during infection 
and explains the relatively short half-life of neutrophils (6-8 hours) compared to other 
leukocytes in the circulation. Migration of mature neutrophils from the bone marrow through 
trans-endothelial pores and into the bloodstream is tightly controlled by several factors. The 
most prominent cytokine is granulocyte colony stimulating factor (G-CSF) (Semerad et al., 
2002) along with the balance in expression levels of chemokine receptors CXCR4 and CXCR2 
Figure 1.4 Development of neutrophils in the bone marrow and granule formation. A 
schematic representation of neutrophil maturation in the bone marrow during granulopoiesis 
that is characterized by appearance of granules.  Neutrophil granules carry a rich variety of 
antimicrobials and signalling molecules that are divided into three types primary, secondary 
and tertiary granules during neutrophil maturation. 
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on the surface of neutrophils that determines their retention or release from bone marrow 
into the circulation (Martin et al., 2003). Neutrophil release from bone marrow is CXCR2 
dependent, the binding partner for CXCL1 and CXCL2 in human or neutrophil chemokine (KC) 
and macrophage inflammatory protein-2α (MIP-2α) in mice respectively, whereas, CXCR4 is 
essential for retention of neutrophils to bone marrow (Eash et al., 2010). Senescent 
neutrophils up-regulate CXCR4 expression and they home to the bone marrow from the 
circulation in CXCR4-dependnt manner (Martin et al., 2003). The use of the small molecule 
antagonist for CXCR4, AMD3100, in humans or mice results in the rapid mobilization of 
neutrophils from bone marrow to blood (Liles et al., 2003, Broxmeyer et al., 2005). Consistent 
with this finding, an in vivo study using transgenic mice carrying a myeloid specific deletion of 
CXCR4, showed a significant reduction in the number of neutrophils in the bone marrow and 
increased numbers in the circulation (Eash et al., 2009), confirming the key role for CXCR4 and 
its ligand CXCL12/SDF-1 in regulating neutrophil mobilization or retention in bone marrow.  
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1.2.2. Neutrophil recruitment cascade 
Neutrophils are the most abundant white blood cell in the circulation and account for two 
thirds of all peripheral blood leukocytes. They are found in two different pools; the circulating 
pool, which are freely circulating in the peripheral blood and the marginated pool, which are 
neutrophils adhering to the endothelium of small vessels. It has been suggested that from the 
circulating pool neutrophils are recruited to sites of inflammation and tumours (Friedman, 
2002).   
 It is well accepted that during transmigration into tissue neutrophils become activated as a 
result of their interaction with vascular walls that induce a number of functional and 
phenotypic changes (Beyrau et al., 2012). For example, a study compared changes in the 
expression of surface receptors of blood and bronchalveolar lavage fluid neutrophils between 
normal and patients with sarcoidosis and found that lung neutrophils switch to the activated 
phenotype in both the healthy and disease group. The key changes in activated phenotype 
were characterized by modulation of adhesion receptors (Mac-1/CD11b, L-selectin/CD62L, α4 
integrins /CD49d, ICAM-1/CD54) and the immunoglobulin receptor (FcγRII/CD32), but 
expression of the anaphylatoxin receptor (C5a/CD88) and CEACAM8/CD66b were 
independent of the disease state (Fortunati et al., 2009). Neutrophils use the increased 
expression and activation of adhesion molecules on their surface to bind to their counter-
ligands expressed on the surface of activated endothelial cells such as E-selectin (CD62E) and 
intercellular adhesion molecule-1 (ICAM-1/CD54). These interactions allow tethering of 
neutrophils on the endothelium surface where they encounter specific chemokines (CXCL1-3, 
CXCL5 and CXCL8 amongst others) presented on glycosaminoglycan chains that decorate the 
endothelial cell surface. Chemokine binding to neutrophil cell surface receptors CXCR1 and 
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CXCR2 influence integrin avidity, which causes neutrophils to firmly adhere to the endothelial 
cell surface. Neutrophils then migrate between the endothelial cells in a PECAM-1/CD31-
dependent mechanism and migrate towards the inflammatory site in a chemokine 
concentration-dependent manner (Chosay et al., 1998). The up-regulation of chemokine 
receptors (CCR1, CCR2, CCR3, CCR5, CXCR3 and CXCR4) on the surface of infiltrated 
neutrophils from patients with chronic inflammatory lung diseases and rheumatoid arthritis 
compared to circulating neutrophils from healthy individuals may account for the increased 
disease severity in these people (Hartl et al., 2008). During trans-endothelial migration 
neutrophil function was altered to prolong the survival of recruited neutrophils during 
inflammation in vitro (McGettrick et al., 2006). Moreover, using labelled neutrophils in a 
zebrafish model to measure the lifespan of tissue neutrophils in vivo, Dixon et al showed that 
tissue neutrophils had an extended half-life (around 120 hours) in comparison to circulating 
counterparts (Dixon et al., 2012). These data suggest that the tissue microenvironment 
contains factors that extended neutrophil life in order that they can exert their effects.  
1.2.3. Neutrophils, inflammation and wound repair  
During tissue-associated injury, inflammation is an essential event to protect the host from 
infection. Inflammatory mediators are released by injured or infected cells to defend against 
bacteria and facilitate the activation and directed migration of different leukocytes from the 
circulation to the site of damage. Neutrophils are the first recruited effectors cells to arrive at 
the site, followed by monocytes and lymphocytes. Neutrophils serve as a potent source of 
cytokines that can further mediate leukocyte adherence to the vascular endothelium (Werner 
and Grose, 2003). Once at sites of inflammation neutrophils can phagocytose microbes or 
necrotic cell debris to remove them from the environment. They can also degranulate to 
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release a plethora of molecules that act as antimicrobial peptides or directly kill organisms 
such as superoxide. Neutrophils store and secrete two important players in remodelling the 
extracellular matrix and re-vascularising of the damaged/infected area; MMP-9 and VEGF 
(Gaudry et al., 1997). They can release MMP-9 in active form (tissue inhibitor of 
metalloproteinases (TIMP)-free form), unlike other cells of body, indicating their potent 
proangiogenic activity (Ardi et al., 2007). The recently identified mechanism neutrophils use 
to defend against pathogens is neutrophil extracellular trap (NETs) (Brinkmann et al., 2004). 
As the name indicates, neutrophil trap pathogens via release of their core DNA and DNA 
binding proteins. Further analysis of NETs, identified 24 neutrophil proteins and enzymes, 
including elastase (proteases), histones (antimicrobial), cathepsins, and lactoferrins, MPO 
among many others toxic molecules that can induce host cell injury (Urban et al., 2009).     
The most important regulatory mechanism is that normal inflammation is self-limiting and 
will diminish gradually after the causative agent is removed or repaired. This is in contrast to 
cancer that has been described as wounds that never heal (Dvorak, 1986), suggesting that 
normal inflammation and cancer share some common features. 
Inflammation has emerged as a new hallmark of malignancy (Colotta et al., 2009) and there 
is an accumulating body of evidence to associate persistent infection and chronic 
inflammation with tumour formation. For instance, patients with chronic ulcerative colitis and 
Crohn’s disease tend to be at a higher risk of developing colon carcinoma (Eaden et al., 2001, 
Ullman and Itzkowitz, 2011) whereas, Helicobacter pylori infection has been identified as the 
main causative agent of gastroduodenal ulcers and gastric cancer (Ernst and Gold, 2000). 
Evidence has also linked increased numbers of the oral microbe Porphyromonas gingivalis (P. 
gingivalis) with malignant OSCC (Gallimidi et al., 2015). This is because P. gingivalis is the main 
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causative agent of periodontitis that is associated with chronic oral inflammation with 
increased influx of neutrophils into the oral tissue (Lakschevitz et al., 2013) and poor oral 
hygiene and periodontitis has been linked with increased risk of oral cancer (Orbak et al., 
2005). 
A key feature of cancer-related inflammation includes infiltration of immune cells and such 
immune responses were firstly thought to reflect an attempt by the immune system to 
eliminate tumour cells. However, numerous studies have since showed that transformed 
tumour cells escape this immunosurveillance in order to initiate tumour progression 
(Sakakura and Chikamatsu, 2013).  
The involvement of reactive oxygen species (ROS) in inducing DNA damage and promoting 
carcinogenesis has been reported in many cancer diseases (Kumar et al., 2008a). High levels 
of ROS were detected in the serum and neutrophils of advance stage OSCC when compared 
to controls (Das et al., 2007). Other neutrophil-secreted products such as neutrophil 
gelatinase–associated lipocalin (NGAL), a protein found in activated neutrophils have been 
correlated with HNSCC tumorigenesis (Wang et al., 2015). 
1.2.4. The emerging role of neutrophils in cancer 
Neutrophils have been observed in close association with tumour cells and within the tumour 
vasculature since the 1980s (Welch et al., 1989) but the exact role of neutrophils in human 
cancers is only just being unravelled. It is becoming clear that tumour-associated neutrophils 
(TAN) play an important role in malignant transformation, tumour progression, angiogenesis 
and immune surveillance (Mantovani et al., 2011) which will be discussed in the following 
section: 
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1.2.4.1. Tumour-infiltrating (associated) neutrophils  
Although TANs make up only between 5-25% of cellular tumour mass (Eruslanov et al., 2014), 
a variety of human cancer studies have linked the number of neutrophils encountered within 
the tumour microenvironment with disease progression and clinical outcome, which suggests 
that these cells may have a role in tumour progression. For example, a study by Trellakis and 
colleagues in head and neck cancer showed a higher percentage of infiltrating neutrophils 
were associated with poor survival in advance disease compared to non-disease tissue 
(Trellakis et al., 2011b, Trellakis et al., 2011a). Similar findings have been observed in gastric 
adenocarcinoma patients, where immunohistochemical analysis determined that elevated 
level of CD15+ neutrophils correlated with poor patient survival (Zhao et al., 2012). The 
presence of increased numbers of neutrophils has also been observed in patients with renal 
cell carcinoma (Jensen et al., 2009a), and hepatocellular carcinoma (HCC) (Zhou et al., 2012, 
Kuang et al., 2011) and their levels related to reduced survival times in these patients 
(summarized in Table 1.1). 
 
 
 
 
 
Tumour type 
Neutrophils 
marker 
Clinical 
outcome 
Mechanism 
of 
recruitment 
Ref. 
Colorectal 
carcinoma 
CD66b 
Shortened 
patient survival 
ND 
(Rao et al., 
2012) 
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Hepatocellular 
carcinoma (HCC) 
CD66b 
CD15+ 
neutrophils 
Poor patient 
survival 
CXCL16 
CXCL5 
CXCL1 
CXCL2 
CXCL3 
and CXCL8 
(Gao et al., 
2012) 
(Zhou et al., 
2012) 
(Kuang et al., 
2011) 
Melanoma CD66b Poor prognosis 
Expression of 
pSTAT3 
(Jensen et 
al., 2012) 
Head and neck 
squamous cell 
carcinoma 
(HNSCC) 
CD66b 
MPO 
Poor patient 
survival in 
advanced disease 
CXCL8 
MIF 
(Trellakis et 
al., 2011a) 
(Dumitru et 
al., 2011) 
Non small cell lung 
cancer (NSCLC) 
CD66b 
Poor clinical 
outcome 
ND 
(Ilie et al., 
2012) 
Broncheoalveolar 
adenocacinoma 
Morphological 
identification 
Poor patient 
survival 
Correlated to 
high CXCL8 
production 
(Bellocq et 
al., 1998) 
Renal Cell 
Carcinoma (RCC) 
CD66b 
Increased tumour 
size and short 
recurrence-free, 
cancer-specific 
and overall 
survival 
ND 
(Jensen et 
al., 2009a) 
Breast Cancer 
Neutrophil 
elastase 
Lower recurrence 
free survival 
ND 
(Yamashita 
et al., 1995) 
Non-Hodgkins 
lymphoma 
CD15, 
elastase, 
nuclear 
morphology 
Indirect link, 
neutrophils were 
main source of 
APRIL which is 
linked to patient 
survival 
ND 
(Schwaller et 
al., 2007) 
Gastric 
adenocarcinoma 
CD15 
Lymph 
node/distant 
metastasis, 
tumour stage and 
patient prognosis 
ND 
(Zhao et al., 
2012) 
 
Table.1.1: Association of TAN with clinical outcome in human cancers. ND= not determined 
1.2.4.2.  Circulating neutrophils in cancer patients 
Many studies have used the neutrophil to lymphocyte ratio in peripheral blood (NLR) as a 
predictor of mortality of patients with cancer. A negative impact of an elevated 
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neutrophils/lymphocyte ratio for patient survival was found in various cancers including 
breast (Azab et al., 2012), non-small cell lung cancer (Cedres et al., 2012), oral (Perisanidis et 
al., 2013), nasopharyngeal (An et al., 2011), ovarian cancer (Cho et al., 2009) and colon cancer 
(Ding et al., 2010). A more detailed analysis in HNSCCs showed that neutrophils not only 
increased in numbers NLR but also the presence of an immature population of CD16-positive 
neutrophils was detected in the peripheral blood of these patients. Functionally, these 
neutrophils had a reduced capability to release reactive oxygen species and reduced 
apoptosis in patients with HNSCC compared to controls (Trellakis et al., 2011b). Others have 
observed that peripheral blood neutrophils in oral cancer patients have a shortened life-span 
that may be due to an increase in activity of proteins participating in extrinsic apoptotic 
pathway; Fas-associated protein with death domain (FADD) and caspase-8 activity (Jablonska 
et al., 2009). 
1.2.4.3. Neutrophil phenotype: N1 versus N2 
Until recently, neutrophils were thought to be a short-lived homogeneous cell type that 
arrives rapidly at the site of an infection or injury as professional phagocytes. These cells then 
die and are then engulfed by macrophages, which is necessary for the resolution of 
inflammation. A growing body of evidence has challenged this notion and the presence of 
longer life-span (5.4 days) human neutrophils in tumours has been reported (Pillay et al., 
2010), suggesting that the tumour microenvironment is capable of generating conditions that 
prolong TAN survival. Wislez et al, showed that tumour-derived GM-CSF and G-CSF from 
patients with bronchoalveolar adenocarcinoma inhibited 24-hour spontaneous neutrophil 
apoptosis in vitro (Wislez et al., 2001). Moreover, the ability of neutrophils within the tumour 
to develop a distinct phenotype that is polarized into two distinct sub-groups (N1 & N2) 
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similar to that described for tumour-associated macrophage (TAM) has been recently 
identified (Galdiero et al., 2012). Fridlender and colleagues found that TANs can present with 
a hyper-segmented, anti-tumorigenic (N1) phenotype, with enhanced ability to eradicate 
tumour cells, enable activation of cytotoxic T lymphocytes, and have increased expression of 
pro-inflammatory cytokines such as tumour necrosis factor-α (TNF-α) with a simultaneous 
reduction in immunosuppressive Arginase-1 (Arg-1) levels. The most characteristic features 
for N2 TAN are increased expression of the pro-angiogenic genes, c-myc and STAT3, known 
regulators of VEGF, MMP9, as well as increased secretion of CCL2, CCL5 that promote 
monocyte recruitment and Arg-1 from neutrophils, thus promoting immunosuppressive 
functions. Up-regulation of CXCR4 receptor expression on the surface of N2-TAN has also 
been reported (Jablonska et al., 2010). There is also evidence that N2 TAN display a ring-like 
nuclear structure that resembles an immature neutrophil morphology (Andzinski et al., 2016). 
This immerging evidence has been obtained mainly from murine models of cancer and may 
not directly relate to human TAN because of species-specific differences. To date there are 
very few studies examining human TAN with just one describing TAN isolated from freshly 
removed early stage lung tumour tissue. Phenotypically, these TANs displayed the cell surface 
markers CXCR1Lo, CXCR2Lo, CD62LLo and CD54Hi with a distinct CC and CXCR profile CXCR4Hi, 
CXCR3Hi, CCR7Hi and CCR5Hi. Unexpectedly, this subset of neutrophils can induce T-cell 
proliferation and increase IFN-γ production, indicating that the early stages of tumour growth 
TAN display markers that have been previously described as an N1 phenotype (Eruslanov et 
al., 2014).  
1.2.4.4. TAN or MDSC 
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It is worth noting the relationship between myeloid-derived suppressor cells (MDSC) and 
TANs. MDSC consist of a heterogeneous mixture of immature myeloid cells, immature 
granulocytes, monocytes-macrophages, dendritic cells and myeloid progenitor cells 
characterized by their immune suppressive behaviour.   In contrast to tumour-bearing mice, 
where MDSC are well characterized based on the expression of myeloid cell markers Gr-1 and 
CD11b (markers also expressed by murine neutrophils), there is much controversy and lack of 
a uniform marker to identify human MDSC.  Major markers employed for immune-
phenotyping of human MDSC include the common myeloid markers CD11b and CD33 and 
HLA-DRneg/low but do not include markers for mature myeloid cells such as CD40, CD80 and 
CD83.  MDSC can be subdivided to CD14+ monocytic MDSC (MoMDSC) (CD14high, CD15neg, 
CD16high) or CD15+ granulocytic MDSC (GrMDSC) (CD14neg/low, CD15+, CD16neg) (Greten et al., 
2011). Both subsets have the ability to supress T-cell responses either via reactive oxygen 
species (ROS) from GrMDSC or depletion of L-arginine mediated by Arg1 and iNOS from 
MoMDSC. However, the differences between GrMDSC and neutrophils in cancer patients are 
less clear and are overlapping. A study in renal cell carcinoma (RCC) showed no morphological 
difference between MDSC and PMN isolated from the peripheral blood of patients, indeed 
the authors demonstrated that human MDSC resemble activated PMN.   These CD15+MDSC 
express high levels of CD11b, CD66b, and VEGFR1, while only a small amount of CD62L and 
CD16 was detected in peripheral blood of RCC patients in compared to control granulocytes. 
GrMDSC from RCC patients release high levels of arginase I, a cytokine that plays a significant 
role to impair T-cell function, similar observations have been  found when neutrophils were 
activated in vitro (Rodriguez et al., 2009). Similarly, a subpopulation of CD66b+PMN was 
identified from the peripheral blood of HNC patients using density gradient centrifugation. 
This neutrophilic MDSC population was found to have longer survival times in blood and lack 
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expression of CXCR1 and CXCR2, which diminished their migration property when compared 
to mature normal neutrophils of the same patients (Brandau et al., 2011). To further 
discriminate TAN from GrMDSC and naive bone marrow neutrophils (BMN) isolated from 
mice, Fridlender and co-workers used a transcriptomics approach to compare the three cell 
populations. They found that TAN are a distinct population of neutrophil and mRNA of BMN 
and GrMDSC are more closely related to each other than to TAN. The most significant 
difference between TAN and either GrMDSC or BMN can be summarized by the up-regulation 
of anti-apoptotic NF-κB genes (IEX-1, SOD-2, GADD-45B, BCL-2A1), cytokine and chemokine 
genes (CXCL1, CXCL2 and CCL3), genes related to proteolysis (MMP-13, MMP-14, TIMP-1), 
whereas the level of mRNA involved in cytoskeleton organization and biogenesis, granule 
protein and respiratory burst were notably down-regulated (Fridlender et al., 2012).    
1.2.5. Tumour-derived factors mediating neutrophil recruitment to tumours    
To be recruited to the tumour site, neutrophils must exit the vasculature and transmigrate 
into tissues. As described previously, neutrophil extravasation is a tightly regulated process 
that comprises capturing of free flowing neutrophils by the activated vascular endothelium, 
followed by firmer adhesion and rolling of neutrophils along the vessel wall that will allow 
interaction between chemokine and their receptor on the neutrophils surface, before the 
transmigration across the endothelial cell barrier into inflammatory tissue along a 
chemotactic gradient (reviewed in (Williams et al., 2011)). The following section will classify 
the potential tumour-derived chemotactic factors involved in neutrophil migration in to 
mediators that belonging to chemokine subfamily or non-chemokine inflammatory.  
1.2.5.1. Chemokine and chemokine receptors 
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The role of chemokines in the pathogenesis of cancer is diverse but mainly they are known 
for their ability to induce cell migration. Chemokines are small chemoattractant peptides (8-
17kDa) that are characterized by the presence or absence of the sequence motif glutamic 
acid-leucine-arginine (ELR) and by four conserved cysteine residues. Chemokines bind to 
seven-transmembrane G-protein-coupled receptors (GPCR). By far the most studied 
neutrophil attracting chemokines in human are CXCL8 (IL-8) and CXCL6 (GCP-2) that bind to 
both CXCR1 and CXCR2, whereas CXCL1 (GROα), CXCL2 (GROβ), CXCL3 (GROγ), CXCL5 (ENA-
78) and CXCL7 bind to CXCR2 on the surface of neutrophils (Lee et al., 1992, Ahuja and Murphy, 
1996a). In murine neutrophils, CXCR2 is very similar to human CXCR2 but binds to KC, a murine 
chemokine with CXCL-8 homology,  (Cacalano et al., 1994), and MIP-2. Although the 
expression of CXCR1 has been detected in mice (Fan et al., 2007), data suggests that CXCR2 is 
predominantly responsible for neutrophil recruitment. As depletion of CXCR2 in inflammatory 
mice model resulted in significant inhibition of recruitment of neutrophils to the peritoneal 
cavity in response to LPS inoculation and CXCR2-/- mice showed almost complete abrogated 
of neutrophils up to two weeks following mycobacterial infection (Gonçalves and Appelberg, 
2002). The expression of CXCR2 has been detected in and non-leukocytic cells such as 
endothelial cell, epithelial cell as well as tumour cells (Murdoch et al., 1999, Desurmont et al., 
2015). The importance of CXCR2 in tumour progression will be further discussed in section 
(1.2.5.1.1). 
 For some of these members of this family the biological activities have already been well 
established in vitro and in vivo. For example, the expression of CXCL8 has been found to be 
highly up-regulated in various human malignancies; for instance, brain, breast, colon, cervical, 
gastric, lung, melanoma, ovarian, Hodgkin’s disease, prostate, renal cell carcinoma and B-cell 
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chronic lymphocytic leukaemia as well as by different cell lines (Xie, 2001). However, many 
studies point to the connection between CXCL8 secreted by tumour cells derived from several 
types of carcinomas or from cells within the tumour stroma and neutrophil infiltration, 
indicating that intratumoral CXCL8 expression is a potent neutrophil chemoattractant within 
the tumour micro-environment (Haqqani et al., 2000, Bellocq et al., 1998). A recent in vitro 
and in vivo study in HNSCC showed that CD66b+ neutrophil infiltration was associated with 
high level of CXCL8, along with detection of high concentrations of CCL4 (MIP-1b) and CCL5 
(RANTES) in the serum of patients (Trellakis et al., 2011a, Trellakis et al., 2011b). This result 
was confirmed by another group who showed that isolated neutrophils migrated towards 
conditioned media collected from the hypopharyngeal squamous cell carcinoma cells line 
(FaDu) that expresses considerable amounts of CXCL8 and CXCL1 (Bru et al., 2009). 
Overexpression of adhesion protein carcinoembryonic antigen-related cell adhesion molecule 
1 (CEACAM1) in tongue squamous cell carcinoma (TSCC) has been linked with increased 
infiltration of neutrophils (Wang et al., 2014). 
CXCL5 was identified as a potent chemoattractant of neutrophils in vitro. Furthermore, a 
murine tumour model and immunohistochemical studies showed a correlation between 
overexpression of CXCL5 and elevated numbers of CD66b+ neutrophils infiltrating into HCC 
tissue that was associated with poor prognosis in HCC patients (Zhou et al., 2012).  The role 
of other chemokines in neutrophil recruitment has been rarely studied, although an elevated 
level of CXCL6 was detected from an osteosarcoma cell line and in patients with 
gastrointestinal tumours that were associated with granulocyte neutrophilic recruitment 
(Proost et al., 1993, Gijsbers et al., 2005).  A separate study also showed that administration 
of CXCL6 neutralizing antibodies in a melanoma mice model, injected subcutaneously with 
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GCP-2 overexpress melanoma cell, reduced tumour growth and metastasis when compared 
to un-treated mice, as well as inhabiting neutrophil migration in vitro (Verbeke et al., 2011). 
Other inflammatory mediators can have an indirect effect on the recruitment of neutrophils. 
For instance, a clinical and experimental study in HCC showed that pro-inflammatory IL-17 in 
the peritumoral stroma of HCC is a critical mediator for the recruitment of neutrophils into 
tissues by up-regulating the expression levels of several chemokines including CXCL1, CXCL2, 
CXCL3 and CXCL8 from epithelial cells compared with intratumoral areas. The same study 
showed microlocalization of CD15+ neutrophils and IL-17 in the peritumoral stroma by 
immunohistochemistry while only marginal levels of CD15 and IL-17 were detected in the 
cancer nest. Additionally, blocking of chemokine receptors CXCR1 and CXCR2 by specific 
monoclonal antibodies markedly reduced neutrophil migration induced by IL-17-treated liver 
epithelial cells L02 (Kuang et al., 2011). Similarly, a significant increase in TANs was observed 
in HCC cell line expressing high levels of CXCR6 receptor via producing pro-inflammatory 
cytokines, such as IL-1β, IL-6, CXCL8 and IL-17F secreted by this cell (Gao et al., 2012). 
The common denominator among all the studies on ELR+ chemokines is that they mainly act 
by high-affinity binding to CXCR2 that is expressed abundantly by neutrophils and plays a role 
in tumour development. The effect of using a specific CXCR2 antagonist (AZ10397767) on 
neutrophils was demonstrated in a lung tumour model. A significant reduction in the number 
of TAN was observed in mice treated with the CXCR2 inhibitor and this was accompanied with 
retardation in tumour growth.  The authors suggested that these infiltrating cells provide a 
secondary source of mediator that can stimulate tumour cell proliferation (Tazzyman et al., 
2011). This notion is supported by the finding HCC cell proliferation, migration and metastatic 
potential can be induced by CXCL5 expression, a chemokine that also binds exclusively to 
27 
 
CXCR2. Further analysis for the mechanism underlying HCC proliferation and invasion 
indicated that CXCL5 induced several signalling pathways including PI3K-AkT and ERK1/2 
pathway that was dependent on CXCR2 activation (Zhou et al., 2012). 
1.2.5.1.1. Role of CXCR2 and other receptor in cancer  
The chemokine receptor CXCR2 binds exclusively to ELR+ CXCL chemokines, including CXCL1-
3 and CXCL5-8 (Ahuja and Murphy, 1996b). These ELR+ CXCL chemokines are generally 
considered chemoattractants for neutrophils, which are the major leukocyte cell population 
expressing the CXCR2 receptor. In addition to neutrophils, CXCR2 expression has also been 
found on several types of malignant cells where it has been associated with an aggressive 
phenotype. For example, overexpression of CXCR2 was detected on tumour cells in patients 
with metastatic colon cancer. Treatment of patients with 5-fluorouracil (5FU) chemotherapy 
induced CXCR2 transcripts levels in liver metastases that was associated with poor patient 
outcome (Desurmont et al., 2015). Treatment of HCT116 and Caco2 colorectal cancer cells 
with SCH-527123, a selective CXCR2 antagonist, inhibited phosphorylation of the NF-
κB/MAPK/AKT pathway, and reduced cell migration and invasion by interfering with the 
CXCL8/CXCR2 axis (Ning et al., 2011). Moreover, blocking CXCR2 induced apoptosis in human 
colon carcinoma cells, whilst reducing their motility and proliferation in vitro (Varney et al., 
2011). Administration of SCH-527123 in a murine colon cancer model showed no detectable 
difference on primary tumour growth between treated and untreated mice, but significantly 
reduced the number of metastases, highlighting the role of CXCR2 in tumour cell locomotion 
and angiogenesis. This anti-metastatic activity was found to be associated with diminished 
blood vessel formation within the metastatic lesion. In contrast, using a Lewis lung cancer 
(LLC) murine model, Keane and colleagues showed that depletion of CXCR2 had a significant 
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inhibitory effect on both primary tumour growth as well as lung metastases formation that 
was also associated with reduced angiogenesis (Keane et al., 2004).  
CXCR2 activation may result in autocrine signalling, as CXCL8 gene transfectants in colorectal 
cancer cells increased cell proliferation and migration activity (Ning et al., 2011). Similar 
observations were demonstrated in other tumour cells, where elevated levels of CXCR2 and 
its ligands (CXCL1-3) were detected in oesophageal and lung cancer, further suggesting an 
autocrine loop to induce cell proliferation (Wang et al., 2006, Keane et al., 2004). 
CXCR2 has been implicated indirectly in tumour growth via recruitment of leukocyte to 
tumour sites. As mentioned previously, accumulation of neutrophils has been reported in 
various malignancies (see section 1.2.4) and neutrophil migration to tumour sites was found 
to be CXCR2-dependent (Jablonska et al., 2014). The authors showed that administration of 
anti-CXCR2 antibodies in both melanoma and fibrosarcoma xenograft murine model 
supressed tumour growth by inhibiting neutrophil infiltration and tumour angiogenesis 
(Jablonska et al., 2014). Accumulating evidence has reported the ability of ELR+ CXCL 
chemokines to act as angiogenic agents in a direct or indirect manner. For example, increased 
expression of CXCL8 from malignant colonic epithelial stimulated chemotaxis of human 
microvascular endothelial cells that express CXCR2 (Heidemann et al., 2003). Therefore, it is 
not surprising that neutralizing CXCR2 with specific antibodies impaired angiogenesis in vivo 
(Addison et al., 2000). 
Beside the well-described role of neutrophils as a mediator of angiogenesis, CXCR2 has been 
found to be responsible for recruitment of CXCR2+CD11b+Ly6Gh neutrophil-like MDSC that 
have immunosuppressive activity. Treatment targeting this CXCR2 MDSC population showed 
an enhanced response to checkpoint blockade treatment with anti-programmed death-1 (PD-
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1) in a rhabdomyosarcoma (RMS) mouse model (Highfill et al., 2014, Katoh et al., 2013). 
Depletion of CXCR2 in a murine pancreatic cancer model, provided compelling evidence of 
the importance of CXCR2 signalling in neutrophil infiltration to tumours (Steele et al., 2016). 
Depletion of neutrophils using an anti-Ly6G strategy decreased metastasis and increased the 
recruitment of anti-tumour CD3+ T cells (Steele et al., 2016).  
1.2.5.1.2. Duffy antigen receptor for chemokines binding to CXCR2 ligands 
A protective role of CXCR2 in early tumorigenesis has been recently proposed. In a process 
known as oncogene-induced cellular senescence (OIS), activation of a specific oncogene 
results in the entry of cells into an irreversible growth arrest state known as cellular 
senescence. Here senescence cells were found to secrete CXCL6 and CXCL8 via NF-кB and 
C/EBPβ proinflammtory transcription factors. In addition, OIS was associated with 
overexpression of CXCR2 (Kuilman et al., 2008). Further evidence supports this notion, as 
inhibiting CXCR2 in tumour cells impaired cell cycle arrest and reduced the DNA-damage 
response, whilst overexpression of CXCR2 in cells restored the senescence phenotype (Acosta 
et al., 2008).  
Some ELR+ CXC chemokines, such as CXCL8, CXCL1 and CXCL7 can bind to Duffy antigen 
receptor for chemokines (DARC), a seven transmembrane receptor expressed on erythrocytes 
and other cells that is structurally similar to chemokine receptors. Binding of these ELR+ CXC 
chemokines to DARC does not induce a downstream signalling event by either GPCR or Ca +2 
flux (Neote et al, 1994), and this is proposed to be due to the absence of the highly conserved 
DRY motif from the intracellular loop of DARC that is essential for G protein binding and signal 
transduction (Hadley and Peiper, 1997).DARC are presumed to function as decoy receptors, 
mopping up excess chemokine in the microenvironment and therefore limiting their activity. 
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DARC that is expressed on erythrocytes can absorb CXCL8 from circulation to limit the 
stimulation of leukocytes (Darbonne et al., 1991) . Addsion et al, who demonstrated that 
expression of DARC within tumours could alter the progression of the disease, provided 
further evidence. The authors showed that overexpression of DARC in lung cancer cells 
resulted in enlarged tumours when implanted into a xenograft model, but histological 
examination showed significant increases in tumour necrosis, with reduced tumour cell 
viability and metastasis formation in vivo (Addison et al., 2004). The same negative regulatory 
affect was observed when DARC was overexpressed in a breast cancer model, where tumour 
growth and metastasis were also reduced (Wang et al., 2006). 
1.2.5.2. Other molecules involves in neutrophil infiltration  
Apart from ELR+ chemokines there has been a number of studies describing other factors that 
support neutrophil recruitment to tumours. A recent in vivo study demonstrated a 
neuropeptide, gastrin-releasing peptide (GRP), induced neutrophil recruitment via a GPCR 
that was dependent on the PI3K and MAPKs signalling pathway, similarly to other 
chemoattractant molecules. This migration was abolished using RC-3095, specific inhibitor for 
GRP receptor (Czepielewski et al., 2012). High mobility group box 1 protein (HMGB1) is a 
highly conserved chromatin-binding factor that aids transcription. It is passively released from 
stressed or necrotic cells and acts as an alarm signal to activate innate immune responses, in 
particular phagocytes that can then clear the cell debris (Scaffidi et al., 2002). Orlova and 
colleagues found that HMGB1 injected into the peritoneum of mice rapidly recruited 
neutrophils that was dependent on co-expression of the integrin heterodimer CD11b/CD18 
and the receptor for HMGB1, receptor for advanced glycation end products (RAGE) on 
neutrophils (Orlova et al., 2007).  
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1.2.5.3. Macrophage migration inhibitory factor  
1.2.5.3.1. Characteristics and biological activity  
As its name indicates macrophage migration inhibitory factor (MIF) was first described as an inhibitor 
of random macrophage migration and activation (David, 1966) from a study aimed at understanding 
delayed type hypersensitivity reactions. Subsequent studies have reported that MIF expression is 
ubiquitous in a variety of cells including monocyte/macrophages (Calandra et al., 1994), lymphocytes, 
eosinophils (Rossi et al.), neutrophils (Daryadel et al., 2006), and non-immune cells such as endothelial 
cells (Nishihira et al., 1998) and epithelial cells (Imamura et al., 1996). In addition, the expression of 
MIF has been detected in several tissues and cells, especially those tissues exposed to the environment; 
for example, lung, gastrointestinal and skin (Shimizu et al, 1996). The discovery that MIF is produced 
from corticotrophic cells of the pituitary gland, classify it as a hormone as well as cytokine. Another 
distinctive feature of MIF is that it can overcome the anti-inflammatory effect of glucocorticoids to 
enable a sustained inflammatory response (Bernhagen et al., 2007). There is much evidence to 
demonstrate that MIF plays a significant role in various inflammatory and autoimmune disease, such 
as sepsis (Bozza et al., 1999), acute respiratory distress syndrome (ARDS) (Lai et al., 2003), 
glomerulonephritis (Yang et al., 1998) atherosclerosis (Das et al., 2013), rheumatoid arthritis (Morand 
et al., 2006) and lupus (Foote et al., 2004). Unlike many other cytokines, pre-formed MIF can be stored 
intracellularly and expressed constitutively without de novo protein synthesis (Bacher et al., 1997).  
X-ray crystallographic studies of human and rat MIF revealed a homotrimer structure, each monomer 
consisting of four β sheet and two α helices connected by hydrogen bonds (Suzuki et al., 1996).  
Although not directly related to the chemokine superfamily, MIF shares a structural similarity with 
chemokines as it contains a conserved Glu-Leu-Arg (ELR) motif that is present in many CXCL 
chemokines. However, in MIF an aspartic acid (Asp/D) amino acid residue replaces the glutamate 
(Glu/E) making the sequence DLR in MIF. This motif is consequently known as “pseudo-(E)LR” motif 
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(Hébert et al., 1991)Also, 3D structural analysis has revealed a striking similarity between the 
monomeric form of MIF and dimeric form of CXCL8 (Weber et al., 2008) (Fig.1.5).   
MIF has unique enzymatic catalytic activity toward D-dopachrome or L-dopachrome tautomerase to 
give 5,6-dihydroxyindole-2-carboxylic acid (DHICA)(Rosengren et al., 1996).  The MIF tautomerase site 
is located in the N-terminus with the proline motif being essential for activity as a single proline 
mutation at this site showed reduction in the catalytic activity along with impaired cytokine activity 
(Stamps et al., 1998). A significant reduction in the level of superoxide generated by neutrophils 
incubated with mutant MIF was observed compared to wild-type MIF, indicating the importance of 
the catalytic site for MIF’s biological activity (Swope et al., 1998, Bendrat et al., 1997).  Binding of MIF 
to its cell surface receptor, CD74 (also known as the MHC class II-associated invariant chain (II)), is not 
enough to initiate signal transduction mechanisms as CD74 has a short intracytoplasmic tail of only 46 
amino acids (Shi et al., 2006). However, MIF mediates activation of signal-regulated kinase 1 
(ERK1)/ERK2), members of the family of mitogen-activated protein kinases (MAPKs), by binding to a 
CD74/CD44 complex (Leng et al., 2003). MIF has also been reported to bind to CXCR2 and CXCR4 
(Bernhagen et al., 2007). While it is predicated that there is a two site binding interaction between the 
N-loop of MIF with the N-terminal domain of CXCR2 and between the MIF pseudo (E)LR motif and 
extracellular loops of CXCR2 (Kraemer et al., 2011), the binding site of MIF with CXCR4 are still to be 
revealed.  
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1.2.5.3.2. MIF as inflammatory molecule and chemotactic cytokine  
MIF has been recently classified as having “chemokine-like functions (CLF)” because some of 
its activity is similar to those observed in chemokines, leading to many changing its name from 
MIF to CLF. MIF is released from cells under inflammation, infection and in response to stress 
Figure 1.5 Crystal structure and amino acid sequence comparing MIF to CXCL8 (Tillmann et 
al., 2013)  
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and it is able to induce leukocyte recruitment (Gregory et al., 2004) .MIF has been identified 
as a non-cognate ligand of chemokine receptor CXCR2 and CXCR4 (Bernhagen et al., 2007). 
However, MIF lacks the critical cysteine residues in its N-terminus that is present in classical 
chemokines. The precise biological function of MIF has not yet been fully revealed but 
evidence suggest that MIF is capable of inducing an immune response either by acting directly 
on immune cells or indirectly by activating other stimuli to the immune system. For instance, 
MIF has been shown to act as inflammatory cytokine and that upon release can trigger 
cytokine production such as, CXCL8, CXCL6, TNF-α, INF-γ, IL-1β and IL-12 from macrophages 
(Onodera et al., 2004). These MIF-activated macrophages can induce further inflammatory 
stimuli by releasing free radicals (White et al, 2001). Beside macrophages, MIF has been 
reported to mediate the recruitment of monocytes, neutrophils (Dumitru et al., 2011, 
Trellakis et al., 2011a) and T-cells (Bernhagen et al., 2007). Interestingly, the presence of MIF 
in the tumour microenvironment has been reported to alter anti-cancer immunity response.  
MIF was found to have a direct inhibitory effect on NK cells, and the use of neutralizing 
antibodies against MIF abrogated this effect (Apte et al., 1998). Another study investigated 
the mechanism MIF employees to inhibit NK cell activity; the authors showed that MIF 
reduced the ability of NK cells to recognize tumour cells via downregulation of NK cell receptor, 
NKG2D (natural killer group 2D) (Krockenberger et al., 2008). In addition, high levels of MIF in 
a neuroblastoma model inhinited T lymphocyte activation, via the IFN-γ pathway, resulting in 
arrest of cell growth and increased cell death (Yan et al., 2006). MIF is also essential for the 
immunosuppressive activity of monocytic MDSCs in melanoma, and treatment with a small 
molecule MIF enzymatic antagonist, 4-IPP, significantly reduced T-cell activity (Yaddanapudi 
et al., 2016). 
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There is considerable evidence to demonstrate the central role that MIF plays in the 
inflammatory response indirectly. Deletion of MIF gene from macrophages impairs the 
response to pathogenic bacteria and lipopolysaccharide due to a significant downregulation 
of Toll-like receptor 4 (TLR4), the signal-transducing molecule of the LPS receptor complex 
(Roger et al., 2001).In addition, MIF has been found to downregulate the tumour suppressor 
p53 in fibroblast and macrophage, inducing cell survival (Hudson et al., 1999).  
1.2.5.3.3. MIF in cancer 
Clinical reports has described increased expression of MIF in variety of human tumours 
including breast (Xu et al., 2008), prostate (Meyer-Siegler et al., 2005), osteosarcoma (Han et 
al., 2008), colon (He et al., 2009), gastric (He et al., 2006), neuroblastoma and glioma 
(Mittelbronn et al., 2011). Recently, overexpression of MIF was detected from HNSCC patients 
and correlated with poor patient outcome and tumour progression (Kindt et al., 2013b).  
MIF employs a variety of mechanisms that contribute in tumorigenesis and invasiveness of 
cancer. First, MIF can induce tumour cell survival via inducing the phosphoinositide-3-kinase 
(PI3K)/Akt signalling pathway, which leads to phosphorylation of the proapoptotic proteins 
BAD and Foxo3 supressing apoptosis (Lue et al., 2006) or via down-regulation of tumour 
suppressor gene p53 (Hudson et al., 1999). Second, MIF signalling via CD74 leads to sustained 
activation of MAPK extracellular-signal regulated kinase ERK 1/ERK 2 (Lue et al., 2006). MIF-
induced phosphorylation of ERK1 and ERK2 is mediated by the CD74/CD44 complex has also 
been associated with cell proliferation (Shi et al., 2006). Inhibition of MIF or it is receptor using 
CD74 neutralizing antibodies significantly decreased the proliferation of DU-145 prostate 
cancer cell in vitro (Meyer-Siegler et al., 2006). Knockdown of MIF reduced the tumour growth 
rate in a xenograft model of hepatocellular carcinoma (Huang et al., 2014) ,while MIF 
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overexpression in vivo enhanced tumour growth and metastasis formation (Funamizu et al., 
2013). Investigations using knock out MIF in tumour cells showed reduced proliferation via 
induction of growth related protein such as Bax, caspase-3, while anti-apoptotic proteins Bcl-
2, pAkt, and p53 were decreased (Guo et al., 2015, Huang et al., 2014). Collectively these data 
point to the ability of MIF to induce proliferation of tumour cell in an autocrine manner.  
Interestingly, overexpression of MIF induces epithelial-to-mesenchymal transition (EMT) 
phenotype in pancreatic cancer cells. EMT is an aggressive feature characterized by decreased 
E-cadherin and increased vimentin expression in MIF expressing cancer cells and is associated 
with diminish responsiveness to chemotherapy (Funamizu et al., 2013). MIF has also been 
reported to induce migration of cancer cells in vitro (Ren et al., 2003, Shimizu et al., 1999). 
One of the most important activities of MIF is its ability to act as a pro-angiogenic cytokine.  
Several published studies show that MIF can promote endothelial cell proliferation and 
motility (Chesney et al., 1999, Yang et al., 2000). Tumour-derived MIF has been reported to 
induce macrophages to upregulate angiogenic cytokines, such as CXCL8, CXCL1 and CXCL7 
(White et al., 2001). In support of the role of tumour-derived MIF, deficiency of MIF in a B16 
melanoma tumour model showed that isolated tumour-associated macrophages (TAMs) 
display an M2/pro-tumuoral phenotype.  The level of pro-inflammatory cytokines, TNF-α, IL-
12, cyclooxygenase-2 (COX-2) and inducible NOS (iNOS) were higher in TAM from tumour 
bearing MIF-deficient mice in compared to MIF wild-type mice (Yaddanapudi et al., 2016). 
Similarly, in an inflammatory model, the chemotactic response of neutrophils to CXCL1 (KC) 
was significantly impaired in MIF-deficient mice (Santos et al., 2011). 
A recent study showed that the strong expression of MIF by tumours was associated with neutrophil 
infiltration that positively correlated with disease stage and negatively with disease outcome (Dumitru 
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et al., 2011, Trellakis et al., 2011a). The authors also showed that cross-talk between tumour cells and 
immune cells is necessary for cancer progression and altering the tumour microenvironment. For 
example, HNC cells were able to enhance the viability of neutrophils and induce the releases of 
inflammatory factor, such as CCL4, CXCL8 and MMP-9 in vivo (Dumitru et al., 2011, Trellakis et al., 
2011a). These findings indicate the importance of the interaction between HNC and neutrophils in 
modulation of neutrophils biology and cancer progression. Interestingly, a distinct pattern of TAN 
infiltration as disease progress was observed in OSCC patients, as T3-T4 OSCC presented with higher 
neutrophil infiltration within the intratumoural region and higher neutrophil/lymphocyte ratio in the 
invasive front than T1-T2 OSCC tumours (Caldeira et al., 2015). Furthermore, expression of MIF has 
been found to be up-regulated by tumour hypoxia (Koong et al., 2000). Tumour hypoxia induces 
activation of hypoxia inducible factor α (HIF α), a transcription factor that controls expression of 
several key genes involves in tumour growth, invasiveness and angiogenesis, such as, vascular 
endothelial growth factor (VEGF) (Shweiki et al., 1992), lysyl oxidase (LOX) (Erler et al., 2006)and 
connective tissue growth factor (CTGF) (Higgins et al., 2004) . Deletion of MIF in pancreatic 
adenocarcinoma cells demonstrated that stabilization of HIF-α is MIF-dependant in hypoxia (Winner 
et al., 2007).  
MIF knockdown murine models of ultraviolet B (UVB) showed a 45% reduction in epidermal 
tumorigenesis as a result of chronic exposure UVB irradiation. A further investigation showed that 
MIF-deficient mice not only had reduced neutrophil infiltration but they also show a diminished ability 
of the tumour to progress and grow mainly via stimulation of p53 and reduced levels of VEGF in the 
skin of these mice when compared to wild-type controls (Martin et al., 2009).  
1.2.5.3.4. Targeting MIF in cancer 
Thus far, three main approaches have been utilised in cancer studies to examine the role of 
MIF including the use of small molecules inhibitors, indirect stabilization of MIF and the use 
of monoclonal antibodies against MIF. Anti-MIF antibodies have been successfully generated 
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by Baxter and use of these showed a significant affect in reducing tumour growth in a prostate 
and colon xenograft model (Kerschbaumer et al., 2012, Hussain et al., 2013, He et al., 2009) 
Interestingly, the authors demonstrated that the binding region of anti-MIF was located 
within oxidoreductase motif.  Today, the use of anti-MIF antibodies to treat patients with solid 
tumours is in Phase 1 trial (clinicaltrials.gov.NCT01765790). 
The use of small molecular weight inhibitors that interfere with the enzymatic activity site of 
MIF is widely used in cancer biology. ISO-1, the gold standard MIF inhibitor, binds to the 
tautomerase active sit of MIF and restricts the pro-inflammatory activity of MIF (Al-Abed et 
al., 2005). The use of ISO-1 has been validated in multiple xenograft models, such as in lung 
(A549) (Rendon et al., 2007) prostate (DU145) (Meyer-Siegler et al., 2006) and glioblastoma 
(LN229) (Schrader et al., 2009) and has demonstrated significant results in controlling tumour 
growth. In a DU-145 xenograft prostate cancer model, treatment with 20 mg/kg of ISO-1 
showed a significant reduction in tumour volume and blood vessel formation compared to 
control mice.  Although, exogenous ISO-1 can inhibit the intracellular tautomerase activity of 
MIF (Al-Abed et al., 2005), tumour tissue showed no difference in total MIF protein content 
while MIF released in the serum of mice was significantly reduced in ISO-1 treated mice, 
suggesting that the MIF secreted form the tumour has been affected by ISO-1 treatment 
(Meyer-Siegler et al., 2006). Similarly, ISO-1 administration in colon carcinoma xenograft 
model showed the same suppresser effect on tumour growth via interfering with 
angiogenesis (He et al., 2009). Despite the interesting in vivo result, the use of ISO-1 in human 
clinical trial is limited, because of enzymatic kinetic and route of administration 
(interaperitoneal).  
1.2.5.4. Neutrophil-derived molecules in cancer progression 
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As neutrophils play a well-established role in host defence and in killing invading 
microorganisms they produce secreted products, such as ROS, cytokines and proteinases, that 
are also capable of causing damage to host tissue and altering tumour cell behaviour in many 
aspects. The following section will describe the main neutrophil-derived molecules and their 
role in cancer progression and is summarised in figure 1.6. 
1.2.5.5. Role of neutrophils in tumour initiation and carcinogenesis  
As already mentioned, neutrophils are an abundant source of reactive oxygen (ROS) and 
nitrogen (RNS) species that are produced via the activity of an oxidant generating system 
within the phagososmes (Fialkow et al., 2007). In a mouse model, a strong link was observed 
between neutrophil infiltration and increased DNA mutation frequency in tumour cells. This 
Figure 1.6 Schematic diagram summarising the role of TANs in tumour progression. 
Neutrophil-derived molecules play an essential role in tumour development from initiation to 
metastasis to distant sites. 
40 
 
genotoxic capacity was proposed to be due to inducible nitric oxide synthase (iNOS) released 
from TANs and was measured using mutation at the hypoxanthine phosphoribosyltransferase 
(Hprt) locus (Sandhu et al., 2000). Other investigators point to the role that neutrophil 
accumulation in inflamed tissue may play toward cancer progression. Several colon cell lines 
were co-cultured with neutrophils in order to mimic chronic exposure within the tumour 
environment were tested in vitro. Activated neutrophils were able to induce DNA damage and 
replication error in colon epithelial cells via products other than ROS/RNS (Campregher et al., 
2008).   
1.2.5.6. Role of neutrophils in tumour growth, progression and metastasis  
Several lines of evidence have shown that TANs can secrete factors that affect tumour cell 
proliferation. Neutrophil elastase (NE), the major component of neutrophil azurophilic 
granules, is a serine proteinase and was found to induce tumour cell proliferation in Lewis 
lung carcinoma cells by hyperactivity of the phosphoatidylinositol-3-kinase (PI3K) pathway 
and administration of NE inhibitors in mice reduced lung tumour growth by 69% (Houghton 
et al., 2010).  
In addition, NE was found to be important in remodelling of the ECM, thus facilitating invasion 
and metastasis of tumour cells (Mainardi et al., 1980) as neutrophil-derived proteinases 
(elastase, cathepsin-G, protease-3) were reported to cause activation of MMP-2 and 
cooperating with membrane type-1 matrix metalloproteinase (MT1-MMP) to enhance cell 
invasiveness (Shamamian et al., 2000).  In response to TNF-α or GM-CSF, neutrophils release 
protease and heparanase that degrade components of the extracellular matrix (ECM) as they 
transmigrate across endothelium (Mollinedo et al., 1997). The release of ECM degrading 
enzymes alters the expression of cell surface adhesion molecules and provides the neutrophil 
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with the ability to extravasate from the circulatory system, invade the surrounding solid tissue 
and play a crucial role in altering the tumour microenvironment. Of the proteases released by 
neutrophils, matrix metalloproteinases have been found to be a key player in promoting 
tumour progression. There are two types of MMPs within neutrophils, collagenase/MMP-8, 
and gelatinase B/MMP-9 located in secondary and tertiary granules, respectively. It was 
demonstrated that TAN, enhance invasion and metastasis of rat mammary adenocarcinoma 
cells through the secretion of elevated levels of MMP-9 and heparanase that remodel the 
ECM (Welch et al., 1989). 
Other effectors exist within primary granules, antimicrobial peptides called human defensins 
have also been found to promote proliferation of a human lung epithelial cell line via the 
mitogen activated protein kinase (MAPK) signalling pathway (Aarbiou et al., 2002). Recent 
studies revealed that TANs induce a feedback effect on tumour cells. Dumitru and co-workers 
demonstrated that HNSCC supernatant stimulates p38-MAPK in neutrophils, which strongly 
increases the production of CCL4, CXCL8 and MMP-9 (Dumitru et al., 2012); factors that have 
been associated with tumour progression. For example, an association was found between 
CXCL8-induced neutrophil recruitment with increased tumour growth of a highly tumorigenic 
and metastatic melanoma cell line (Schaider et al., 2003). 
Circulating tumour cells can use neutrophils as a vehicle to pass through the endothelial cell 
wall and this is another mechanism by which neutrophils facilitate tumour metastasis. Studies 
have shown that tumour cells (melanoma and lung) secreted CXCL8, causes neutrophil 
recruitment and increases the expression of adhesion molecules β2–integrin (LFA-1, 
CD11a/CD18) on neutrophils that influence tumour cell binding by a “two-step adhesion” 
mechanism involving binding to the endothelial as well as the tumour cell via intracellular 
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adhesion molecules-1 (ICAM-1) (Huh et al., 2010, Slattery and Dong, 2003). Similarly, 
neutrophils were also found to promote liver metastasis by up-regulation of Mac-1 (Spicer et 
al., 2012). Alternatively, TNF-α-stimulated neutrophils up-regulated the expression of 
carbohydrate sialyl Lewis X (sLeX) on non-small cell lung cancer (NSCLC) and increased it is 
binding to selectin receptor (E-selectin) on the endothelial cell surface (St Hill et al., 2011).  
Dumitru and colleagues notice that TAN infiltration was associated with increased expression 
of a cytoskeleton protein that is involved in cellular migration and invasion, cortical actin 
binding protein (CORTACTIN) in oropharyngeal cancer. The investigators provided evidence 
that neutrophils are required to induce migration of tumour cell via release of factors that 
phosphorylated CORTACTIN (Dumitru et al., 2013). Furthermore, neutrophils primed with 
HNC derived MIF have been shown to enhance the adhesion and migration properties of 
tumour cells in vivo (Dumitru et al., 2011).  
A recent study demonstrated that tongue cancers containing high numbers of neutrophil 
infiltrate were associated with lymph node metastasis and predicted a poor clinical outcome 
(Wang et al., 2014). A very recent finding identified a new mechanism neutrophils use to 
mediate tumour cell seeding in the pre-metastatic niche. Coffelt and co-workers showed that 
tumour cells cooperate with gamma delta (γδ) T cells to promote a TAN phenotype via IL-17 
expression. Moreover, neutrophil depletion by neutralizing IL-17 significantly reduced the 
metastatic spread to pulmonary and lymph node in a breast cancer mouse model (Coffelt et 
al., 2015). Increased expression of IL-17 from neutrophils of OSCC patients has been observed 
but no further investigation on the metastasis process was carried out in HNSCC (Garley et al., 
2009). 
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In line with the observation that neutrophil numbers increase in the peripheral blood of 
patients with advanced stage of HNSCC (Trellakis et al., 2011a), gene and surface analysis of 
circulating neutrophils from patients with the advance malignancy demonstrated that these 
express a pro-tumorigenic TAN-like phenotype. Further studies using a tumour bearing mice 
model, showed that these neutrophils enhance tumour metastasis (Zhang et al., 2015). 
1.2.5.7. Role of tumour-associated neutrophils in angiogenesis 
Mounting evidence supports the association between TANs and the process of angiogenesis 
and neovascularization (Tazzyman et al., 2009). The mechanism by which neutrophils 
facilitate the formation of new blood vessels is believed to be mediated by the secretion of 
chemokines, protease and growth factors from internal pre-stored granules. These molecules 
can either stimulate angiogenesis directly or indirectly via remodelling of extracellular matrix 
or by promoting the release of angiogenic molecules.  Neutrophils were found to be a plentiful 
source of the potent angiogenic vascular endothelial growth factor (VEGF) (Gaudry et al., 1997) 
and active recruitment of neutrophils containing VEGF has been observed in human 
endometrium during endometrial proliferation and angiogenesis through menstrual cycle 
(Mueller et al., 2000). An in vitro study showed that conditioned medium from neutrophils 
infiltrating A549 spheroid contains elevated level of VEGF and MMP-9 that were responsible 
for microvascular endothelial cell proliferation and tubule formation (Tazzyman et al., 2011). 
Furthermore, Bv8 has recently been identified as a neutrophil-derived mediator of tumour 
angiogenesis using rat insulin promoter (RIP)-T-antigen (Tag) transgenic mouse model of 
pancreatic cancer. This protein is structurally similarly to endocrine gland derived VEGF (EG-
VEGF) both of which bind to receptors known as prokineticin (PKR) 1/EG-VEGF receptor 1 
(PKR1/EG-VEGFR1) and PKR2/EG-VEGFR2 that are expressed on endothelial cells. Blocking 
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Bv8 using neutralizing antibodies at an early tumour stage resulted in a reduction in the 
number of pancreatic islets undergoing angiogenic switch and reduction in tumour infiltrating 
CD11b+ Gr1+ cells than controls (Shojaei et al., 2007). 
Other neutrophil-derived molecules play a role in tumour vascularisation by degrading the 
ECM to facilitate endothelial cell and pericyte movement and stromal re-modeling that is 
crucial for angiogenesis. Of this, MMP-9 was identified as an essential indirect factor during 
the angiogenic switch. Immunohistochemical analysis showed that accumulated 
peritumoural neutrophils within HCC were the major source of MMP-9 in the tissue. An 
association was found between the high infiltration of neutrophils with angiogenesis and 
tumour progression at the tumour invading edge, and in vivo depletion of neutrophils 
significantly inhibited tumour angiogenesis and tumour growth (Kuang et al., 2011). In 
addition to its effect on the ECM, it has been shown that neutrophil-derived MMP-9 can 
promote the release of potent pro-angiogenic factors such as VEGF (Nozawa et al., 2006). 
Interestingly, neutrophils were found to release MMP-9 free of negative regulator, tissue 
inhibitors metalloproteinases (TIMP-1) and upon stimulation neutrophil TIMP-free proMMP-
9 release in tumour microenvironment in a pro-enzyme form which is easily and rapidly 
converted to its biologically protolytic active form (Bekes et al., 2011). Furthermore, it has 
been reported that neutrophils secrete cytokines that can stimulate tumour cells to produce 
angiogenic factors. For instance, when neutrophils were co-cultured with human breast 
cancer cells, they released a large quantity of Oncostatin M (OSM), which is a pleiotropic 
cytokine belonging to the IL-6 family. Neutrophil-derived OSM enhanced the expression of 
VEGF from T47D and MDA-MB-231 breast cancer cell lines and increased the invasive and 
detachment capacity of the cells (Queen et al., 2005).  
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Figure 1.7 Mechanisms of neutrophil recruitment and neutrophil-mediated tumour 
angiogenesis. Neutrophils are recruited into the tumour from the circulation via the 
production of ELR+ chemokines or MIF that bind to CXCR2. Once inside the tumour, 
neutrophils can influence angiogenesis directly or indirectly. The direct 
mechanisms include release of such angiogenic factors as VEGF, ELR+ chemokines 
and Bv8 that promote endothelial cell migration and proliferation. The main indirect 
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mechanism appears to be the release of TIMP-1-free MMP-9 upon degranulation. TIMP-1-
free MMP-9 has a dual role; it liberates the pro-angiogenic growth factors (VEGF & FGF-2) 
that are sequestered in the stromal matrix and also degrades components of the ECM. In 
addition, neutrophils can also secrete factors such as oncostatin M that stimulates tumour 
cells to increase their VEGF production and CCL2/CCL5 
that may support the recruitment of TAM.   
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1.2.5.8. Role of Neutrophils in Immunomodulation 
The possible mechanisms by which TAN can regulate innate and adaptive immune cell 
responses are less clear. However, evidence has shown that TAN are not only able to recruit 
more inflammatory cells to the tumour micro-environment but they can also induce 
suppressive effects on other immune cells. For example, neutrophils have been shown to 
inhibit T-cell effector functions. One explanation for the suppression of T-cell proliferation 
and activation is due to release of stored Arg-1from neutrophils that can cause degradation 
of extracellular arginine, an element required to activate T-cells (Rotondo et al., 2009). In 
addition, TAN mediated the recruitment of an immunosuppressive subset of T-cells, known 
as T-regulatory (T-regs) via the production of CCL17 (Mishalian et al., 2013). The same group 
showed previously that levels of CCL17 from N2 TAN was significantly higher compared to N1 
TAN in this tissue (Fridlender et al., 2012). In agreement with this observation, Zhang et al 
reported that circulating neutrophils which exhibit an N2 TAN phenotype in the blood of 
patients with advanced cancer have an immunosuppressive function on peripheral leukocyte 
by increased expression of Arg-1(Zhang et al., 2015). 
Traditionally, neutrophils can exert cytotoxic effect on tumour cells but there are several lines 
of evidence to suggest that tumour cells can escape the immune response directly or 
indirectly. For instance, when the direct contact between neutrophils and FaDu cells was 
prevented using antibodies against adhesion molecules, tumour cell-mediated lysis by 
neutrophils was significantly reduced (Bru et al., 2009).   
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1.3. Hypothesis  
Tumour-derived factors drive neutrophil recruitment and induce polarisation by interacting 
with receptors on their cell surface. Interfering with this ligand-receptor interaction will 
reduce neutrophil recruitment to HNSCC that may disrupt tumour progression. 
1.4. Aims  
1. To examine distribution pattern and number of TAN in biopsies of HNC  
2. To characterise a 3D in vitro model of HNSCC and use this to better understand the 
mechanism by which neutrophils are recruited into HNC tumour 
3. Study the effect of neutrophil depletion and MIF inhibition on immune cell 
recruitment and tumour growth in vivo  
4. To examine if MIF and HNSCC-derived factors affect human neutrophil phenotype.  
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Chapter 2: Material and Methods 
2.1. Materials    
2.1.1. Reagents 
Reagents  Supplier  
Agarose type V Sigma-Aldrich 
Bovine serum album (BSA) Sigma-Aldrich  
Cell Tracker TM Green  Invitrogen, UK 
CXCR2 antagonist (AZ10367797) AstraZeneca, UK 
CXCR2 antagonist (SB-265610) GlaxoSmithKline 
CXCR4 antagonist (AMD3100) Sigma-Aldrich 
Dimethylsulphoxide (DMSO) Sigma-Aldrich 
4',6-diamidino-2-phenylindole (DAPI)  Invitrogen, UK 
FACS lysis buffer   
Foetal bovine serum (FBS) Sigma-Aldrich 
fMLP (f-Met_Leu-Phe) Sigma-Aldrich 
Ficoll-Paque TM plus  GE Healthcare 
HBSS medium without Ca+2, Mg+2or phenol red  Fisher Scientific  
MIF antagonist (ISO-1)  Millipore 
Penicillin/streptomycin  Sigma-Aldrich 
Phosphate-buffered saline  Sigma 
Recombinant human CXCL1 Peprotech, UK 
Recombinant human CXCL5 Peprotech, UK 
Recombinant human CXCL8 Peprotech, UK 
Recombinant human MIF  Peprotech, UK                                                                 
Recombinant human TGF-β Peprotech, UK                                                                 
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Recombinant human TNF-α Peprotech, UK 
Recombinant human INF-γ Peprotech, UK                                                                 
RPMI-1640 Sigma-Aldrich 
Sterile water Baxter, UK 
Thiazolyl Blue Tetrazolium Bromide (MTT) powder Sigma, M5655 
0.25%Trypsin/EDTA Sigma  
Non-enzymatic cell dissociation solution   
2.1.2. Equipment 
Instrumentation Manufacturer 
Applied Biosystems 7900HT Fast Real-Time PCR System Life technologies 
Avanti J-26 XP Centrifuge Beckman Coulte 
Automated Cellular Imaging System III Dako, Denmark 
Attune Autosampler Flow Cytometry Life technologies, USA 
Axiovert 200M microscope Zeiss, Germany 
Class II Safety Cabinet Walker, UK 
Colorimetric (spectrophotometric) plate reader Infinite® M200, TECAN, USA 
Cytospin CytoFuge 2 
Cryostat Leica, Germeny 
FACS Calibur Becton-Dicknson, USA 
FACS LSRII Becton-Dicknson, USA 
Galaxy CO2 incubators Eppendorf 
High-Speed Centrifuge Sigma-Aldrich 
MACSmix tube rotator Miltenyi Biotec 
MACSexpress Separator Miltenyi Biotec 
Microtome Leica, Germeny 
NanoDrop 1000 ThermoFisher, UK 
Spanning disc  confocal system PerkinElmer UltraView 
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Slide Stainer Leica, Germeny 
TissueFAXS plus 200 system TissueGnostics GmbH, 
Austria 
 
2.1.3. Commercial kits 
Commercial Kits Supplier 
ABC Vectastain kit alkaline phosphates mouse IgG Vector Labs 
ABC Vectastain Elite kit peroxidase rabbit IgG Vector Labs 
Alkaline phosphate substrate kit  Vector Labs 
ArC™ Amine Reactive Compensation Beads ThermoFisher 
BDTM CompBeads (anti-mouse IgƘ/negative control 
compensation particle set) 
BD biosciences 
Bioline Isolate RNA mini kit Bioline 
BrdU (B5002) Sigma 
CCL4 ELISA kit  R & D system 
CXCL8 ELISA kit Peprotech 
DAB substrate Kit  Vector Labs 
FACS lysis buffer BD biosciences 
Human cytokine array panel A  R & D system 
High Capacity cDNA Reverse Transcription kit Life Technologies 
MIF ELISA kit R & D system 
LIVE/DEAD™ Fixable Blue Dead Cell Stain Kit Invitrogen 
Vectastain Elite ABC Kit Rat IgG Vector Labs 
Vector Red substrate (SK-5100) Vector Labs  
VEGF ELISA kit  R & D system 
TACS Annexin V apoptois  kit (4830-01-K) Trevigen 
TMB substrate BD biosciences 
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2.1.4. Buffers  
Solution Preparation 
Acidified Isopropanol 1 µl Hydrochloric acid to 1 ml isopropanol 
FACS buffer PBS + 0.1% BSA + 0.1% sodium azide 
Cryopreservation 
media 
90% FCS and 10% DMSO 
Formalin agarose 2 g of Agarose dissolved in 90 ml of distilled water and mixed with 10 
ml of 40% formaldhyde 
 
2.1.5. Antibodies  
Antibody (Clone) Working 
concentration 
Labelled Supplier Applic
ation 
Goat Anti-Mouse IgG As required AlexaFluor® 
488 
Invitrogen, 
UK 
IC 
Anti-Mouse IgG As required R-
phycoerthrin(P
E) 
Sigma IC 
Rat anti-mouse Ly6G (1A8) 1:50 R-
phycoerthyrin 
(PE) 
BD 
Bioscience 
IMF 
Rat anti-mouse F4/80 
(CI: A3-1) 
1:50 Alex flour-488 AbD Serotec IMF 
Anti-mouse CD31 (Clone 390) 1:50 Allophycocyani
n(APC) 
eBioscience, IMF 
Rat IgG2a 1:50 AlexaFlour488 Santa Cruz 
(sc-3896) 
IMF 
Rat IgG2a 1:50 APC eBioscience IMF 
Anti-mouse IgG F(ab) fragment 
R-PE 
1:50 PE  IMF 
Mouse anti-human CD66b 
(80H3) 
1/50 (IHC) UL Beckman 
Coulter 
IHC/Fl
ow 
Mouse anti-human MIF 
antibody(10C3) 
25 μg/ml Biotin Biolegend IHC 
(Hum
an 
sectio
n) 
Mouse anti-human ICAM-1   Abcam Flow 
Rat anti-human CD31 /DIA-310 
(SZ31) 
1:20 UL Dianova IHC 
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Rabbit anti-PIMO antisera 1:20 UL Hypoxyprobe IMF 
Rabbit anti-human MIF 
antiserum (FL-115) 
1:50 UL Santa Cruz IHC 
(mous
e 
sectio
n) 
rabbit serum IgG Isotype control As required UL Abcam IHC 
Sheep anti-BrdU (ab2285) 1:20 HRP Abcam IHC 
Mouse anti-human MIF (10C3) 1:20 Biotin Biolegend IHC 
2.1.6. Cells 
  Adherent Cells 
Cell line Source Tissue Culture Medium Supplier 
FNB6 Immortalized normal 
keratinocyte (Buccal) 
 
Green’s Medium 
330 ml DMEM, 108 ml 
F-12, 50 ml FCS, 5 ml 
P/S, 1.25 ml 
Amphotericin B, 2 ml  
Adenine, 0.5 ml T3, 25 
µl EGF, 80µl 
Hydrocortisone, 2.5 ml 
Insulin, 500µl Cholera 
Toxin 
 
Beatson Cancer 
Institute, Glasgow, UK 
OKF6 Immortalized normal 
keratinocyte (floor of the 
mouth) 
Defined keratinocyte 
serum-free medium 
(GIBCO) + 1 ml growth 
supplement 
James Rheinwald, 
Brigham and 
Women's Hospital, 
Harvard Institutes of 
Medicine, Boston, 
USA 
SCC-4 OSCC (tongue) 
 
250 ml DMEM, 250 ml 
Ham’s nutrition 
mixture F12, 10% FCS, 
1% P/S + 50 µl 
Hydrocortisone 
ATCC 
SCC-9 OSCC (tongue, HPV-ve) 
 
DMEM (low 
glucose),10% FCS, 1% 
P/, 2mM L-glutamine 
 
ATCC 
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SCC2 Hypopharynx carcinoma 
(HPV+) 
DMEM (low glucose), 
10% FCS, 1% P/S, 2mM 
L-glutamine  
 
Prof. S. Gollin, 
University of 
Pittsburgh School of 
Public Health, 
Pittsburgh, USA 
SCC89 Tonsil carcinoma (HPV-) DMEM (low glucose), 
10% FCS, 1% P/S, 2mM 
L-glutamine  
 
Prof. S. Gollin, 
University of 
Pittsburgh School of 
Public Health, 
Pittsburgh, USA 
SCC72 Tonsil carcinoma (HPV-) DMEM (low glucose), 
10% FCS, 1% P/S, 2mM 
L-glutamine  
 
Prof. S. Gollin, 
University of 
Pittsburgh School of 
Public Health, 
Pittsburgh, USA 
H357 OSCC (tongue) 
 
Green’s medium (see 
FNB6) 
  
 
Prof. Steven Prime, 
University of Bristol, 
UK 
T5 OSCC (buccal) 
 
Green’s medium (see 
FNB6) 
 
Beatson Cancer 
Institute, Glasgow, UK 
FaDu Hypopharygeal 
carcinoma (HPV-) 
 
RPMI-1640, 10% FCS,  
1% P/S, 2mM L-
glutamine 
ATCC 
 
Cells cultured in suspension 
 
Cell line Source Tissue Medium Origin 
THP-1 Acute Monocytic 
leukemia 
RPMI-1640, 10% FCS, 
1% P/S, 2mM L-
glutamine 
ATCC 
 
Primary human cells 
Cell number Source Tissue Medium Origin 
OK334 Buccal mucosa Green’s medium (see 
FNB6) 
 
Healthy volunteer  
NOK340 Buccal mucosa  Green’s medium (see 
FNB6) 
 
Healthy volunteer 
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NOF316 Wisdom tooth extraction  DMEM+10% FCS+ 1% 
P/S +L-glutamine 
Healthy volunteer 
NOF320 Wisdom tooth extraction DMEM+10% FCS+ 1% 
P/S +L-glutamine 
Healthy volunteer 
NOF343 Wisdom tooth extraction DMEM+10% FCS+ 1% 
P/S +L-glutamine 
Healthy volunteer 
 
All normal oral keratinocytes (NOKs) and fibroblasts (NOFs) were isolated from biopsies 
obtained from patients during routine dental procedures with written, informed consent 
(ethical approval number 09/H1308/66; cells were used with permission from Dr Helen 
Colley).  
2.2. Methods 
2.2.1. Cell Culture  
2.2.1.1. Routine cell culture procedure 
Using aseptic technique in all procedures; FaDu cells were cultured in tissue culture flaks with 
their specific media (See tables 2.1.6) and incubated at 37˚C with 5% CO2 in a humidified 
incubator. The morphology and cell growth was monitored by microscopy. Cells were allowed 
to grow until they reached 80% confluence whereupon they were either sub-cultured for use 
in experiments or maintained as stock cultures. Growth medium was replenished every 2-3 
days by aspirating half of the medium and replacing it with fresh medium. Cells were tested 
on regular basis for the presence of mycoplasma.  
2.2.1.2.  Hypoxic cell culture 
Normal or cancer cell lines were seeded in triplicate at 1×105 cells per well in 6-well plates.  
Cells were incubated with 2 ml of specific media and were allowed to attach for the next 24 
hours at 37°C, 5% CO2 in a humidified incubator under normoxic (21% O2) conditions. Non-
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adherent cells were removed, fresh 1.5 ml serum-free medium added and cells cultured under 
hypoxic (0.5% O2) or normoxic (21% O2) conditions for 24 hours. Following incubation, cell 
culture conditioned medium was collected, centrifuged at 5000 rpm for 5 minutes to remove 
cell debris and stored at -70 ˚C for further analysis.  Cells were harvested from the wells using 
trypsin/EDTA, centrifuged at 1000 rpm for 5 minutes and the cell pellet stored at -70˚C for 
total RNA extraction.  
2.2.1.3. Sub-culturing adherent cells  
Cell culture medium was removed and cells were washed twice with sterile phosphate buffer 
saline (PBS) without calcium and magnesium. Pre-warmed Trypsin/EDTA solution was added 
and cells incubated for 3-5 minutes at 37 °C, 5% CO2 to detach the monolayer from the flask 
surface. Upon cell detachment an equal volume of serum containing growth medium was 
added to neutralise the trypsin activity, and the cell suspension was centrifuged at 1000 rpm 
for 5 minutes. The cell pellet was then re-suspended in the required volume of medium and 
the number of cells determined using a haemocytometer. For general passaging, cells were 
seeded at 1 × 106 in pre-warmed fresh culture medium in 75 cm2 tissue culture flasks.       
2.2.1.4. Sub-culturing suspension cells  
THP-1 cell cells were seeded between 2-4× 105 cells/ml in their specific medium (Table 2.1.6) 
and maintained by renewing the medium every 2 to 3 days. Expansion of cells was continued 
until they reached approximately 8 × 105 cell/ml; whereupon cells were collected by 
centrifugation at 1000 rpm for 5 minutes then cells resuspended with fresh pre-warmed 
media to 2-4× 105 cells/ml. Cells were incubated at 37 °C, 5 % CO2 in a humidified incubator 
in flasks in an upright position. Although, THP-1 can be cultured in vitro up to 25 passages, 
but for the propos of our study, cells were used within 10 passages after thawing to prevent 
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unwanted phenotypic drift, as it has been reported that THP-1 are sensitive for culture 
condition and it could alter their response (Aldo et al., 2013). 
2.2.1.5. Cell counting 
Routine cell counting was performed using a haemocytomer.  After harvesting cells, 10 µl of 
a cell suspension was added to a clean chamber and the number of cells counted using an 
inverted microscope with a 10 x objective. The number of cells were counted in four of the 1 
mm corner square, as shown in the figure 2.1 below, and then the average number of cells 
was multiplied by 104 to calculate the number of cells in 1 ml. If the sample was diluted before 
counting, then the number of cell/ml was multiplied by the dilution factor to calculate the 
final concentration of cells.  
The viability stain Trypan Blue was used to determine cell viability. Live cells can exclude the 
dye from the inside of cells and so only dead are stained blue under light microscopy. The 
number of cells within the haemocytometer was counted as before and cell viability was 
determined according to following formula:     
% Cell Viability  = 
number of blue (dead) cells
number of total cells 
 × 100 
Greater than 90% viable cells were used in each experiment.  
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Figure 2.1 Counting chamber haemocytometer. Cells were counted in larger squares (Red).      
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2.2.1.6. Cryogenic preservation and recovery 
For long-term storage, cells were re-suspended at a density of 1× 106 cells/ml in freezing 
medium (90% FBS, 10% DMSO), aliquoted into cryovials, and then placed into a cooling box 
(Mr.Frosty) at -80°C for overnight; this allows the temperature to be lowered slowly by 1°C 
/min prior to the cells being transferred to liquid nitrogen.  
To resurrect cells, cryovials containing cells were thawed rapidly in a 37˚C water bath.  The 
cells were slowly re-suspended in 9 ml pre-warmed medium and centrifuged at 1000 rpm for 
5 minutes to remove any remaining DMSO. Pelleted cells were re-suspended in 5 ml specific 
medium, placed in a T25 cm2 tissue culture flask and incubated at 37°C, 5 % CO2 in a 
humidified incubator as previously described. After 24 hours, non-adherent cells were 
removed and fresh medium was added.  
2.2.2.  Neutrophils isolation and culture   
2.2.2.1. Isolation of human neutrophils from peripheral blood using density 
centrifugation 
Density gradient centrifugation was used to isolate human neutrophils from whole blood 
according to the modified method by Ferrante and Thong (Ferrante and Thong, 1978). 
Periperhal blood was collected by venipuncture from healthy volunteers with written, 
informed consent (University of Sheffield Ethical Approval). Blood was anticoagulated with 
3.8% sodium citrate (1 part to 9 parts blood) and centrifuged at 400 x g for 20 minutes to 
separate the serum from cells. The upper serum layer was removed and the remaining blood 
cells were diluted 1:1 with HPSS without Ca+2 or Mg+2. The blood mixture was layered slowly 
over 20 ml of Ficoll-Paque and centrifuged at 400 x g for 40 minutes at room temperature 
with the break set to 0 to separate cells. Following centrifugation, the blood was separated 
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into four distinct layers (Fig. 2.2), the top three layers were carefully removed and discarded. 
Neutrophils are present within the lower polymorphonuclear granulocyte/erythrocyte layer 
at the bottom of the tube. Erythrocytes were lysed by hypertonic lysis using ice cold sterile 
water for 30 seconds followed by the addition of an equal volume of 1.8% NaCl to bring the 
suspension to an isotonic state.  Cells were centrifuged at 400 g for 15 minutes and the 
process repeated 3-4 times until all erythrocytes had been lysed. Neutrophils were then 
washed in HPSS without Ca+2 or Mg+2 and counted before being resuspended to the required 
cell density. Cell viability was assed using Trypan blue (2.2.1.5) and neutrophil viability was 
greater than 90% in all experiments. Neutrophil purity was evaluated by flow cytometry using 
the neutrophil-specific marker CD66b. The neutrophil sample was discarded if signs of 
neutrophil activation was observed at any step during the isolation process. 
2.2.2.2. MACSexpress separation for neutrophil isolation  
Figure 2.2 Schematic diagram for layers obtained after Density gradient centrifugation 
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This method allows for the fast isolation of neutrophils from whole blood without the need 
for density centrifugation or erythrocyte lysis. The procedure uses a cocktail of antibody-
conjugated beads that are specifically designed to bind to erythrocytes and other leukocyte 
populations besides neutrophils. The neutrophils are then purified by immunomagnetic 
negative selection. Venous blood was collected from healthy volunteers into EDTA 
anticoagulant tubes. The lyophilized antibody cocktail was prepared freshly before each cell 
separation according to manufacture instructions and the final cocktail mixture used in the 
recommended volume of whole blood. For example, for 8ml of blood, one vial of antibody 
cocktail was reconstituted in 2 ml buffer A by pipetting up and down 3 to 4 times. Then 2 ml 
of buffer B was added to the cocktail mixture and mixed gently for 3 to 4 times. Eight ml of 
blood was transferred into a 15 ml universal tube and mixed with 4 ml of the prepared 
antibody cocktail and incubated in a MACSmix tube rotator at approximately 12 rpm for 15 
minute. Following this incubation, the mixture removed from the rotator and placed in a 
magnetic field using a MACSexpress Separator without the lid for 15 minutes. The cell fraction 
was collected from the supernatant from the front wall of the tube and the supernatant 
containing the neutrophils was suspended in sterile HBSS without calcium and magnesium 
and the number of cells determined using a haemocytometer.  Cell purity of the isolated 
neutrophils was evaluated by flow cytometry using the neutrophil-specific marker CD66b and 
a yield of >95% neutrophils with >95% viability was used in downstream applications.  
 
 
2.2.2.3.  In vitro differentiation of neutrophils into an N1 or N2 phenotype  
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Directly after isolation, neutrophils were suspended at a concentration of 1×106 cells/ml; a 
portion of the suspension was removed for flow cytometric staining on naive (untreated) 
neutrophils. Neutrophils were stimulated with 25 ng/ml human recombinant TGF-β for N2 
polarisation (Fridlender et al., 2009), 100 ng/ml human recombinant INFγ for N1 polarization 
(van Egmond et al., 2001), 100 ng/ml human recombinant MIF or incubated with serum free-
conditioned medium collected from FaDu spheroids for 8 or 24 hours at 37°C, 5% CO2 under 
humidified conditions. Untreated cells were incubated under the same conditions and used 
as a negative control.  At the end of incubation period, the neutrophil condition medium was 
collected and centrifuged at 1000 rpm for 10 minutes to remove cell debris.  The supernatant 
was then filtered through a 0.2 μm filter, aliquoted and then frozen at -70oC for later analysis. 
Cell pellets were collected and resuspended in FACS buffer analysed by flow cytometry to 
measure the expression of N1 or N2 markers as described in section 2.2.9.7. 
2.2.2.4. Cytospin preparation and staining  
The morphological properties of treated neutrophils were studied using light microscopy.  
Cells were resuspended in HBSS with 1% BSA to aid cell adherence to microscope slides. One 
hundred µl of a 2.5×105 cell suspension was loaded into a cytospin funnel and centrifuged 
onto Superfrost slides. The slides were left to air-dry overnight and then stained with 
haematoxylin and eosin (H&E).  
 
 
2.2.3. Culture of multi-cellular tumour spheroids (MCTS)  
2.2.3.1. Tumour spheroid culture 
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FaDu MCTS were generated from single cell suspensions using the liquid overlay technique 
(Carlsson and Yuhas, 1984). Tumour cells were prevented from adhering to the tissue culture 
plastic by covering each well of a 96-well plate with a layer (100 μl/well) of 1.5% agarose in 
serum-free media and allowed to dry at room temperature for 1 hour. Pre-coated agarose 
plates stored inverted at 4 °C for use for up to 8 weeks. FaDu cells were cultured as 
monolayers, harvested as described in 2.2.1.4 and re-suspended at 1× 105 cells/ml in culture 
medium, then 100 μl of the cell suspension was added to each well of a pre-warmed agarose-
coated plate and incubated at 37˚C, 5% CO2 for 6-7 days (unless otherwise stated). Tissue 
culture medium was replaced every 2 days by adding 100 μl of fresh medium to each well and 
then removing 100 μl medium. The size of the resulting spheroids was measured using 
Axiovision software (Zeiss) to obtain a growth curve.  
2.2.3.2.  Generation of MCTS conditioned medium  
Media conditioned by FaDu MCTS was generated for the analysis of secreted cytokines, 
chemokines and growth factors and to stimulate neutrophils. To generate FaDu MCTS 
conditioned medium day-6 MCTS were washed three times with serum-free RPMI and 
incubated with or without TNF-α (50 ng/spheroid) at 37˚C in a 5% CO2 incubator for 5 hours. 
Condition media was collected, centrifuged at at 1000rpm for 10 minutes to remove cell 
debris, filtered through a 0.2 μm, aliquoted and then stored at -70oC for later analysis. 
 
 
2.2.3.3.  Neutrophil and monocyte Infiltration into FaDu MCTS 
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Day-6 FaDu MCTS were stimulated with 50 μl TNF-α (final concentration 50 ng/spheroid) in 
serum-free media and spheroids incubated overnight. The following day MCTS were washed 
with serum-free RPMI media three times. Freshly isolated neutrophils or THP-1 cells were re-
suspended in 10 ml pre-warmed serum-free RPMI containing a final concentration of 2 μM 
CellTracker GreenTM and incubated for 45 minutes at 37˚C, 5% CO2, after which a 500µl of FBS 
was added and the cells centrifuged at 1000 rpm for 5 minutes. The cell pellet was re-
suspended in serum-free RPMI and incubated for another 15 minutes at 37˚C, 5% CO2. Cell-
tracker-labelled neutrophils were counted and re-suspended at 6×105 cells/ml; 50 μl of cell 
suspension were added to each well containing a single FaDu MCTS and incubated for 
increasing lengths of time at 37˚C in a 5% CO2 incubator to allow neutrophil infiltration. In 
some experiments, neutrophils were pre-exposed to synthetic CXCR2 antagonist AZ-
10397767 (25 nM) or SB-265610 (100 nM) and/or CXCR4 antagonists AMD3100 (500 ng/ml) 
or FaDu spheroids were pre-incubated with MIF antagonist ISO-1 (4,5-Dihydro-3-(4-
hydroxyphenyl)-5-isoxazoleacetic acid methyl ester) at concentration of 500 µM for 1 hour 
prior to being added to the assay. DMSO was added as a vehicle control and incubated for the 
same length of time. 
At the end of assay, MCTS were collected in a 25 ml universal tube and culture media 
collected, filtered and stored for further analysis (see section 2.2.3.1). FaDu MCTS were then 
washed three times in PBS to remove non-infiltrated neutrophils and individual spheroids 
were placed in microtubes in the presence of 300 μl of 0.25% trypsin/EDTA solution for 10 
minutes. MCTS were disaggregated by flicking the microtube, then 700 μl of media was added 
to neutralize the effect of the trypsin/EDTA. Disaggregated MCTS were centrifuged at 5,000 
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rpm for 2 minutes, after which the cells were re-suspend in 300 μl 1% paraformaldehyde and 
stored in the dark at 4˚C until analysis by flow cytometry.  
2.2.3.4. Collecting, fixing and processing MCTS for immunostaining    
MCTS were collected in 25ml universal tubes, then, after the MCTS had settled to the bottom 
of the tube, excess media was removed and the spheroids were washed with PBS 3-4 times. 
After final wash MCTS were fixed with 10% PBS-buffered formalin overnight; then after 
transferring to a flat bottomed plastic embedding tray, the excess fixative was removed and 
the MCTS were embedded using a solution of 2% agarose and 4% formaldehyde (the solution 
was slowly added so as not to disturb the MCTS). The agarose was allowed to set before 
placing in a cassette and then paraffin-wax embedding. Using a microtome, 5 μm sections of 
embedded MCTS were cut, placed onto Superfrost glass slides and dried for later analysis.  
For frozen sections, spheroids were embedded in optimum cutting temperature (OCT) 
medium and rapidly frozen using dry ice or liquid nitrogen. Ten μm sections were cut, placed 
onto Superfrost glass slides and dried prior to store at -80˚C for later analysis. 
2.2.4. Functional assays 
2.2.4.1.  Migration assay  
Neutrophils migration towards chemoattractants or CM was tested using a 48-well micro-
chemotaxis chamber and the number of cells migrated through a porous membrane during a 
specified period of time was assessed by flow cytometry.  Chemokines or control were diluted 
in serum-free RPMI supplemented with 0.1% BSA (filter- sterile) with 1% antibiotics and 28 μl 
added to the lower wells of the chamber and overlaid with a nitrocellulose membrane filter 
(3 μM pore size). After the upper part of chamber was assembled, 50 μl of neutrophil cell 
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suspension (1×106 cells/ml) was added to the upper wells and chamber incubated for 3 hours 
at 37˚C in a 5% CO2 incubator. At the end of incubation period, non-migrated neutrophils were 
removed from the upper wells by tapping the chamber on clean tissue and the content of the 
lower wells were transferred to micro-tubes containing 300 μl of 1% paraformaldehyde for 
further analysis by flow cytometry (see section 2.2.9.2). Chemoattractant used were: CXCL1, 
CXCL5, CXCL8, MIF and fMLP at varying concentrations or buffer alone as a control. 
 
2.2.4.2. Cell viability assay (MTT)  
This assay was applied to test the cytotoxicity of ISO-1 on FaDu cells by measuring the 
metabolic activity of these cells as a surrogate marker for viability. Briefly, cells were 
harvested as described in section 2.2.1.3 and seeded at 4,000 cells per well in a 96-well plate. 
Then 10 µl of a solution of ISO-1 or vehicle control (DMSO) at double the desired final 
concentration was added to the cells and incubated for 2, 24, 48, and 72 hours. At the end of 
incubation time, cells were washed with PBS and 100 μl fresh medium added. MTT solution 
was prepared by dissolving 0.5 mg/ml Thiazolyl Blue Tetrazolium Bromide (MTT) powder, in 
PBS and 100 µl of the MTT solution was incubated with the cells for 2 hours. The mitochondrial 
dehydrogenases of living cells can reduce the yellowish MTT dye to an insoluble formazan 
(dark blue). The blue crystals formed were solubilized by the addition of 50 µl acidified 
isopropanol and the intensity of the colorimetric reaction measured using a plate reader at 
540 nm with correction readings taken at 630nm. Reading were normalized to a control 
sample of untreated (100% viable) cells.   
2.2.5. Molecular assays  
2.2.5.1.  RNA extraction  
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Total RNA from cell pellets was isolated using Bioline Isolate RNA mini kit, according to the 
manufacturer’s instructions.  Briefly, cell pellets were lysed and filtered by centrifugation for 
1 minute at 11,000g. Then an appropriate amount of 70% ethanol was added to the 
homogenized lysate to improve binding of the RNA to the silica-based membrane of the spin 
column during centrifugation. Complete removal of genomic DNA was achieved by incubation 
with DNase I for 15 minutes. Column-bound RNA was washed three times and eluted in 
RNase/nuclease-free water. The concentration and purity of the isolated RNA was measured 
using a NanoDrop spectrophotometer and only RNA samples with high-purity (A260/A280 ratio) 
more than or equal to 2.0 were used for complementary DNA preparation and qPCR analysis. 
2.2.5.2.  Complementary DNA (cDNA) preparation 
Single stranded cDNA synthesized from total RNA was achieved using High Capacity cDNA 
Reverse Transcription kit, according to manufacturer’s instructions. In this protocol, 300 ng of 
total RNA was reverse transcribed per reaction containing the following reagents: 
Component Volume/Reaction(µl) 
10 ✕ RT Buffer 2 
25 ✕ dNTP Mix (100 mM) 0.8 
10 ✕ RT Random Primers 2 
MultiScribe™Reverse Transcriptase 1 
Nuclease-free water 5.2 
Sample RNA (300 ng) 9 
Total per Reaction 20 
 
Samples were then loaded in a thermal cycler and recommended protocol was followed as 
instructed below.  At the end of the run, reverse transcription reactions were stored at -20 ˚C 
for qPCR.  
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                                   Step 1              Step 2             Step 3         Step 4  
Temperature  16 °C  42 °C  85 °C  4 °C  
Time  10 min  120 min  5 min  ∞  
 
2.2.5.3. Quantitative polymerase chain reaction (qPCR) 
Quantitative detection of target genes (MIF, VEGF) was achieved using pre-designed 
TaqMan® primers. In each of 96-well plate, a mixture of target gene (labelled with FAM 
reporter) and suitable reference control (labelled with VIC reporter) were added to the 
following mixture of reagents: 
   
Reagents µl/well 
Master Mix (life Technology) 5 
TaqMan®gene’s primers 0.5 
Endogenous control primers  
 
0.5 
cDNA 0.5 
Nuclease-free water 3.5 
Total volume  10 
Each sample was run in triplicate in the 96-well plate and negative control (no cDNA) sample 
was run for quality control. PCR plates were centrifuged briefly before loading into the ABI 
7900HT Fast Real-Time PCR machine with the following thermocycle settings: 
Initial hold at 50˚C for 2 minutes, DNA Polymerase Activation at 95˚C for 10 minutes, followed 
by 40 cycles of Annealing and Extension at 95˚C for 15 second, 1 minute at 60˚C, respectively.                      
The relative quantification comparative delta threshold cycle (ΔCT) value was used to 
calculate fold change gene expression using the 2ΔCt  equation.  
2.2.6. Immunoassays  
69 
 
2.2.6.1. Chemokine/cytokine protein arrays 
Human cytokine array panel A (ARY005, R&D system) was used to screen conditioned medium 
generated from FaDu MCTS, according to manufacturer’s instruction. In this assay, different 
antibodies have been spotted in duplicate on nitrocellulose membranes. Conditioned 
medium was mixed with biotinylated detection antibodies prior to loading to the BSA-blocked 
membrane. At the end of incubation period, captured proteins were visualized using 
chemiluminescent detection using hyper-film. The relative expression levels of each cytokine 
were determined by densitometry using Quantity One software (Biorad, CA, USA). Here, the 
intensity of each dot was measured by drawing a circle around its circumference and 
comparing its intensity to the negative control. 
 
2.2.6.2. Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA was used to measure the levels of MIF, VEGF, CXCL8 in the conditioned medium 
collected from various experiment according to the manufacturer’s instructions. Wells of a 
96-well plate was coated with the recommended concentration of capture antibody and 
incubated at room temperature overnight. The following day, unbound antibody was 
removed and nonspecific binding sites blocked with a BSA-containing solution before 
samples/standards were incubated for 2 hours at room temperature. Unbound protein was 
removed by washing with wash buffer and the recommended concentration of biotinylated-
detection antibody was incubated for 2 hours. Finally, horseradish peroxidase (HRP)-
conjugated streptavidin was added to each well for 30 min at room temperature followed by 
TMB substrate and the colorimetric reaction was measured using micro-plate reader set to 
450nm and 540nm for correction.  The reading at 540nm was subtracted from the reading at 
450nm before averaging the reading of each samples/standards. A standard curve was 
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created using Deltasfot software by generating four parameter logistic (4-PL) curve fit and the 
concentration of target protein was obtained from standard curve.  
2.2.7. Immunohistochemistry  
2.2.7.1. De-waxing of tissue  
IHC was used to detect the presence of a cell specific marker in tissue sections. Paraffin-
embedded tissue was sectioned (5 µm) and mounted onto adhesive SuperFroset slides. 
Complete removal of paraffin was achieved by treating the slides with two changes of Xylene. 
Then the tissue was rehydrated through descending concentrations of ethanol (100%, 95%, 
75%) before endogenous peroxidase sites were blocked using 3% H2O2 diluted in methanol 
for 15 minutes. The sections were washed in water in preparation for antigen retrieval.     
2.2.7.2. Antigen (Epitope) retrieval methods  
Methylene bridges formed during the tissue fixation process can mask the antigen binding 
site. These antigen sites can be ‘un-masked’ using a variety of treatments; each treatment 
being dependent on the primary antibody used. For many antibodies heat-induced epitope 
retrieval (HIER) is the method of choice but different buffers may be used in this process. For 
the anti-BrdU antibody used in this study acidic antigen retrieval (AAR) using 10 mM 
anhydrous citric acid (pH 6) buffer was used to denature DNA and permit the access of anti-
BrdU antibodies to the previously incorporated BrdU label.  In contrast, a basic sodium citrate 
buffer (pH 6) was used for other antigen retrieval methods. For both buffers, 0.5% Tween-20 
was added to enhance antigen un-masking. The antigen retrieval solution was pre-heated to 
95°C and slides were immersed in buffer for 15 minutes. The buffer was then removed from 
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the steamer and slides allowed to cool to ambient temperature for approximately 15 minutes 
before being transferred to PBS with 0.05% Tween 20 (TBS). 
2.2.7.3. Detection of neutrophils in MCTS   
Neutrophils within MCTS were identified using the neutrophil-specific marker, CD66b (also 
known as carcinoembryonic antigen-related cell adhesion molecule 8) . Following fixation and 
antigen retrieval using sodium citrate buffer (see section 2.2.7.2), tissue sections were 
incubated overnight at 4°C with normal horse serum to block non-specific binding sites. The 
following day, serum was removed and 4 µg/ml mouse monoclonal anti-human CD66b or 
Isotype control diluted in TBS buffer was added to each slide and incubated for 60 minutes at 
room temperature. After washing the unbound antibody three times with TBS, biotinylated 
anti-mouse secondary IgG antibody from vector kit (VECTOR Ltd, Peterborough, UK) was 
added for 30 minutes at room temperature. The advantage of using a biotinylated antibody 
is to amplify the staining signal by formation of an avidin-biotin complex.  After washing with 
TBS a solution of streptavidin-conjugated HRP was added and incubated for 30 minutes at 
room temperature. Colour was developed using the DAB chromogen from Vectorstain and 
the reaction was stopped by washing in distilled water. Slides were counter-stained with 
Haematoxylin, 0.1% acid alcohol, Scott’s tap water, dehydrated in ethanol (95% then 100%) 
and then dipped in xylene, prior to mounting in DPX and coversliping.  
2.2.7.4. Immunolocalization of CD66b and MIF in OSCC tissue sections  
The detection of neutrophils in human biopsy tissue sections using CD66b was carried out as 
described in section 2.2.7.3. However, in this protocol, an alkaline phosphatase detection 
system was used according to manufacturer’s instructions and Vector Red substrate was used 
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to localize the neutrophils in tissue sections by incubating in substrate for 30 minutes to allow 
red/magenta colour development. The reaction was stopped by washing the slides in TBS 
buffer followed by rinsing in water. For dual staining the sections were incubated for 60 
minutes at room temperature with normal horse serum before the addition of biotin-
conjugated monoclonal mouse anti-human MIF antibody (Biotin anti-Human MIF) at a 
concertation of 25 μg/ml.  Mouse IgG at the same concentration was used as a control. 
Sections were incubated overnight at 4°C and washed three times with TBS. Next, the sections 
were incubated with streptavidin-conjugated HRP for 30 minutes at room temperature, 
followed by TBS washes and then colour development with DAB chromogen for 10 minutes. 
The reaction stopped by washing the slides in distilled water before slides were counter-
stained with haematoxylin and mounted as described previously.  
2.2.7.5. MIF staining of FaDu Tumour Xenografts   
The expression level of MIF in both treated (Ly6G & ISO-1) and control (PBS) groups of FaDu 
xenograft murine models were examined in tissue sections using a polyclonal rabbit anti-
human MIF antiserum. Slides were de-waxed and treated with sodium citrate buffer for 
antigen retrieval (see section 2.2.7.1 and 2.2.7.2). Tissue sections were blocked with normal 
goat serum for 60 minutes at room temperature before the addition of 1:50 diluted anti-MIF 
antiserum diluted in neat goat serum or a rabbit serum IgG Isotype control and the slides 
incubated overnight at 4 °C. The following day, the slides were washed in TBS and then 
incubated with secondary biotinylated goat anti-Rabbit antiserum from Vectastin Elite kit as 
per the manufacture guidelines, followed by colour development using DAB chromogen. The 
remaining procedure was carried out as in section 2.2.7.3.  
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For this study, a semi-quantitative approach was applied using a modified ʽquickscoreʼ 
method (Detre et al., 1995). The main factors considered in this method is the staining 
intensity of the tumour cells within sections corresponding to 0 = no staining, 1 = week 
staining, 2 = moderate staining and 3 = intense staining.  The second factor is the proportion 
of positive (brown) cells in each field of view that is scored from 0 to 4 (0 = no cells positive, 
1 = 1-25% of cells, 2 = 26-50% of cells, 3 = 51-75% of cells and 4 = 76-100% of cells). All the 
slides were examined under low power (10 x magnification) and scored by an oral pathologist 
(Dr Keith Hunter). The intensity score was multiplied by the proportion of positive stained 
cells to give an overall score for each section.   
2.2.7.6. Bromodeoxyuridine  and CD31 dual labelling to identify proliferating cells and 
the endothelium in sections of FaDu tumour xenografts 
Actively proliferating cells in each of the treated (ISO-1, anti-Ly6G) and control group was 
detected using anti-BrdU antibody (sheep polyclonal anti-BrdU HRP). Mice were injected with 
100 mg/kg of the thymidine analog, BrdU, (see section 2.2.2.10) that is incorporated into 
newly synthesised DNA, while the endothelial marker CD31 was used to evaluate the 
presence and number of blood vessels in the same section. Following sample preparation 
(section 2.2.7.1), antigen retrieval was by HIER in 10 mM citric acid (section 2.2.7.2), then 
tissue sections were incubated with normal rabbit serum to block non-specific sites for 1 
hours at room temperature. Samples were then incubated with rat anti-human CD31 or rat 
IgG isotype for 24 hours at 4°C. Slides were washed in TBS and the ABC alkaline phosphatase 
detection system was used as per the manufacture instructions. Vector Red substrate was 
used to visualise the immunoreactive areas by incubating with substrate for 30 minutes 
before the reaction was stopped by incubating slides in TBS buffer then water.  Sections were 
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blocked again with normal rabbit serum for 30 minutes and then directly labelled with HRP-
conjugated anti-BrdU antibody diluted at 1:20 in TBS or Sheep IgG isotype control overnight 
at 4°C. Sections were then incubated with Streptavidin-HRP for 30 minutes, followed by 
incubation with DAB chromogen substrate for 10 minutes. The reaction was stopped by 
washing in water and the samples counterstained with haematoxylin prior to mounting in 
DPX and coversliping as described previously.  
2.2.7.7. Image analysis of MPO immunostained HNSCC tissue section  
MPO-immunostained whole sections were scanned automatically using an ACIS® inverted 
research microscope at 40 x magnification. These images of can be digitally visualised using 
the associated software. In the image analysis, MPO+ neutrophils were defined as cells with 
dark brown staining and this colour selection was maintained for analysis of all images. For 
analysis of tumour sections, a circle representing 40 x in diameter (0.53mm) were randomly 
placed in each area of interest. Eight individual fields of view were found to be the minimum 
number required to minimize data variation (see section3.4.3). The number of neutrophils in 
each of the following areas within the sections were measured automatically using image 
analysis software: (1) invasive front of the tumour (2) tumour stroma (3) tumour body and (4) 
areas of necrosis (Fig. 2.3)  
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2.2.8. Immunofluorescence staining 
2.2.8.1. Staining of hypoxic areas in MCTS 
The presence of hypoxia (low oxygen concentration) in MCTS was determined using the 
hypoxic marker, Pimonidazole hydrochloride (PIMO). PIMO was diluted 1:200 in pre-warmed 
serum free medium and 10 µl added to each well containing an MCTS and incubated for 2-3 
hours at 37°C. At the end of the incubation period, MCTS were collected, washed in PBS and 
snap-frozen as describe in section 2.2.3.4. MCTS were then cyrosectioned into 6 µm sections 
onto Superfrost slides and fixed in cold acetone (4°C) for 10 minutes. Sections were washed 
in PBS before the addition of rabbit anti-PIMO antisera, diluted at 1:20 in TBS with 0.1% 
bovine serum albumin (BSA), and incubated for 1 hour at room temperature.  The sections 
were further washed before incubation with Texas red-conjugated secondary antibody for 
30-45 minutes at room temperature. Slides were washed twice in cold TBS and nuclei 
Figure 2.3 Representative example for evaluation of MPO+ immunostaining in 
paraffine-embedded HNSCC section. Distribution of MPO+ cells was evaluated in four 
tumour compartments; tumour invasive (blue circle), tumour invasive (black circle) and 
tumour body (Green circle) by selecting eight random filed per area 
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counterstained with DAPI for 2 minutes. Finally, slides were washed with TBS and mounted 
with ProLong Gold anti-fade, coverslipped and left to cure for 24 hours in dark before being 
analysed by fluorescent microscopy.    
2.2.8.2. Immunolocalization of monocyte/macrophage, neutrophils and endothelium in 
FaDu tumour xenografts 
OCT-embedded frozen tumours were cut into 6µm thick sections and placed on super-
adhesive slides.  Sections were warmed to room temperature and washed for 5 minutes with 
PBS prior to blocking with normal rabbit serum for 30 minutes at room temperature. Serum 
was removed and 100 µl of antibody cocktail (see table of antibodies in section 2.1.5) or 
isotype control were applied and incubated for 30 minutes at room temperature in the dark. 
Slides were then washed three times in TBS, 5 minutes each in duration. After the final wash, 
sections were counterstained with 5µg/ml DAPI diluted TBS for 2 minutes, then rinsed in 
excess TBS. ProLong Gold Anti-fade mountant was applied to slide to avoid loss of 
fluorescence signal during analysis performed with a PerkinElmer UltraView spinning disc 
confocal microscope at 488 nm excitation (F4/80-Alexflour 488; green), or mixed gas argon-
krypton laser at 568 nm (Ly6G-PE; yellow green) and 647 nm (CD31-APC; red) excitation and 
UV laser, at 355 nm (DAPI, deep blue) with the appropriate emission filters. 
2.2.8.3. Image analysis of immunofluorescence-stained tumour xenografts sections  
To quantify the number of infiltrated neutrophils, macrophage and blood vessel density in the 
fluorescently stained xenograft sections, 10 random fields for each tumour section were 
captured using a PerkinElmer confocal system with a 10 x objective. The images were acquired 
as Z-stacks and captured using Volocity software (version 6.3). Images were analysed by 
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thresholding the images and measuring intensity and area of fluorescence in mm3 per 
microscopic field that was then converted to pixel density for each wavelength.  
2.2.9. Flow Cytometry 
2.2.9.1. Analysis neutrophil viability and purity  
The purity of neutrophils isolated from whole blood was determined by flow cytometry based 
on expression of the neutrophil-specific cell surface marker, CD66b. Cells washed in FACS 
buffer twice, and re-suspended in 100 µl of ice-cold FACS buffer containing 2.5×105 cells. 
Neutrophils were incubated with appropriate concentration (1:50) of APC-conjugated CD66b 
and incubated for 30 minutes on ice in the dark. Cells were washed with cold FACS buffer and 
the viability of purified blood neutrophils assessed using LIVE/DEAD™ Fixable Blue Dead Cell 
Stain Kit. This dye reacts with intracellular amines in cells with compromised cell membranes 
resulting in a strongly fluorescent intensity in dead cells compared to live cell populations.  
Cells were washed with protein/azide free-PBS and re-suspended in 1 ml of PBS.  Then 0.25 
µl of freshly reconstituted dye was added to the cell suspension and incubated at room 
temperature for 30 minutes. Cells were then centrifuged, washed with 1 ml PBS, fixed with 
300 μl of 1% paraformaldehyde and kept in 4˚C until flow cytometry was performed. To 
achieve gating based on viable cells only, cells were killed by heat-shock where cells were 
incubated for 5 minutes in a water bath at 70 °C and then transferred to ice for 5 minutes. 
Then untreated cells were mixed with the heat-shock treated cells at a 1:1 ratio and the 
viability dye added as described above. 
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2.2.9.2. Flow cytometric analysis of neutrophil chemotaxis using celltracker  
A FACS Calibur or ATTUNE was used to analyse migration of neutrophils toward control media 
or media containing various chemoattractants. The contents of the lower wells of a 48-well 
Boyden chamber were collected and fixed in 300 μl 1% paraformaldehyde (as described in 
section 2.2.2.4). The forward incidental light scatter (Fsc) and side incidental light scatter (Ssc) 
detectors were set to values that optimised visualisation of granulocytes. A threshold was set 
on the Fsc detector to exclude small sub-cellular particles from data acquisition. Samples were 
then acquired for a set time of 30 seconds. The number of events registered by the flow 
cytometer during this time was used as a measure of relative chemotaxis rate of neutrophils 
from the upper wells across the membrane to the lower wells of the Boyden chamber 
(Tazzyman et al., 2011). 
 
 
( A )  ( B )  ( C )  ( D )  
Figure 2.4 Dot plot show gating strategy applied after neutrophils isolation. Other leukocyte 
populations were removed by negative selection (A), followed by single cell gating (B) and 
exclusion of dead cell (C) and neutrophils were selected using CD66b+ marker (D).   
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2.2.9.3. ICAM-1 expression by FaDu cell  
FaDu cells were seeded at 5×105 cells/well in 6 well plates and allowed to adhere at 37˚C in a 
5% CO2 incubator. After 24 hours incubation, the medium was removed and 2 ml of TNF-α 
containing medium (50 ng/ml), a pro-inflammatory cytokine known to induce the expression 
of ICAM-1 (Chiu et al., 2004), was added and the cells incubated overnight. The following day, 
media was removed and replaced with fresh media with or without TNF-α for 5 hours and 
incubated at 37˚C in a 5% CO2 incubator after which conditioned media was collected and 
stored at -20˚C for analysis by ELISA. Cells were washed twice with PBS prior to removal from 
tissue culture plates by addition of 750 μl non-enzymatic cell dissociation solution for 15 
minutes at 37˚C. The effect of cell dissociation solution was neutralized by the addition of an 
equal volume of medium to each well and the cell suspension centrifuged at 5000 rpm for 2 
minutes to the pellet cells. Each sample was then re-suspended in 50 μl of mouse anti-human 
ICAM-1 or mouse IgG1 control antibody (10ug/ml) in FACS buffer (PBS + 0.1% BSA + 0.1% 
sodium azide) and incubated on ice for 45 minutes. Excess antibody was then removed by 
washing with 1 ml FACS buffer followed by centrifugation at 5000 rpm for 2 minutes. The 
supernatant was discarded and the cell pellets re-suspended in 50 μl of anti-mouse IgG Fab2 
fragment R-PE antibody diluted 1:50 in FACS buffer and incubated on ice for 30 minute in the 
dark. Finally, cells were washed as before and cell pellets re-suspend in 300 μl, 1% 
paraformaldehyde and kept at 4˚C until flow cytometry was performed. 
Expression of ICAM-1 on day 6 FaDu spheroids was detected by disaggregating 3 spheroids 
from each treatment with 300 μl of non-enzymatic cell dissociation solution for 15 minutes 
at 37˚C; then 700μl of media was added and cells centrifuged at 5000 rpm for 2 minutes to 
pellet cells. The cells were re-suspended in 50 μl FACS buffer and 50μl of mouse anti-human 
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ICAM-1 or mouse IgG1 control, as described previously. Excess antibody was removed by 
addition of 1 ml FACS and then centrifuged at 5000 rpm for 2 minutes. The supernatant was 
discarded and the cell pellets re-suspended in 50μl of Alexa Fluor® 488 goat anti-mouse IgG 
followed by incubation on ice for 30 minutes in the dark. Finally, cells were washed as before 
and cell pellets re-suspended in 300 μl, 1% paraformaldehyde and kept in 4˚C until flow 
cytometry was performed. 
2.2.9.4. Flow cytometric analysis of neutrophil/monocyte infiltration to MCTS  
Dissociated spheroids (as described in section 2.2.3.3) containing neutrophils or monocytes 
were analysed by flow cytometry. The cell population was sorted according to forward scatter 
(Fsc) and fluorescence to allow differentiation between immune cells (neutrophils or THP-1 
cells) and tumour cells (Fig. 2.5 -A&B). Each sample was collected until the flow cytometer 
had registered 10,000 events and then the data stored and analysed using CellQuest™ (Becton 
Dickinson) software. For analytical purposes, and after making sure the detector was 
optimised to visualise both cell populations, a mixture of labelled neutrophils or THP-1 cells 
and tumour cells were plotted as Fsc against fluorescence and a gate was placed around green 
fluorescent neutrophils only. This gate was applied to all of experiential test groups and the 
number of events represented as % infiltration. 
2.2.9.5. CXC receptor expression on whole blood  
Expression of CXCR receptors (CXCR1, 2 and 4) were stained on neutrophils, monocyte and T 
cells from isolated whole blood anti-coagulated with a 1 in 10 dilution of 3.8% sodium citrate. 
200 µl of whole blood was added to Eppendorf tubes and mixed with 100 µl of FACS buffer 
containing CXCR1, CXCR2, CXCR4, CD66b, CD14 or IgG mouse control antibody (final 
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concentration 10 µg/ml), and the cells incubated at room temperature for 30 minutes. Cells 
were washed twice with 1 ml FACS buffer and centrifuged at 5000rpm for 2 minutes. After 
removal of supernatant 50 µl of R-phycoertherin-conjugated anti-mouse antibody was added 
to each tube or directly R-phycoertherin-conjugated CD3 antibodies and cells incubated for 
30 minutes on ice in the dark. Cells were washed and RBC lysed by the addition of 1 ml FACS 
lysis buffer and incubated for 10 minutes at room temperature in the dark. Cells were 
centrifuged as before and the lysis step repeated until the removal of all erythrocytes. Finally, 
cells were re-suspended in 300 μl 1% paraformaldehyde and kept on ice until flow cytometry 
was performed. For each sample 10,000 events were collected. Three populations 
corresponding to granulocyte, monocyte and lymphocyte sub-populations were distinguished 
by flow cytometry based on their forward (Fsc) and side scatter (Ssc) characteristics. During 
analysis of each of the receptor a gate was set around the required cell population based on 
expression of a cell specific marker (CD66b = neutrophils, CD14 = monocytes, CD3 = T cells) 
(Fig. 2.6); then the relative median fluorescence intensity was obtained after subtracting IgG 
background fluorescence.  
2.2.9.6. Analysis of necrosis and apoptosis  
Neutrophil cell death by apoptosis and necrosis after exposure to ISO-1 were determined 
using flow cytometry. Neutrophils were isolated (section 2.2.2.1) and reconstituted at 1×106 
cells in media containing 10 nM recombinant MIF. Cells were then treated with ISO-1 or 
vehicle control (DMSO) at equivalent concentrations of 0.05 μM 0.5 μM, 5 μM, 50 μM, 500 
μM or 5000 μM for 24 hours at 37˚C. After incubation, cells were pelleted by centrifugation 
at 6000 rpm for 2 minutes, washed with ice cold PBS and labelled with Annexin V-FITC that 
binds to phosphatidylserine (PS) of cells undergoing apoptosis while propidium iodide (PI) 
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enters permeabilised cells and binds to the DNA of necrotic cells according to manufacturer's 
instructions. Cells were analyzed using a LSRII cytometry (BD Biosciences) equipped with Cell 
Quest software for cells acquisition and data analysis. 
 
2.2.9.7. Multicolour phenotypic characterization of polarized neutrophils  
Immediately after incubation with polarising agents (see section 2.2.2.3) cells were washed 
once with ice cold FACS buffer and resuspended in 100 μl FACS buffer at final concentration 
of 2.5×105 cells/test.   Cell markers were classified into four groups based on antibody 
fluorochrome availability and expression levels; CXCR receptor (CXCR1, CXCR2, CXCR4), 
adhesion molecules (CD62-L, ICAM-1), CC receptor (CCR5) and Fcγ receptor (CD64).   A cocktail 
of antibodies at optimized concentrations (table below) was added to neutrophils to a final 
volume of 100 μl, in addition to 2.5 µl neutrophil specific marker CD66b-APC for each tube. 
Annexin V-FITC  
P
I 
Figure 2.5 Analysis of ISO-1 traeted neutrophils using Annexin V and Propidium Iodide (PI).   
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Unstained cells were used as negative control and stained cells were used as florescence 
minus one (FMO) controls for each of the four groups for cell gating and to exclude any 
spectral overlap due to use of multiple fluorochromes. Cells were incubated at 37 ˚C for 1 
hour for CCR5, while all other antibodies included in the panel were incubated on ice for 30 
minutes.  At the end of incubation period, cells were washed once with 1 ml FACS buffer and 
then with protein/Azide free-PBS before being re-suspended in 1 ml of PBS.  Then, 0.25 µl of 
freshly reconstituted LIVE/DEAD™ Fixable Blue Dead Cell dye was added to cell suspensions 
and incubated with cells for 30 minutes on ice. Cells were then pelleted by centrifugation and 
washed with 1 ml PBS before fixation with 300 μl of 1% paraformaldehyde. Cells were kept at 
4˚C until flow cytometry was performed. 
 
Table 2.1. Reagents used to identify N1 and N2 polarised neutrophils. All antibodies were 
purchased from eBioscience, +++ = strong expression, ++ = moderate expression, +/- = weak 
expression, - = no expression  
2.2.9.8. Compensation for multicolour flow cytometric experiments 
Specificity  Fluorochrome Ab clone Dilution/
100 µl 
Staining 
condition  
Expression 
on Blood 
neutrophils  
CXCR1(CD181) FITC eBio8F1-1-4 2.5 µl 4 ˚C +++ 
CXCR2 (CD182) PE eBio5E8-C7-
F10 
2.5 µl 4 ˚C +++ 
CXCR4 (CD184) PE-Cyanine7 12G5 2.5 µl 4 ˚C + 
ICAM-1 (CD54) PE YN1/1.7.4 2.5 µl 4 ˚C +/- 
L-Selectin (CD62L) FITC  2.5 µl 4 ˚C +++ 
CCR5 (CD195) PE NP-6G4 1.5µl 37˚C +/- 
Fc γ receptor 1 
(CD64) 
FITC 10.1 2.5 µl 4 ˚C - 
CD66b APC G10F5 2.5 µl 4 ˚C ++ 
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Compensation controls were used to determine the extent of fluorochrome spectral overlap 
in all detectors using two types of beads; BDTM CompBeads for each of the fluorochrome 
labelled antibodies used in the study or ArC™ Amine Reactive Compensation Beads for 
LIVE/DEAD™ staining according to manufacture instructions. Firstly, the unstained cell sample 
was run through LSRII Cytometer (BD Biosciences) with a three-laser (blue/red/violet) 
configuration, to set up the voltages for each of the fluorescence channels used. Then, tubes 
containing the BDTM CompBeads with attached fluorochrome-conjugated antibodies were run 
on the flow cytometry and the gate was adjusted on a single bead population. Then, using a 
histogram plot, a gate was placed around the negative and positive bead population for each 
of the fluorochromes used. Finally, spectral overlap values were converted by mathematical 
algorithms within the instrument software (DB FACSDiva software) to yield accurate 
compensation values.  
2.2.9.9. Gating and analysis of multicolour flow cytometry  
Cells were firstly gated using FSC and SSC, followed by single cell gating and then positive 
selection of live cells (Fig. 2.5). Neutrophils were gated using the neutrophil-specific marker 
CD66b (APC) and then expression of target cell surface markers on the neutrophil population 
was examined after adjusting the gating using the FMO control. The median fluorescence 
intensity (MFI) of the target population was compared to controls and normalized as follows: 
Normalized MFI    =    
Median fluorescence intensity (MFI) of positive staining
Median fluorescence intensity (MFI)of unstained sample
 
 
2.2.10. Murine tumour xenografts model   
Male CD1 nude mice aged 8-weeks, were purchased from Charles River, UK. All mice were 
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kept in ventilated cages with food and water provided and maintained in pathogen-free 
conditions in the Field Laboratories, Veterinary Services Unit, Medical school, University of 
Sheffield. FaDu cells, were suspended in PBS (pH 7.4) at a density of 5 × 107 cells/ml and each 
animal received a subcutaneous (S.C) injection of 5 × 106 cells (100 μl). Once xenografts were 
established, tumours were measured every third day using measuring callipers and tumour 
volume calculated based on modified ellipsoidal formula = (length × width2)   
Tumours were allowed to grow for 3 days and mice were assigned randomly into groups (n = 
5 per group) before beginning the treatment schedule (Fig. 2.8). The control group received 
Intraperitoneal (i.p.) injections of 100 μl PBS three times a week over a 3 week period, with 
the treatment groups receiving either 200 µg anti-Ly6G in PBS or 100 μl ISO-1 twice weekly at 
20 mg/kg by the same route. For all groups, tumour volumes were monitored regularly, and 
the experiment ended 3 weeks after treatment or when tumours reached the maximum 
permitted size (15 mm diameter). To assess FaDu tumour cell proliferation, mice were 
injected i.p with 100 mg/kg BrdU for 1 hour before being Schedule 1 culled.   
Blood sample was collected from cardiac puncture and stored at -80°C for further analysis. 
Tumours were removed and divided into two; one section was placed into labelled microfuge 
tubes and snap-frozen in OCT, then transferred to -80°C for further analysis. The other half of 
the tumour was fixed in 10% PBS-buffered formalin and paraffin-wax embedded for 
immunohistochemical analysis (section 2.2.7.5 & 2.2.7.6).   
86 
 
 
2.2.11. Statistical analysis  
All experiments were repeated a minimum of three times and results are expressed as mean 
± standard deviation (SD) or median ± 25-75% quartile ranges (min and max) unless otherwise 
stated. Data was subjected to normality testing and statistical significance was evaluated 
using an unpaired Student’s t-test (parametric) or Mann-Whitney U test (non-parametric) to 
test the difference between two variables and one-way ANOVA (parametric) of Kruskal–Wallis 
test (non-parametric) for multiple variables. p-values of ≤ 0.05 were considered statistically 
Figure 2.6 Experimental design of xenograft murine model. CD-1 nude mice subcutaneously 
with FaDu cells and tumours allowed to grow before treatment start. Mice received 
Intraperitoneal dose of vehicle (PBS), anti-Ly6G (200 µg) and ISO-1 (20 mg/kg) for period of 
three weeks.  BrdU were injected one hour prior to culled schedule. 
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significant. All statistical evaluation was performed using GraphPad Prism software 
(GraphPad Prism software, CA, USA). 
2.2.12. Ethics 
Ethical approval for the use of volunteer’s peripheral blood in this study was approved by The 
University of Sheffield Ethics Committee. All volunteers participated in the study with written, 
informed consent. Use of archival tumour tissue was permitted with National Ethical Approval  
(08/S0709/70) and the isolation and use of normal oral keratinocytes was permitted with 
National Ethical Approval (09/H1308/66).  All animal experiments were conducted in 
accordance with the UK Home Office Regulations under the Animals (Scientific Procedures) 
Act 1986 and the awarded project licence number under which these protocols were 
performed is PPL:40/3424 (Dr Munitta Muthana). In addition, the University of Sheffield 
Animal Welfare & Ethical Review Body approved all the in vivo experiments performed in this 
study.  
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Chapter 3: Histological localization of Tumour-Associated 
Neutrophils in a cohort of patients with head and neck squamous 
cell carcinoma 
3.1. Introduction  
Several clinical studies have shown that TAN are associated with poor patient prognosis in a 
variety of human tumours including renal cell carcinoma (Jensen et al., 2009b), hepatocellular 
carcinoma (HCC) (Kuang et al., 2011), non-small cell lung cancer (Ilie et al., 2012), gastric 
adenocarcinoma (Zhao et al., 2012), colorectal carcinoma (Rao et al., 2012) and melanoma 
(Jensen et al., 2012). To date, few studies have examined the presence of TAN in HNSCC. Wan 
et al (2014) observed high levels of TAN in squamous cell carcinoma of the tongue whilst 
Trellakis and colleagues demonstrated that patients with advanced stage HNSCC tumours (T4) 
displayed higher levels of neutrophil infiltration compared to early stage T1 and T2 tumours 
and that levels of TAN related to poor patient prognosis (Trellakis et al., 2011). These studies 
examined TAN enrichment within the body of the cancerous epithelium, often termed 
tumour nests. However, tumours do not solely consist of tumour nests but also contain large 
areas of stromal tissue that is comprised of fibroblasts and blood vessels that surrounds the 
tumour epithelium. Moreover, the tumour epithelium itself can be sub-divided into the 
invasive front (the region of the tumour that invades into the stromal tissue) and the tumour 
body. In oral cancer, tumour cells at the invasive front of the tumour (IFT) have been found 
to behave differently from those within the tumour body. For example, cells located at the 
IFT have been shown to have a high proliferative activity (Piffko et al., 1997) and display more 
aggressive characteristics that are important for tumour spread and metastasis (Bànkfalvi and 
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Piffkò, 2000). The different areas within a tumour create distinct tumour microenvironments 
that may have different capacities to recruit leukocytes and so it is possible that neutrophil 
recruitment is not evenly distributed within tumour tissue.  For example, Kuang et al showed 
that 72 cells/field were detected in the peri-tumoural stroma and only 8.7 cells/field were 
present in the cancer nests in HCC (Kuang et al., 2011). Moreover, these peri-tumoural 
neutrophils were exclusively found to express MMP-9, a known inducer of angiogenic 
regulatory molecules, which stimulate the angiogenesis of adjacent tumour cell.  These data 
suggest that TAN within different tumour locations may experience different stimuli leading 
to the generation of different phenotypes or alerted responses that may have profound 
effects on tumour invasion or progression. However, to date, little is known about the spatial 
distribution of TAN in HNSCC. Based on this it was hypothesised that the microenvironment 
within different tumour sites will cause TAN to be preferentially recruited to some sites more 
than others and that neutrophil-tumour cell interactions at these sites could influence tumour 
behaviour and as a result clinical outcome.  
3.2. Aims 
To evaluate the number and location of TAN within biopsies of HNSCC tumour tissue using 
immunohistochemical staining for TAN to enable an investigation of their distribution pattern 
in each of the following areas:  invading front of tumour, tumour stroma, tumour nest and 
necrotic tumour areas.  
 
 
3.3. Methods 
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The presence of neutrophils in normal healthy oral mucosa compared to tumour tissue was 
evaluated in biopsies from 9 normal healthy volunteers and 9 patients with clinically 
diagnosed HNSCC. Sections were stained with neutrophil-specific anti-CD66b antibody (as 
described in section 2.2.7.4) and the number of neutrophils per high power field (HPF = x40 
magnification) were counted in five random field. Cells within blood vessels were exclude 
form the analysis.  
To examine TAN within specific tumour areas, neutrophils within paraffin-wax embedded 
histological tissue sections from 30 HNSCC patients were stained using an anti-MPO antibody 
followed by visualization using DAB chromagen. Tissue sections were digitally scanned using 
a 40x objective attached to an ACIS inverted research microscope. The images of section were 
visualised on screen and tumour areas were selected manually by placing circles of 40 x in 
diameter (0.53mm) in different regions of the tumour tissue. Cumulative means were 
calculated from eight individual fields of view to minimize data variation. Images were 
analysed digitally using ACIS III image analysis software (see section 2.2.7.7 for detailed 
method).   
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3.4. Results  
3.4.1. The presence of neutrophils in normal and cancer tissues 
In general, CD66b cells were not detected in the epithelium or stroma of normal healthy tissue 
(Fig. 3.1) (for patients demographic see appendix I, table 1). In contrast, in the HNSCC tissue 
sections the presence of CD66b cells were detected mainly in tumour stroma tissue with a 
median number of 3.6 TAN/HPF. In contrast, fewer CD66b neutrophils were detected within 
the tumour epithelium (median number 0.4 TAN/HPF). There was a statistical significant 
difference between the number of CD66b neutrophils in the tumour epithelium compared to 
normal epithelium (p=0.0294) and also the number of CD66b cells in the tumour stroma 
compared to the normal stroma (p <0.0001) (Fig. 3.2) 
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Figure 3.1 Detection of CD66b+ neutrophils in healthy and cancer tissue. A panel of nine 
normal and nine HNSCC tumour tissue sections were screened for the presence of neutrophils 
using the neutrophil-specific marker CD66b (A) Healthy tissue form buccal mucosa shows 
stratified squamous epithelium (NE) with underlying lamina propria or connective tissue (NS) 
(B) moderately differentiated OSCC of the tongue with tumour epithelium (TE) cells, 
containing large nuclei and increased nuclear-to-cytoplasmic ratio (left top). Dense 
Lymphocytic infiltration was observed in tumour stroma (TS) with neutrophils infiltration 
(bottom left, arrows). 
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Figure 3.2 Detection of CD66b neutrophils in healthy and cancer tissue. A panel of nine 
normal and nine HNSCC tumour tissue sections were screened for the presence of neutrophils 
using the neutrophil-specific marker CD66b. The number of neutrophils was counted per high 
power filed (HPF)(40x). Non-parametric Mann Whitney test was used to show a statistically 
significant difference between the number of CD66b neutrophils in TE compared to NE 
(*p=0.0294) and number of CD66b cells in the tumour stroma compared to the normal stroma 
(****p <0.0001) 
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3.4.2. Study of MPO localization patient demographics   
In this study, pathological specimens from 30 patients with HNSCC were examined. These 
patients comprised of 10 (30%) women and 20 (70%) men with an average follow up time of 
47.03 months (range 6-144 months).  The average age of the patients was 60 (ranging 
between 37-83). The HNSCC lesions were located in retromolar trigone (RMT) (n=5, 16%), 
floor of mouth (FOM) (n=15, 50%), anterior tongue (AT) (n=6, 20%), posterior tongue (PT) 
(n=2, 6.6%), hard palate (HP) (n=1, 3.3%) and soft palate (SP) (n=1, 3.3%). Lymph node 
involvement was observed in all the cases.  Thirteen (42.3%) cases had a single lymph node 
metastasis (N1), 8 (26.6%) with metastasis in multiple lymph nodes (N2b), 3 (10%) with 
metastasis in the bilateral or contralateral lymph nodes (N2c) and 5 (16.6%) with distant 
metastasis. Five (16.6 %) patients had recurrence, 3 (10%) patients had a secondary primary 
tumour, and 6 (20%) of the patients the data were not available.  During the follow-up, 1 (3%) 
patient died of disease (DOD), 6 (20%) died of an unrelated cause (DUR), 14 patients (46.6 %) 
were disease free (DF) and 2 (6.6%) patient was alive with disease (AWD).   
Patient characteristics are summarized in  appendix I (Table 2), while the full details about the 
patients that participated in this study have been published previously (Alkureishi et al., 2010).  
3.4.3. Selection of observation field 
In order to obtain the number of areas of assessment for each parameter required to 
minimise variation, cumulative means plots were constructed. Presence of MPO+ neutrophils 
was evaluated in four tumour compartments; (a) invasive front of tumour, (b) tumour stroma, 
(c) tumour body, (d) necrosis centre of tumour, if present. These areas were defined 
accordingly:  
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The invasive front (IF) is the periphery or the leading edge of the tumour as it progress.  It 
comprises tumour tissue and breaks through the sub-epithelial connective tissue. Tumour 
Stroma (TS) is the connective tissue separating the solid tumour nest and is often 
accompanied by a desmoplastic stromal reaction and a dense inflammatory infiltrate (Fig. 3.3-
A). The tumour body (TB) is located in central tumour areas where the characteristic of 
squamous carcinoma is well represented by irregular cell shape (Polygonal), enlarged 
cytoplasmic membrane and large nucleus with multiple prominent nucleoli (Fig. 3.3-B). Area 
of necrosis were identified by fragmented cells, nuclear shrinkage and cellular debris 
surrounded by tumour epithelium. The necrotic centre (NC) was associated with dense 
infiltration of leukocytes (fig. 3.3-C)    
Figure 3.3. Photomicrographs of HNSCC tumour section shows the distribution of MPO+ 
cells within tumour. The presence of MPO+ neutrophils was observed throughout the tissue 
(left, Scale bar=1mm ) and the localization of MPO+ neutrophils was evaluated in four tumour 
compartments;  (A) Red dots line separated tumour invasive (TI) area from tumour stroma 
(TS) (B)Tumour body (C) and necrotic centre. The numbers of MPO+ was quantified in each 
of the patient in the cohort (right,Scale bar=200µm). 
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Cumulative means plot analysis showed that the variability in most assessments was 
minimised upon assessing eight individual HPF, selected at random in the area of interest (Fig. 
3.4) and so in subsequent analysis each area within a histological section was evaluated with 
8 HPF per area of interest for each patient tumour section in order to obtain representative 
data. 
3.4.4. Spatial Distribution of MPO+ Neutrophils in Histological Sections of HNSCC  
Figure 3.4 Cumulative means required for adjusting the variability for the image analysis to 
quantify the intensity of MPO immunostaining. Cumulative means calculated by adding up 
the mean of each view field to the sum of its predecessors as you go along, for the eight fileds 
to determine the value that lie above or below, for example, M1= number of cells in field 1 + 
number of cells in field 2.   
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The distribution of neutrophils in HNSCC was investigated in paraffin-embedded tissues 
sections from 30 HNSCC patients. The presence of neutrophils was visualized by 
immunostaining and the number of MPO-positive cells was quantified by digital image 
analysis and in each of the selected area and presented as mean number of cells ± SEM/HPF.  
The presence of MPO+ cells was detected in all cases, except one, throughout the tissue.  
Figure 3.5 shows that there was much variation in the number of neutrophils in each tumour 
site analysed in each patient. The tumours of some patients contained numerous neutrophils 
at some or all of the tumour sites analysed whilst others contained very few. When the 
median values of all the patients were calculated and compared the presence of MPO+ 
neutrophils in the different tumour compartments showed that the number of MPO+ cells in 
the tumour stroma (TS) was 366±109 cells/HPF and 172±62 cells/HPF was detected in the 
tumour invasive front (TI). The number of MPO+ cells in tumour body (TB) was only 37±10 
cells/HPF. In contrast, the number of MPO+ cells observed in the centre of the necrotic tissue 
was 3059±602 cells/HPF (Figure 3.6).  Thus, the density of MPO+ cells in necrotic tissue (NC) 
was significantly higher in comparison to TI, TS and TB (P<0.0001) (Fig. 3.6-C). To evaluate the 
prognostic importance of MPO+ cells in each of the tumour compartments, the data was 
analysed according to patient survival status (Fig.3.7). No correlation was found between 
overall survival and number of MPO+ cells in any of the tumour areas analysed. This result 
was expected as this pilot cohort was too small to allow robust survival analysis.  
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Figure 3.5 Individual patient analysis for MPO+ neutrophil infiltration in different tumour 
compartments showing variation between the cases.  Number of MPO+ neutrophils 
calculated in eight fields in each of selected area presented as box and whisker blot with 
minimum and maximum number of MPO+ cells detected.  X-axis represent the 30 individuals 
included in this study.  The band inside the box represent the median.   
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Figure 3.6 A screen for distribution of MPO+ neutrophils in HNSCC tissue. High MPO+ 
neutrophils was observed in tumour stroma (A) and invasive front of the tumour tissue (B), 
whereas the presence of MPO+ neutrophils toward in the tumour body was scarce (D). The 
accumulation of MPO+ neutrophils was predominant within the necrotic tissue (C). Scatter 
plot of the thirty patients involved in the study showing the median differential localization 
of MPO+ neutrophils in selected areas of tumour, the intensity of MPO+ cells was significantly 
different in the necrotic centre compared to TI, TS, TB using one way ANOVA (p< 0.0001). 
Scale bar = 50 uM 
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Figure 3.7 Analysis of infiltrated neutrophils in HNSCC tissue. Paraffin-embedded OSCC 
samples were stained with MPO and distribution of MPO+ neutrophils were evaluated in each 
of invading front of tumour (TI) and tumour stroma (TS), tumour nest and necrotic areas 
according to patient’s survival show no significant difference (Students t-test)   
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3.4.5. Presence of necrosis associated with influx of high number of neutrophils  
Based on the above data, we predicted a correlation between presence of necrosis and 
number of neutrophils in tumour tissue. Large areas of necrosis were observed in 17 patients 
(57%) and this was associated with the influx of large number of neutrophils to the tissue 
(median number of neutrophils 944 cells/tumour) when compared to the 13 patients (43%) 
with no apparent necrosis where the number of neutrophils were significantly lower (median 
number of neutrophils 14 cells/tumour, P<0.01) (Fig. 3.8).  The reduction in number of 
neutrophils in the absence of necrosis was associated with better outcome, since 61.5% (n=8) 
of patients were free of disease, and 15% (n=2) were alive with disease and one patient died 
of an unrelated disease. On the other hand, the presence of neutrophils in patients with 
necrosis were associated with death in 35.5% (n=6), 35.5% (n=6) were free of disease while 
the survival for 5 (30%) patients were unknown. 
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Figure 3.8 MPO+ neutrophils level in necrotic areas in a cohort of biopsy tissue from HNSCC 
patients. Patients were grouped according to the presence (A and C) or absent (B and D) of 
necrotic tissue. Mann-Whitney U test was used to compare the statistical significance of 
intensity of the stain between the two groups (E).The infiltration index of MPO+ neutrophils 
in tissue with necrosis was significantly higher (median number of neutrophils 944 
cells/tumour) when compared to tissue with no necrosis (median number of neutrophils 14 
cells/tumour; p<0.001). 
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3.4.6. Association of MPO+ neutrophils with T stage  
Cases were classified into two groups according to T stage. Among the 30 patients studied 70% 
(n=21) had T1-T2 tumours and 30% (n=9) had T3-T4 tumours. Statistical comparison using 
Mann-Whitney U test was applied to evaluate the impact of T status on the distribution of 
neutrophils in tumour tissue. In general, the number of MPO+ cells present in the T1-T2 
tumour was slightly higher than T3-T4 lesion, although there was a no statistically significant 
difference in the MPO+ index in the tumour with median number of 16 cells/tumour versus 
9.5 cells/tumour, for T1-T2 and T3-T4 respectively (Fig. 3.9).  In addition, no significant 
difference was observed between late and early stage of MPO+ cells detected in the tumour 
stroma with median of 67 cells/tumour for T1-T2 group versus 54 cells/tumour for T3-T4 
tumours (Fig. 3.9-B). The lowest number of MPO+ infiltration was detected in tumour body 
with median number of 5.7 cells/tumour and 3 cells/tumour for T1-T2 and T3-T4, respectively 
(Fig. 3.10).   The data also showed an increased number of neutrophils MPO+ accumulated in 
the necrotic tissue of T1-T2 patients with median number of cells 677 when compared to late 
stage tumours (T3-T4) but once again this was not statistically significant (Fig. 3.9).  In 
conclusion, patients with T1-T2 tumour had abundant accumulation of neutrophils at the NC 
(2016 cells), which was significantly higher than neutrophils detected at TS (344 cells), TI (204 
cells) and TB (29 cells) (Fig. 3.10-A). On the other hand, patients with advanced stage (T3-T4) 
had fewer numbers of MPO+ cells detected in the tissue with similar pattern of distribution. 
The highest accumulation was observed in NC with mean value of 894 cells, followed by TS 
199.8 cells, very few in TI (65 cells) and almost no cells was detected at TB (18 cells) (Fig. 3.10-
B)  
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Figure 3.9 Analysis of MPO+ distribution according to T stage of disease.  There was a high 
infiltration index of MPO+ neutrophils observed in T1-T2 (n=21) patients in compared to T3-T4 
(n=9) and there was no significant difference in the number of MPO+ neutrophil infiltration 
between T1-T2 and T3-T4 lesions. Data are displayed as median +/- interquartile range.  Mann-
Whitney U test was used to calculate significant differences.   
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Figure 3.10 Frequency of MPO+ cells in each tumour compartment according to disease 
stage.  Multiple comparisons using one way ANOVA test was used to compute distribution 
of MPO+ cells at different stage of disease. Patients at early stage T1-T2 had more 
neutrophils accumulation at TI, TS, NC while patients with advance stage T3-T4 show no 
evidence of MPO+ cells in TB and very few in TI. However, the predominate accumulation of 
MPO+ cells was presented at NC of T3-T4, then in TS. Data are displayed as Median ± 
interqurtile range. *** p<0.0001, ** p<0.005, * p<0.05. 
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3.5. Discussion  
The concept of cancer related inflammation was raised as a new hallmark of cancer by 
(Hanahan and Weinberg, 2011) and emerging evidence has demonstrated the presence of 
large populations of inflammatory cells within the tumour microenvironment, including 
tumor-associated neutrophils (TAN).  
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As a tumour grows its complexity increases and it invades the surrounding connective tissue, 
often termed the tumour stroma, in which tumour cells are involved in cross-talk with the 
stromal cells.  The tumour neighbourhood includes a multitude of cells such as fibroblasts, 
pericytes, endothelial and immune cells. The communication between all these cell types has 
been shown to influence the tumour microenvironment such as oxygen tension, tissue 
necrosis, local inflammation and degradation and remodelling of extracellular matrix (ECM) 
leading to tumour angiogenesis (Curry et al., 2014). For this purpose, the distribution of 
infiltrated neutrophils in different HNSCC tumour compartments including invading front, 
stroma, tumour body and necrotic areas was examined.  
Despite the small study sample size, and the inability to perform Kaplan-Meier survival plots 
due to lack of clinical information, several important observations were noted. MPO+ 
neutrophils were present throughout cancer tissue samples with most of neutrophils 
accumulating in the stromal tissue and necrotic areas rather than in the tumour body. The 
number of neutrophils infiltrating into the necrotic foci was significantly higher than other 
areas, suggestes that neutrophils might be recruited to areas of necrosis under the influence 
of specific molecules. This feature was also evident at all stages of cancer progression, 
suggesting its prolonged importance over the life-span of a tumour. Like macrophages, 
neutrophils are innate immune phagocytes that are pre-programmed to engulf cellular 
necrotic debris in order to clear areas of cellular material during wound healing so it is 
reasonable that neutrophils are recruited to sites of necrosis to clear debris and so neutrophils 
could be directed to these necrotic sites under the influence of chemoattractants.  
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Evidence that necrotic cells can cause neutrophil accumulation has been observed in vivo. 
Injection of P388 necrotic leukemic cells in the peritoneal cavity in mice induced neutrophil 
infiltration into the site of injection via the production of chemokines KC and MIP-2, 
suggesting that neutrophils are attracted to tumours by necrotic cues (Tanimoto et al., 2007). 
Another study showed that necrotic but not apoptotic cells release both nuclear factor and 
secreted protein HMGB1, which has the ability to trigger inflammation and enable neutrophil 
recruitment to sites of tissue injury (Scaffidi et al., 2002). In fact, HMGB1 protein is responsible 
for the Mac-1-dependent neutrophil recruitment via the receptor for advanced glycation end 
products (RAGE) present on neutrophils (Scaffidi et al., 2002). Further investigation showed 
that deletion of HMGB-1 diminished the ability of necrotic tissue lysates to induce neutrophil 
migration but did not affect macrophage ability to migrate to HMGB-1 null tissue lysates. The 
HMGB-1 mediated neutrophils recruitment of was not dependent on CXCR4, as the use of 
small molecule inhibitors AMD3100 or neutralizing antibody did not inhibit the recruitment, 
whereas, deletion of RAGE on neutrophils, significantly reduced migration toward necrotic 
tissue lysate (Huebener et al., 2015). 
 However, it has been demonstrated recently that recruitment of neutrophils to tissue leads 
to what called as ‘inflammatory hypoxia’, where neutrophils can themselves evoke hypoxia 
by depleting sites of molecular O2 as result of reactive oxygen or nitrogen species generation 
(Campbell et al., 2014). Like other solid tumours, HNSCC usually develop a hypoxic 
microenvironment along with necrosis and this also imparts a negative prognostic factor and 
induces a more aggressive cancer phenotype (Swartz et al., 2015). Tumour hypoxia is 
developed as a result of the low oxygen tension in tissue, caused by high cellular demand and 
an inadequate supply of oxygen. Clinical studies have shown that the ‘hypoxic tumour volume’ 
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is now is an important prognostic factor in HNSCC (Dunst et al., 2003). Although there are no 
direct evidence that links the presence of neutrophils in hypoxic tissue in HNSCC but a very 
elegant study using a uterine cancer mouse model, showed that neutrophil recruitment 
occurred at early stages of tumour was associated with development of tumour hypoxia 
(Blaisdell et al., 2015). Other studies have shed light into the underlying mechanism of 
neutrophils homing to sites of localized hypoxia and necrosis.  Hypoxic tissue up-regulates the 
expression of vascular endothelial growth factor A (VEGF-A) which induces the trafficking of 
a specific subpopulation of circulating neutrophils that co-express VEGF receptor1 (VEGFR1), 
CXCR4 and Integrin Subunit Alpha 4 (CD49d). Their recruitment to VEGF-A foci was found to 
be dependent upon activation of VEGFR1 on neutrophils. However, when recruitment of the 
newly identified neutrophil population was inhibited by targeting CD49d in an in vivo model, 
not only was the number of neutrophils migrating to site of hypoxia affected significantly but 
also tumour angiogenesis was impaired (Massena et al., 2015). Of note, in response to 
hypoxia human neutrophils can survive longer in vitro and produce anti-apoptotic effect that 
is associated with up-regulation of hypoxia inducible factor HIF-1α  (Walmsley et al., 2005). 
This evidence supports the notion that neutrophils recruited to low oxygen tension area of 
tumours such as hypoxic and necrotic sites are able to live longer and be more likely detected 
than in other areas and potentially are likely to play a crucial role in disease pathogenesis. 
 
To date, among all studies evaluating the role of TANs from the standpoint of their histological 
localization in cancer tissue it has been shown that the presence of neutrophils either in 
intratumoural or peri-tumoural stromal was associated with poor outcome in various 
malignancies. To the best our knowledge, this is the first study identifying the presence of 
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increased number of neutrophils in necrotic areas compared to other tumour sites and 
demonstrates that patients without necrosis that have significantly lower number of 
neutrophils may have a better prognosis.     
When the distribution of TAN in relation to disease stage was assessed, results showed that 
most of the T1-T2 tumours displayed high numbers of neutrophils in most areas, except the 
tumour nest, whereas tumours at T3-T4 exhibited a lower degree of infiltration.  These 
findings contradicted those of Trellakis et al, (2011), Caldeira et al, (2015) who showed that 
patients with advance stage disease displayed a strong neutrophil infiltration (mean of 71) 
when compared to less advanced tumours (mean of 63) (Caldeira et al., 2015, Trellakis et al., 
2011a). Mouse models have been used to evaluate the localization of TAN at early and late 
stage of tumour growth. There was no difference in the percentage of TAN in early compared 
to later stage tumours of Lewis lung xenograft models, whereas a minor increase at later stage 
was observed in AB12 mesothelioma tumours. The distribution of TAN at the early stage was 
found mainly at the periphery of the tumour, while in more advance stage tumours TAN was 
seen in the tumour periphery and the central parts of tumour (Mishalian et al., 2013). 
In summary, this chapter has shown that neutrophils are recruited to HNSCC in large numbers 
and this occurs in both early and late stage tumours. More specifically, they are preferentially 
recruited to certain sites within tumours such as necrotic areas and this is undoubtedly in 
response to specific chemoattractant cues. There is now increasing evidence that TAN play a 
major role in tumour progression (Tazzyman et al., 2011) in many tumours including HNSCC 
by releasing tumour promoting factors or molecules that stimulate tumour angiogenesis. 
However, little is known about the specific molecules that recruit neutrophils form the 
peripheral blood to HNSCC. These are crucial molecules in directing the fate of neutrophils 
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and their discovery could pave the way for the generation of novel therapeutics. The following 
chapter will investigate the likely neutrophil chemoattractants that HNSCC cells generate and 
which of these are the most important for mediating TAN recruitment in HNSCC. 
  
113 
 
Chapter 4: Mechanisms driving neutrophil recruitment into head 
and neck tumours: in vitro analysis using a multi-cellular tumour 
spheroid model 
4.1. Introduction 
Data from the immunohistochemical analysis of HNSCC patient biopsies (Chapter 3) showed 
accumulation of neutrophils (TAN) in HNSCC tissues. This raises the question of precisely how 
neutrophils are recruited to these tumour sites. Two-dimensional (2D) cell culture models lack 
essential components of the complex tumour microenvironment such as tumour hypoxia, 
necrosis, gradients of nutrients and metabolites, and are therefore an undesirable option to 
represent tumours in vivo. The growth of cancer cells in a three-dimensional (3D) context that 
recapitulate the characteristic features of solid a tumour was made by Sutherland et al in 
1970s (Sutherland et al., 1971), and today these models are known as multi-cellular tumour 
spheroids (MCTS). In these models, aggregates of cells have been shown to mimic common 
properties seen in avascular tumours or intervascular micro-regions of solid tumours in situ. 
As MCTS grow to 200-500µm in diameter, they develop a central area of hypoxia as a result 
of insufficient supply of oxygen, nutrients and accumulation of waste products, and this 
further develops into necrosis when MCTS grow beyond 500 µm. In contrast, the well-
oxygenated rim of the MCTS typically contains large numbers of proliferative tumour cells 
similar to that seen in vivo (Sutherland and Durand, 1984, Groebe and Mueller-Klieser, 1991).  
Many research groups have employed the MCTS model in different tumour biology fields and 
there is overwhelming evidence that cells grown in 3D behave differently to those cultured in 
conventional 2D culture. For example, gene expression and protein profiling of cells cultured 
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in 3D was similar to that observed in a clinical sample than the same cells grown in 2D (Kumar 
et al., 2008b). Moreover, generation of a 3D placental vascular model by co-culturing three 
cells components,  (cytotrophoblasts, villous stromal cells and endothelial precursor cells) 
showed that cells cultured in a 3D system had structurally and morphologically similar 
phenotype to tissues from early placenta (Baal et al., 2009). For these reasons MCTS are now 
frequently used as pre-clinical screening systems in drug evaluation for many new anticancer 
therapies. For example, Hirschhaeuser et al used the MCTS system to test Catumaxomab, a 
trifunctional hybrid monoclonal antibody that binds to tumour cells via epithelial cell 
adhesion molecule (EpCAM), CD3 on T cells and antigen-presenting cells via the Fc receptor, 
thereby linking the three cell types together. Addition of Catumaxomab and peripheral blood 
mononuclear cells to an EpCAM-positive MCTS tumour model showed active tumour killing 
in a realistic 3D in vitro model compared to 2D models (Hirschhaeuser et al., 2009). This model 
also demonstrates the usefulness of MCTS when combined with leukocytes and provides an 
opportunity for the use of 3D methodologies to analyse the interaction of leukocytes with 
tumour cells in a realistic tumour microenvironment in vitro. Such models have been used 
previously to analyse the role of neutrophils in lung cancer (Tazzyman et al., 2011) but none 
have yet been established for use in HNSCC research.  
4.2. Aims 
The aim of the experiments outlined in this chapter were to firstly characterise the features 
of a HNSCC cell line grown as an MCTS (growth, morphology, expression of inflammatory 
molecules etc.) and then to use this model to identify specific factors responsible for the 
recruitment of TAN into HNSCC.  
4.3. Methods  
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MCTS were generated by an agarose over-lay technique (2.2.3.1) using a hypopharyngeal 
HNSCC cell line (FaDu). MCTS were grown in culture until day 6 and then analysed for features 
characteristically observed in avascular tumours in vivo (hypoxia, necrosis and proliferation). 
The release of factors by FaDu MCTS into the culture media was identified using a cytokine 
array (2.2.6.1). The optimum conditions for neutrophils isolated (2.2.2.1) from the peripheral 
blood of healthy volunteers and added to the MCTS either with or without stimulation with 
TNF-α (2.2.3.3) for different time points were assessed.  The infiltration of fluorescent-
labelled neutrophils into FaDu MCTS in presence or absence of receptor antagonists or small 
molecular inhibitors was quantified by flow cytometry (2.2.9.4).  
4.4. Results 
4.4.1. Culture of the head and neck cancer cell line FaDu as MCTS 
The use of in vitro 3D culture systems has been proposed as a valuable tool in cancer research 
that holds several advantages in comparison to monolayer cultures. Although tumour 
spheroids have been made from cancer cells of several tumour types, MCTS made from head 
and neck cancer cells have not been fully characterised. MCTS were generated from FaDu 
cells using the agarose overlay technique. A few hours after initial seeding the FaDu cells 
started to aggregate into small clumps in the centre of each well of the 96-well plate and 
began to adhere to one another. The cells formed a characteristic spherical shape over the 
first 24 hours with an average diameter of 694 μm (Fig. 4.1A). Over the next three days in 
culture the MCTS developed a uniform appearance and increased in size reaching an average 
of 731 μm in diameter at day 3 with very few cells seen unattached to the spheroid border. 
When observed using light microscopy, necrosis could be seen at day 3 (Fig. 4.1-A) as a darker 
area at centre of the growing spheroid and this continued to enlarge as the size of MCTS 
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increased in subsequent days of culture (Figure 4.1A). By day 6 the FaDu MCTS had reached 
a mean diameter of 937 μm and the size gradually increased to reach an average diameter of 
1482 μm by day 13. MCTS growth slowed by day 14 (1457 μm) to reach a maximum diameter 
of 1533 μm at day 15 (Fig. 4.1B). As the MCTS further enlarges the necrotic centre increases 
and the viable rim becomes smaller.  
 Upon histological analysis, the darker area at the centre of FaDu MCTS observed from day 3 
was confirmed as necrosis surrounded by a viable rim of tumour cells. Haematoxylin and eosin 
stained sections showed an expands area of necrosis over time to reach up to 90% of the 
diameter of the whole spheroid by day 15 with a corresponding shrinkage of the outer viable 
rim. As a result of the larger necrotic core, the spheroids become more fragile during the 
histological processing (Fig. 4.2)  
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Figure 4.1 Pharynx SCC cancer cell grows as MCTS in culture (A) Light microscopy 
images of FaDu MCTS in culture over a 15-day period (10x magnification), (B) 
growth curve of FaDu spheroids shows the mean diameter measurements from 
six spheroids ± SD. Scale bar =200µm (C) The diameter of the necrotic core (light 
blue) and the viable rim (dark blue) from FaDu MCTS were measured under light 
microscopy using Axiovision software. 
Figure 4.2 Representative images of haematoxylin and eosin-stained sections of FaDu 
MCTS showing necrotic centre and viable tumour cell rim at day 3 (A), day 6 (B) day 8 
(C), day 10 (D) day 13 (E) and day 15 (F). Scale bar = 200µm   
 ( C ) 
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4.4.2. FaDu MCTS as a model of avascular HNSCC tumours 
Tissue necrosis and hypoxia are characteristic features seen in most of solid tumours. The 
oxygen tension expressed as partial pressure of oxygen (pO2) within primary HNSCC tumour 
was measured 8.6 mmHg (Becker et al., 2002), whereas advance stage SCC was found to have 
even lower oxygen tension as low as ≤ 2.5mmHg which associated with poor prognosis 
(Nordsmark and Overgaard, 2000). Light microscopy suggests the presence of necrosis at the 
central area of FaDu MTCS from day 3. This was confirmed by histological analysis, which 
showed a necrotic focus at the centre of spheroid and tissue architecture breakdown that was 
the same as observed clinically (Fig. 4.3-A&B).  The presence of hypoxia within MCTS was 
measured using the hypoxia-sensitive dye PIMO (Raleigh et al., 1991). MCTS at day 6 were 
selected as these developed a necrotic core but still contain a large viable rim (295 µm) (Figure 
4.2-B). Fluorescence microscopy of PIMO-stained FaDu MCTS showed strong red fluorescence 
staining in the centre of the spheroid that then slightly decreased within the viable rim 
towards the periphery (Fig. 4.3-C). The presence of hypoxia around a necrotic area observed 
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in the MCTS was similar to that observed in HNSCC (Fig. 4.3-D).  Figure 4.3 shows proliferating 
cancer cells (Ki-67 positive cells) that were located in outermost part of the spheroid (Fig. 4.3-
E); an observation that was in line with the distribution of Ki-67 staining observed in a patient 
biopsy of HNSCC (Fig. 4.3-F).  
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4.4.3. Neutrophil infiltration into FaDu MCTS  
HNSCC section  
H&E 
PIMO 
Ki67 
MCTS 
Figure 4.3 Characterisation of in vitro MCTS as a model of avascular HNSCC tumours.  FaDu MCTS 
(A) and HNSCC tumour island (B) showing necrotic centres.  FaDu MCTS stained with pimonidazole 
(C) to demonstrate hypoxia as is commonly observed in HNSCC in vivo (D). Ki67-positively stained 
proliferating cancer cells (Brown) at the well-oxygenated periphery of FaDu MCTS (E) and a human 
biopsy tumour island (F).  Scale bar = 200. Patient biopsy slides were kindly provided by Dr Helen 
Colley. 
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To assess the ability of neutrophils isolated from peripheral blood to infiltrate HNSCC in vitro 
fluorescently-labelled neutrophils were co-cultured with FaDu MCTS (for 2, 5 and 20 h) in the 
absence or presence of 50 ng/ml recombinant human TNF-α (for 5 or 18 h) and infiltration 
measured by flow cytometric analysis of dispersed MCTS (as described in Fig. 4.19-A). TNF-α 
was used as a stimulant because HNSCC are known to be within a pro-inflammatory micro-
environment (Soylu et al., 1994) and this cytokine also regulates expression of adhesion 
molecule intercellular adhesion molecule-1 (ICAM-1) on epithelial cells (Burke-Gaffney and 
Hellewell, 1996).  Flow cytometric analysis showed that neutrophils infiltrated tumours in the 
absence of a pro-inflammatory stimuli but this was significantly (p<0.05) increased by addition 
of TNF-α (Fig. 4.4-B).  In fact, neutrophil infiltration for 2 h was markedly increased upon 
stimulation of FaDu MCTS with TNF-α for 5 h (10.8%) and 18 h (14.5%) compared to un-
stimulated FaDu spheroids (1.3%). Neutrophil infiltration after 5 h co-culture with FaDu MCTS 
was significantly increased after 5 h prior stimulation with TNF-α, reaching a peak of 15% 
compared to un-stimulated FaDu spheroids (2.1%). However, stimulation of MCTS with TNF-
α for 18 h resulted in a reduction in the number of infiltrated neutrophils (11.9%) after 5 h. 
Eighteen hours incubation of neutrophils with FaDu MCTS stimulated for either 5 or 18 h 
showed a reduced level of neutrophil infiltration reaching 10.4% and 11.1% respectively, 
compared to un-stimulated FaDu MCTS (2.6%). A similar trend was observed in all 
experiments (n= 4) although the infiltration rate varied slightly from donor to donor (Fig. 4.4-
B).  
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( B )  
Figure 4.4 Neutrophil infiltration into TNF-α-stimulated FaDu MCTS. (A) FaDu MCTS were 
incubated with fluorescently labelled neutrophils and number of infiltrated neutrophils was 
assessed by flow cytometric analysis.  Dot plot shows the gating around the fluorescently 
labelled neutrophils (FL-1) and the number of neutrophils in FaDu MCTS measured as % 
infiltration. (B) Bar chart of flow cytometric analysis shows stimulation of MCTS with TNF-α leads 
to significant increase of neutrophil infiltration into MCTS over time. One-way ANOVA was used 
to compute the difference in neutrophils filtration after with or without TNF-α stimulation. **** 
P< 0.0001. Data are mean of 3 FaDu MCTS per time point ± SD, and are representative of n=4 
independent experiment.  
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Neutrophil infiltration into FaDu MCTS at selected time points was confirmed by analysing 
frozen (Fig. 4.5A&B) and formalin-fixed, paraffin wax-embedded sections by 
immunohistochemistry (Fig. 4.5-C & D). These data show that neutrophil infiltration into 
MCTS is maximal under pro-inflammatory conditions upon treatment with TNF-α for 5 h 
followed by neutrophil infiltration for 5 h. Since neutrophils are recruited to tumours in vivo 
and MCTS in vitro, it was reasoned that this was due to increased expression of neutrophil 
specific chemotactic factors. Thus, the presence of chemo-attractants in the conditioned 
medium of MCTS was investigated.   
4.4.4. FaDu MCTS secrete neutrophil chemoattractants 
( A )                                                                       ( B )                       
 
 
 
 
 
 
 
( C )                                                                        ( D ) 
Figure 4.5 Neutrophil infiltration into FaDu MCTS. (A) Image of 6µM frozen section of 
day 6 FaDu MCTS showing infiltrated of MCTS with green fluorescently labelled (red 
arrows) neutrophils for 5 h (B) or FaDu MCTS alone. FaDu MCTS were immuno-stained 
for the neutrophil marker CD66b (Red, black arrows; (C) compared to control MCTS (D).   
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To identify factors present in FaDu MCTS responsible for neutrophil infiltration, FaDu MCTS 
were grown until day 6, and were either unstimulated or stimulated with TNF-α in the 
absence of presence of neutrophils and their conditioned medium collected after 5 h and 
analysed by multiplex cytokine array followed by densitometry (section 2.2.6.1). Among 36 
cytokines tested, data shows that unstimulated FaDu MCTS released several well-known 
neutrophil chemokines including CXCL-1 (Gro-α), CXCL-8 (IL-8) and CCL5 (RANTES) and these 
chemokines, particularly CXCL8, were increased by treatment with TNF-α with no further 
increase upon the addition of neutrophils. However, in both unstimulated and stimulated 
MCTS the most abundant protein released was Macrophage migration inhibitory factor (MIF). 
Other molecules released include IL-6, IL-23, IL-1 receptor antagonist (IL-1ra), INFγ and 
SerpinE1 also known as plasminogen activator inhibitor type-1 (PAI-1) (Fig. 4.6 and 4.7).   
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( A ) ( B ) ( C ) ( D ) 
Figure 4.6 Cytokine array analysis of FaDu MCTS conditioned media at day 6 (A) Control 
media alone (RPMI), (B) conditioned media from FaDu MCTS, (C) conditioned media from 
FaDu MCTS stimulated with TNF-α, (D) conditioned media from FaDu MCTS stimulated 
with TNF-α and infiltrated with neutrophils for 5 h. Each cytokine is duplicated with the 
one dot directly above the other and six positive controls can be seen, two at each upper 
corner of the membrane and two in the lower left corner. Each colured box highlights 
detected chemoattractant, from top left to bottom right are: RANTES (CCL5), IL-1ra (IL-
1F3), TNF- α, GRO-α (CXCL1), MIF, IL-6, IL-8 (CXCL8), SerpinE1 (PAI-1). A list of the 
cytokines detected by the arrays is provided in appendix II. 
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Immunohistochemical analysis was then performed to confirm the presence of the most 
abundant cytokines detected from the cytokine array; MIF and CXCL1 in sections of FaDu 
MCTS. Formalin fixed paraffin-wax embedded (FFPE) sections of day 6 spheroid were stained 
for MIF and CXCL1 according to the methods described in section 2.2.7.4. Microscopic analysis 
demonstrated expression of MIF protein throughout the spheroid with slightly increased 
expression around the necrotic centre (Fig. 4.8).  Similarly, expression of CXCL1 was observed 
throughout the spheroid confirming the array data (Fig. 4.8)   
 
Figure 4.7 Densitometry analysis of cytokine array data showing the difference in 
the level of molecules in conditioned media from FaDu MCTS, conditioned media 
from FaDu MCTS stimulated with TNF-α, conditioned media from FaDu MCTS 
stimulated with TNF-α and infiltrated with neutrophils for 5 hours compared to 
control media alone. 
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4.4.5. Expression of ICAM-1 on FaDu cells  
To be recruited to the tumour site, neutrophils must first leave the general circulation by 
extravasation up a chemoattractant gradient into tumour tissue. Once across the 
endothelium, neutrophils enter the tumour using the adhesion molecule ICAM-1 expressed 
on the epithelial cell surface and the integrin CD11a/CD18 on the neutrophil surface (Wu et 
al, 2001). As well as increased chemoattractants, the migration of neutrophils into MCTS may 
also require increased ICAM-1 expression. Therefore, the level of ICAM -1 expressed on the 
cell surface of FaDu cells cultured as monolayers or MCTS was tested using flow cytometry in 
the absence or presence of 50 ng/ml recombinant human TNF-α for 5 and 18 h. There was 
not a significant difference in ICAM-1 expression on the cell surface of FaDu cell monolayer 
after 5 h stimulation with TNF-α (median fluorescence 9.22) compared to un-stimulated 
controls (median fluorescence 6.3). However, the level of ICAM-1 was markedly up-regulated 
upon 18 h TNF-α stimulation (median fluorescence 36.85) (Fig. 4.9-A). Day 6 FaDu MCTS were 
disaggregated, labelled with antibodies raised against ICAM-1 or an isotype-matched IgG 
antibody (negative control) and then analysed by flow cytometry. After 5 h stimulation with 
IgG MIF  CXCL-1 
Figure 4.8 Immunohistochemical identification of MIF and CXCL1 expression in FaDu MCTS. 
6µM FFPE FaDu MCTS were immunostained using IgG control, biotin-conjugated monoclonal 
anti-human MIF antibody or anti-human CXCL1 antibody. Scale bar = 100 µm. 
128 
 
TNF-α, the expression level of ICAM-1 was not significantly different (median fluorescence of 
62) when compared to un-stimulated FaDu MCTS (median fluorescence of 78). However, the 
histogram plot for 18 h TNF-α stimulated FaDu MCTS showed a significantly (p<0.05) high 
level of ICAM-1 expression (median fluorescence of 97) and the presence of another 
population of cells expressing low levels of ICAM-1 (Fig. 4.9-B). This could be due cells at the 
outer surface of the spheroid encountering high levels of TNF-α and therefore expressing high 
levels of ICAM-1, whilst those on the inside of spheroid may not directly experience contact 
with TNF-α and express low levels of ICAM-1. Taken together these data suggest that when 
experiencing pro-inflammatory conditions FaDu MCTS increase expression of chemokines and 
adhesion molecules that are likely to be the reason for the increased neutrophil infiltration.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.6. Neutrophil migration to MCTS chemoattractants 
( A ) FaDu Monolayer ( B ) FaDu MCTS 
Figure 4.9 Flow cytometric analysis of ICAM-1 expression on FaDu monolayers and 
MCTS. Histogram overl y showing IgG negative con rol (black filled histogram), and 
ICAM-1 of un-stimulated FaDu (green), TNF-α stimulated 5 h FaDu monolayers and MCTS 
for 5 (red) and 18 h (blue) significantly increased the expression of ICAM-1 in FaDu 
monolayers (A) and FaDu MCTS (B). 
129 
 
The data from the cytokine array showed that FaDu MCTS express known neutrophil 
chemoattractants and MIF at high levels. Neutrophil migration towards recombinant forms 
of these proteins was performed (as described in section 2.2.4.1) to ensure their 
chemoattractant abilities and to test if MIF was able to act as a chemoattractant. In these 
experiments the bacterial-derived peptide, N-formyl-methionine-leucine-phenylalanine 
(fMLP) (which binds to the G-protein coupled seven-transmembrane formyl peptide receptor 
on neutrophils). Migration towards fMLP and CXCL8 yielded a typical bell-shaped curve with 
a peak of migration at 1 nM for both fMLP and CXCL8 (Fig. 4.10). Migration toward CXCL1 was 
dose-dependent up to 1000 nM, while migration towards CXCL5 peaked at 100 nM (Fig. 4.10). 
Interestingly, neutrophils migrated towards MIF with a classical bell-shaped response with 
peak migration at 10 nM. These data show that human neutrophils migrate towards classical 
neutrophil chemokines (CXCL8, CXCL1, CXCL5) as expected but also specifically migrate 
towards MIF.  
 
 
 
 
 
 
 
 
 
4.4.7. Chemokine receptor expression on neutrophils form whole blood  
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Next the cell surface expression of chemokine receptors on neutrophils (CXCR1 and CXCR2) 
was examined by flow cytometry. Although MIF was first described in the mid-1960s, the first 
identified cell surface receptor for MIF (CD74) was only discovered in 2003 (Leng et al., 2003). 
However, Dumitru et al (2011) showed that neutrophils do not express CD74, suggesting that 
MIF acts and functions through a different receptor. Molecular and cell transfection studies 
have suggested that MIF may bind to CXCR2, CXCR4 and/or CD44 (Bernhagen et al., 2007). 
Therefore, in addition to CXCR1 and CXCR2, expression of CXCR4 and CD44 was also measured 
on CD14-positive monocytes (Griffin et al., 1981), CD3-positive T cells (van Dongen et al., 
1987),  as well as CD66b-positive neutrophils (Torsteinsdóttir et al., 1999). 
Three distinct leukocyte populations were detected by flow cytometry based on size (forward 
scatter FSC) and granularity (side scatter SSC) from whole blood samples from healthy 
volunteers (Fig. 4.11). The most abundant cell population (high cell granularity, gated green, 
CD66b-positive) represents neutrophils, while the red CD14-positive region represents 
monocytes and yellow CD3-positive region represents lymphocytes. The expression of CXCR1, 
CXCR2, CXCR4 and CD44 in each of the three populations is represented in figure 4-12. Data 
were normalised to isotype control and are presented as median  fluorescent intensity 
(Fig.4.12). As expected, the expression of CD66b was highest on neutrophils (17036), when 
compared to monocytes and lymphocytes (7246 and 2208, respectively). CD14 was highly 
expressed on monocytes (44329) in comparison to neutrophils (8009) and lymphocytes 
(3369). Neutrophils were found to express abundant cell surface levels of CXCR1 (30289), and 
slightly less but still marked amounts of CXCR2 (11157), CXCR4 (6752) and CD44 (11617).  On 
the other hand, monocytes were found to express high levels of CD44 (39834) and abundant 
CXCR4 (11985), followed by CXCR2 (9443) with lower expression of CXCR1 (3215). CD3-
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positive T cells expressed low levels of CXCR1 (2793) but moderate levels of both CXCR2 and 
CXCR4 (3673 and 4871 respectively) as well as high levels of CD44 (33077).  These data show 
that neutrophils (and monocytes) express receptors for not only classical neutrophil 
chemokine but also MIF and these data provide an explanation as to why MIF caused 
neutrophil chemotaxis in vitro previously. 
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Figure 4.11 Flow cytometric analysis of receptor expression on human whole blood leukocyte.  
Dot plots show three populations (neutrophils, monocytes, lymphocytes) based on forward 
scatter (FSC) and side scatter (SSC) for size and granularity respectively from whole blood sample 
stained as describe in 2.2.9.5. CD66b/Neutrophils, CD14/Monocyte, CD3/T-Lymphocyte were 
used as specific cell markers for gating and histograms of CXCR1, CXCR2, CXCR4, CD44 surface 
expression for each of the three were compared to isotype control (black line). 
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4.4.8.  MIF is expressed at higher levels by FaDu MCTS than monolayer cultures 
0
10000
20000
30000
40000
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60000
70000
CD66b CD14 CXCR1 CXCR2 CXCR4 CD44
n
M
FI
Neutrophils
Monocyte
Lymphocyte
Figure 4.12 Expression of cell surface receptors on whole blood leukocyte populations by flow 
cytometry. Bar chart summarising the expression of CD66b, CD14 CXCR1, CXCR2, CXCR4 and 
CD44 on neutrophils, monocytes and T lymphocytes. Data are normalised median fluorescence 
intensity (nMFI) ± SEM and are representative of 3 patient samples (n=3). 
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Previous cytokine array densitometry and IHC data showed that MIF is highly expressed by 
FaDu MCTS but these methods are not fully quantitative. Therefore, MIF levels were assessed 
in conditioned medium from 2D and 3D FaDu culture by ELISA. FaDu were seeded at 
1×106cell/ml into T25 flask and allowed to adhere for overnight, then un-attached cell were 
removed and replaced media with serum free media and incubated for 24hours before 
collecting the CM for analysis. FaDu MCTS CM were generated as previously describe at 
2.2.3.2 and collected after 24hours incubation.  Strikingly, ELISA analysis revealed that levels 
of MIF was significantly (p<0.0001) elevated when FaDu were cultured as MCTS compared to 
2D monolayer cultures (576 pg/ml to 89 pg/ml).  A slight but not significant increase in 
expression of MIF was detected upon TNF-α-stimulation (637pg/ml) and MCTS infiltration 
with neutrophils (716pg/ml). Neutrophils secrete very low levels of MIF (56pg/ml) (Fig. 4.13-
B). 
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Figure 4.13 Quantitative measurement of MIF from conditioned media collected from FaDu 
cultured as monolayers or MCTS. (A) t test was used to compare the statistical significance of 
MIF protein level in serum free CM collected from FaDu grown in monolayer and Day 6 FaDu 
MCTS showed a significant increase in level of MIF protein (p<0.0001) in MCTS model (B) 
Stimulation with TNF-α or co-culture with neutrophils dose not stimulate the production of 
MIF from MCTS, while CM collected from NQ detected very low amounts of MIF release into 
media    
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4.4.9. MIF mRNA level in a panel of HNSCC cell line 
Thus far, this study has focussed on the FaDu cell line. However, to ascertain whether the MIF 
high expression observed in the FaDu ELISA data is a global head and neck cancer cell response, 
a panel of normal oral keratinocyte (NOK) and different types of HNSCC (tongue, HPV-, HPV+) 
were screened for gene expression of MIF. All the cells used in this analysis were cultured as 
monolayers as not all cell types can form MCTS.  Quantitative PCR demonstrated that 
although MIF expression was observed in NOK, MIF overexpression was detected in a panel 
of HNSCC.  Of note, the expression level of MIF differed between the tested cell lines, with 
the highest level detected in SCC89 (3), SSC72 (2.2), T5 (1.8), SCC2 (1.7), SCC4 (1.4) with fold 
increases compared to NOK. Surprisingly, the mRNA level of MIF detected from FaDu (0.9), 
SCC90 (0.7) and H357 (0.45) was low and almost the same as NOK (Fig. 4.14-A) showing that 
other cancer cells lines express more MIF than FaDu and that high MIF expression is a 
widespread response. HPV-negative cells generally displayed higher MIF expression levels 
than HPV-positive cells (Fig. 4.14-B) and expression in tongue cancer cells was varied with 2 
out of 3 cell lines showing high expression.  
 
 
 
 
 
 
 
 ( A ) 
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4.4.10. Hypoxia upregulates the expression of MIF in vitro 
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The data provided previously shows that MIF mRNA is highly expressed by HNSCC. In addition, 
IHC studies showed higher MIF expression around the necrotic centre of the MCTS and the 
results in Chapter 3 show that neutrophils are more abundant in the hypoxic/necrotic centres 
of tumours. Taken together these data suggest that expression of MIF may be regulated by 
hypoxia. Indeed, increased expression of MIF in response to hypoxia has been demonstrated 
in other cancers (Larsen et al., 2008). Therefore, a panel of HNSCC cells were subjected to low 
oxygen concentration (0.5% O2) and gene expression of MIF analysed by qPCR. VEGF, a 
cytokine known to be upregulated by hypoxia, was used as a positive control and β2 
microglobulin (B2M) was selected as a housekeeping gene for normalisation of gene 
expression as this gene has been found to be unaffected by hypoxia (Baddela et al., 2014). 
The gene expression for MIF mRNA was generally up-regulated in cancer cells subjected to 
hypoxia when compared to cells cultured in normoxic conditions, but no significant affect was 
observed in normal OK or immortalize NOK. In contrast, a significant increase of MIF mRNA 
expression was observed in H357 (P=0.0147) SCC2 (P= 0.0228) in compare to normoxic 
condition. Even more upregulation of MIF was observed in SCC4, SCC72 and SCC90 (P <0.0001) 
by hypoxia, while no significant difference was detected in FaDu (Fig. 4.15-A). Hypoxia is the 
main regulator of VEGF production in many cells (Buchler et al., 2003) and this was the case 
for all head and neck cells tested in the panel. As expected, the upregulation of mRNA for 
VEGF was detected in most of cancer cells, except H357, when culture under low oxygen 
tension. Highest level of hypoxic-induced VEGF detected in SCC4, SCC90 (P <0.0001), T5 (P= 
0.0140) FaDu (P=0.0045), SCC72 (P=0.0216), SCC89 (P=0.0061) and SCC2 (P= 0.0054) 
compared to cells cultured under normoxic conditions. Unlike MIF, the levels of VEGF 
detected from FaDu cells cultured under hypoxic conditions was significantly increase (Fig. 
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4.15-B), suggesting that MIF upregulation in FaDu may not be as responsive to hypoxia as 
other cancer cells.   
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Figure 4.15 Effect of hypoxia on expression of MIF on a panel of HNSCC. Cells were 
subjected to hypoxic (0.5% O2) or normoxic conditions (21% O2) overnight. The gene 
expression change in each of the tested cell were compared to normoxic cultured cells and 
expressed as fold change in gene expression. Multiple comparison using two-way ANOVA 
test was used to calculate the significant differences. Data are mean ± SEM from three 
independent experiments. * P˂0.05, ** P˂0.005, ***P˂0.0001 
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4.4.11. FaDu cells secrete more chemoattractants when cultured under hypoxic 
conditions. 
Results from the cytokine array showed that FaDu cells produce classical neutrophil 
chemokines (CXCL1 and CXCL8) and MIF. Moreover, MIF gene expression is increased by 
hypoxia and more neutrophils were observed in hypoxic/necrotic areas of HNSCC tumours. 
Therefore, it was reasoned that hypoxic HNSCC cells would produce more chemotactic factors 
and so have increased neutrophil chemotactic capacity. This was assessed by measuring the 
migration of freshly isolated human neutrophils towards serum-free conditioned medium 
generated from FaDu monolayers cultured under normoxic or hypoxic conditions for 24 h. 
The results shown in figure 4.16 indicate that conditioned medium from FaDu cultured in 
normoxic conditioned is chemotactic for neutrophils. However, a significant increase in level 
of neutrophil migration was observed with the conditioned medium from FaDu cultured 
under hypoxic conditions (0.5% O2), showing approximately 2.6 fold increase in neutrophil 
chemotaxis.       
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4.4.12. MIF protein level of in HNSCC tissue sections 
The data presented in this chapter so far has focussed on expression of MIF by HNSCC cell 
lines, in particular FaDu cells. To examine whether MIF over-expression occurs in HNSCC 
cancer, a screen of MIF expression in human HNSCC cancer tissue specimens was conducted 
by immunohistochemically analysis and compared to expression in healthy oral mucosa. The 
intensity of MIF stain was evaluated using a semi-quantitative quick scoring method 
(described in section 2.2.7.5). Low expression of MIF was detected in the basal layer of the 
stratified squamous epithelium in normal tissue (Fig. 4.17- A & B).  The staining intensity was 
significantly (p<0.05) increased in HNSCC epithelium, with abundant expression 
predominantly localized at the surface of tumour (Fig. 4.17- C & D).  In some of the cases 
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Figure 4.16 Migration of neutrophils toward FaDu condition media. Flow cytometric analysis 
of neutrophils migrated towards FaDu conditioned medium collected under normoxic (21% O2) 
or hypoxic (0.5% O2) conditions. The data is expressed as fold change in neutrophil migration 
compared to control media. One –way ANOVA show significant (*p<0.05) increase in migration 
towards hypoxic condition media was observed compared to normoxic conditioned medium or 
medium alone. Data are mean ± SD, n=3 independent experiments.    
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expression of MIF was variable between surface and deeper SCC although statistical analysis 
showed that that there were no significant differences.   
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n=9 
n=17 
n=8 
( E ) 
Figure 4.17 MIF protein expression in a cohort of HNSCC tissue biopsies. Paraffin-embedded 
samples from normal and HNSCC were stained with anti-MIF antibody and stain intensity 
evaluated using a quick-score method. Normal tissue displayed low expression of MIF in the basal 
layer (A and B), while in HNSCC epithelium the level of MIF protein was found to be significantly 
higher in surface epithelium (C and D) and moderate to low expression was detected in the deeper 
cancer cells (SCC). One-way ANOVA test was used to compare the statistical significance of the 
scores of normal and cancer tissue (E). The number of cases in each category is shown in E.        
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4.4.13. Effect of MIF small molecules inhibitor ISO-1 on viability of FaDu  
Neutrophils migrate toward the conditioned medium from FaDu and recombinant 
chemoattractants in Boyden chamber chemotaxis assays. In addition, it was found that FaDu 
MCTS secrete chemoattractants and recruit neutrophils but it is not known which 
chemoattractants or neutrophil receptors are the most important in this process. One way to 
determine this is to block chemoattractant receptors expressed by neutrophils or inhibit 
chemoattractant activity. Small molecule inhibitors of CXCR2 (AZ-767, SB265610) and CXCR4 
(AMD3100) are well-characterised in terms of toxicity and potency (Tazzyman et al., 2011), 
whereas the toxicity of (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxasole acetic acid methyl 
ester (ISO-1), a specific MIF inhibitor, have not previously been determined. The cytotoxic 
effect of ISO-1 on FaDu cells was assessed using MTT viability assay and compared to vehicle 
control (DMSO).  The concentration of ISO-1 that was toxic to 50% FaDu cells (IC50=250 µM) 
was calculated, by plotting the percentage of viable cells against log (concentration, µM) of 
ISO-1. Among the tested concentrations, 500 and 100 µM were found to be the most cytotoxic 
concentration at 24, 48, and particularly 72 h compared to the DMSO control (Fig. 4.18). 
Therefore, a treatment of 50 µM and was selected for the infiltration experiment as it did not 
show toxicity to cells at 24, 48, 72 hours.   
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4.4.14. Effect of ISO-1 on neutrophil viability and apoptosis  
( A ) 
( B ) 
Figure 4.18 Assessment of cell viability of FaDu in response exposure to increasing 
concentrations of ISO-1.   FaDu monolayer were treated with ISO-1 (0.05, 0.5, 5, 50, 500 or 5000 
μM) or it vehicle control DMSO for 24 h. (A) The IC50 of ISO-1 on FaDu was calculated by plotting 
the percentage of viable cells against log (μM) after 24hr ISO-1 treatment. Data are 
representative of 3 independent experiments. (B) ISO-1 was observed to be cytotoxic at higher 
concentrations at 24, 48 and 72 h.  Data are mean ± SEM, n = 3. ** P˂0.005, ***P˂0.0001 
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To determine whether ISO-1 was cytotoxic to neutrophils, freshly isolated neutrophils were 
treated with increasing concentrations of ISO-1 or DMSO for 24 h. The cells were then 
analysed for markers of apoptosis and necrosis using Annexin-V and propidium iodide (PI) by 
flow cytometric analysis (described in section 2.2.9.6). After 24 h 75.1% of untreated 
neutrophils were viable, less than 20% undergo natural apoptosis and 6.3% of the cell 
population was necrotic. The use of 5000 μM ISO-1 was very cytotoxic and ISO-1 treated cells 
displayed 73% necrosis, 11% apoptosis and only 14% viability. However, similar findings were 
observed with the DMSO vehicle control where 87% of cells were necrotic, 7% apoptotic and 
only 1% viable cells were detected, suggesting that the high concentration of vehicle could be 
responsible for the loss of viability. Treatment with 500 μM ISO-1 had negligible effect on 
necrosis (5%) but induced around 25% of apoptosis in cells with 68% of cells being viable. Use 
of drug concentrations ranging between (0.05 to 50 μM) had little effect on neutrophils, with 
almost 70% of cells being viable, approximately 25% apoptotic (not significantly different from 
untreated cells) and less than 5% of population was necrotic (Fig. 4.19). These data showed 
that use of ISO-1 at 50 μM is not significantly toxic and so was used in future experiments.   
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 ( A ) 
Figure 4.19 Flow cytometric analysis of apoptosis and necrosis induced in neutrophils by 
exposure to increasing concentrations of ISO-1.  Freshly isolated neutrophils were treated 
with ISO-1 (0.05, 0.5, 5, 50, 500 or 5000 μM) or it vehicle control DMSO for 24 hours. Cells 
were stained with Annexin V-FITC and PI to determine the level of viability (A), apoptosis (B) 
and necrosis (C). Data are representative of 3 pooled experiments from individual donors. 
Data are mean ± SEM. 
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4.4.15. Infiltration of neutrophils into FaDu MCTS is blocked using specific 
inhibitors. 
Small molecule inhibitors for CXCR2 (AZ767 and SB265610), CXCR4 (AMD3100) and MIF (ISO-
1) were used to determine the importance of these molecules in directing neutrophil 
migration into FaDu MCTS.  Neutrophils from healthy volunteers were pre-incubated with 
saturating concentrations of AZ767 25nM, (Tazzyman et al., 2011), SB265610 100nM, 
(Bradley et al., 2009) or 500ng/ml AMD3100 (Bot et al., 2014) for 1 h to block their respective 
receptors, or FaDu MCTS cultures were incubated with 50 μM ISO-1 for 1 h. DMSO was used 
as a vehicle control.  Untreated FaDu spheroids were then incubated with receptor-blocked 
neutrophils for 5 h, whilst ISO-1 treated FaDu were incubated with untreated neutrophils for 
5 h. Flow cytometric analysis of disaggregated FaDu MCTS was carried out as described in 
section 2.2.4.3 to determine the number of infiltrated neutrophils in treated and control 
MCTS. Neutrophil infiltration into the vehicle control group was an average  19%, whereas in 
the AMD3100 (CXCR4 antagonist)-treated group, neutrophil infiltration was significantly 
reduced to an average  6% infiltration. Treatment with either CXCR2 antagonist (AZ-767 and 
SB265610) caused a significant reduction in neutrophil infiltration up to approximately 5%. 
Moreover, inhibition of neutrophil infiltration using the MIF specific inhibitor (ISO-1) was 
most pronounced at 2.5% (Fig. 4.20).  
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Figure 4.20 Flow cytometric analysis of neutrophil infiltration into FaDu MCTS. Neutrophils 
pre-incubated with CXCR2 antagonist (AZ-10397767 or SB-265610) CXCR4 antagonist 
(AMD3100) and the MIF inhibitor (ISO-1) reduced neutrophil migration into FaDu MCTS 
compared to vehicle control. One-way ANOVA test was used to compare the statistical 
significance of neutrophils infiltration (*P<0.05, **0.01, ***0.001). Data is pooled from six 
individual experiments as mean % of Infiltration ± SEM. 
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4.4.16. Infiltration of THP-1 monocytes into FaDu MCTS is blocked using 
specific inhibitors. 
Previous data showed that human monocytes also express receptors for CXCR2 and CXCR4. 
Moreover, increased numbers of macrophages have been reported in HNSCC with numbers 
correlating to poor prognosis (Fujii et al., 2012). It was therefore interesting to determine if 
blocking these receptors or ISO-1 would inhibit recruitment of monocytes into FaDu HNSCC. 
The human monocytic cell line, THP-1 (Qin, 2012), is the most used cell line to study 
monocytes and macrophages. THP-1 cells are positive for CXCR4 (Schols et al., 1997) and 
CXCR2 (Vogiatzi et al., 2013) and so were used in this study using the same protocol as 
described previously for neutrophils. Untreated THP-1 infiltration into FaDu MCTS at this time 
period was slightly lower than for neutrophils at 13%. THP-1 infiltration was significantly 
inhibited using the CXCR4 antagonist AMD3100 (5.5%). Surprisingly, the use of the CXCR2 
antagonist, AZ-767 showed no significant inhibition of THP-1 infiltration, whereas SB265610 
showed a small but significant reduction in infiltration (8%).  Interestingly, the use of ISO-1 
showed the greatest reduction on THP-1 infiltration to just 3% (Fig. 4.21). 
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4.4. Discussion  
Figure 4.21 Flow cytometric analysis of THP-1 monocyte infiltration into FaDu MCTS. THP-1 
cells were pre-incubated with CXCR2 antagonist (AZ-10397767 or SB-265610), CXCR4 
antagonist (AMD3100) or FaDu MCTS treated with the MIF inhibitor (ISO-1). One-way ANOVA 
test was used to compare the statistical significance, showed CXCR4 and ISO-1 significantly 
reduced monocyte migration into FaDu MCTS compared to vehicle control (*P<0.05, **0.01, 
***0.001). Data pooled from three individual experiments as mean % of Infiltration ± SEM.   
154 
 
FaDu MCTS formation was generated using the liquid overlay method as previously described 
(Carlsson and Yuhas, 1984). The use of MTCS gives advantages over monolayer culture as it is 
more close to the in vivo situation. The multi-cellular, 3D MCTS structures enable MCTS to 
replicate various micro-environmental aspects, such as the oxygen diffusion, glucose, lactate 
and pH gradients, and the distribution of proliferation/quiescent cells within the spheroid 
(Sutherland and Durand, 1984). When tumour MCTS grow larger than 500 µm in diameter, 
they are frequently characterized by hypoxic regions and necrotic centres, therefore they 
resemble avascular tumour in vivo (Hirschhaeuser et al., 2010). The presence of hypoxia 
around a necrotic area observed in the MCTS was similar to that observed in HNSCC tissue 
section.  This is due to failure of oxygen and nutrition delivery beyond the distance of 100-
150μm  (Thomlinson and Gray, 1955). 
Although the use of MCTS in cancer research is widespread there has been little use of these 
models in studies of HNSCC.  MCTS co-culture approaches have been utilised in the field of 
oral cancer to investigate the tumour micro-environment or in tumour therapy related work. 
For example, the formation of tumour (UM-SCC 14C)/fibroblast mixed MCTS were utilised to 
study the effect of anti-EGFR mAb on leukocyte migration towards HNSCC (Hoffmann et al., 
2009). Hirschhaeuser et al, (2009) used FaDu MCTS to test the mode of action and 
effectiveness of catumaxomab in vitro.  In comparison to the results presented here, the FaDu 
MCTS used in their study grew slower, even though they were plated at the same seeding 
density. In this study data generated from growth curves show that after 24 h FaDu cells 
aggregated together and formed a spheroid with average size of 694 µm and these continued 
to grow to reach approximately 1413 µm by day 13 (Hirschhaeuser et al., 2009). Whereas, 
Hirschhaeuser (2009) FaDu spheroids formed after 2 to 4 days, and these reached a diameter 
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of about 900 µm after a week of incubation and then slightly decreased in size but stayed 
over 400 µm the size of the day 0 MCTS. These differences may be due to the culture medium, 
supplements or culture conditions used. The FaDu used in this study were verified using STR 
analysis to rule out cell line contamination. The data provided in this chapter clearly show 
that FaDu MCTS display many of the micro-environmental features on an in vivo HNSCC 
tumour are good in vitro models to represent these cancers. FaDu MCTS have also been used 
to develop a model of oral cancer in order to facilitate the study of cancer invasion using 
human organotypic models (Colley et al., 2011).  
It has been reported that tumour cells are able to recruit and modulate the function of 
neutrophils by a variety of inflammatory mediators and cytokines.  For example, the 
expression of CXCL8, a potent neutrophil chemoattractant, was found to be increased in 
various tumour cells (De Larco et al., 2001). Cytokine analysis of FaDu secreted products 
revealed high levels of the classic neutrophil chemokines CXCL8, CXCL1 as well as CCL5 and 
MIF in the medium from FaDu MCTS. In addition, a small amount of CXCL6 was released from 
FaDu MCTS but only after stimulation with TNF-α. In two separate studies by the same group, 
the serum concentration of CXCL8 was found to be higher in the peripheral blood of HNSCC 
patients than in that of a control group and the use of neutralizing CXCL8 antibodies reduced 
the migration neutrophil towards FaDu conditioned medium in vitro. This finding was 
supported by a subsequent screening array of FaDu conditioned media which showed that 
CXCL8, CXCL6 and MIF were the most abundant cytokines released by these cells (Trellakis et 
al., 2011a, Dumitru et al., 2011); data that are concordant with those of this study. High levels 
of MIF have also been detected in HNSCC patients (Kindt et al., 2013a, Kindt et al., 2013b). 
These data suggest that the MCTS models are replicating those in vivo by secreting 
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chemotactic factors into the culture medium as in vivo tumours secrete these factors into the 
circulation. Data in chapter 3 show high numbers of neutrophils in biopsies of HNSCC and so 
the FaDu MCTS model was used to investigate neutrophil recruitment into tumours.   
Neutrophil infiltration into FaDu MCTS peaked at 5 hours when pre-incubated with TNF-α, 
with similar levels of infiltration induced after 2 hours following pre-incubation with TNF-α 
for 18 h. In contrast, co-cultured FaDu MCTS with neutrophils for 24 h caused a decline in 
their infiltration.  The likely reason for this reduction is possibly due to the limited neutrophil 
life-span, as many studies have reported that neutrophils do not exceed 16-24 hours ex- vitro 
before undergoing apoptosis (Dancey et al., 1976).   
Neutrophil infiltration into FaDu spheroids is most likely to be chemokine and adhesion 
molecule-dependent, as the infiltration of neutrophils into un-stimulated spheroids was 
limited. FaDu MCTS were pre-treated with TNF-α because the tumour micro-environment is 
known to be pro-inflammatory. For instance, many studies have reported elevated levels of 
TNF-α in various tumours, including pancreatic (Schmiegel et al., 1993), renal cancer  (Al-
Lamki et al., 2010) and HNC (Soylu et al., 1994). In lung adenocarcinoma, TNF-α was able to 
induce expression of ICAM-1 on tumour cells in vitro and in vivo facilitating leukocyte 
adhesion and migration (Huang et al., 2004). When FaDu MCTS were pre-treated with TNF-α 
neutrophil recruitment increased several fold in a time dependent manner and this was 
associated with the respective increased levels of chemokines and ICAM-1 expression. ICAM-
1 is an essential adhesion molecule that allows neutrophils to bind to epithelial cells (Dustin 
et al., 1989). It is likely that addition of TNF-α not only increases the secretion of neutrophil 
chemokines but also increases expression of ICAM-1 leading to increased infiltration 
compared to un-treated MCTS. The importance of ICAM-1 in neutrophil recruitment could 
157 
 
have been verified using siRNA or blocking antibodies to ICAM-1 although this was not 
performed in this thesis. One element missing in this tumour MCTS assay when compared to 
in vivo neutrophil recruitment into inflamed tissue or a tumour mass is the binding of 
neutrophils to the endothelium lining the blood vessels during the extravasation.   These 
interactions induce activation of signalling pathway leading to alteration in integrin 
expression, phagocytosis and release of granule content (Zarbock and Ley, 2008). The 
generation of more complex assays using neutrophils delivered under flow to the 
endothelium with MCTS placed below the epithelium have been created (Muthana et al., 
2015) but these were considered too complex for this study.  
Neutrophil recruitment into tumours appears to be dependent on chemokines that bind to 
CXCR1 and CXCR2 expressed by neutrophils. CXCR1 binds CXCL6 and CXCL8 with high affinity 
but binds CXCL1-3, CXCL5 with only low affinity. On the other hand, CXCR2 binds CXCL1-3, 
CXCL5, CXCL6 and CXCL8 all with high affinity (Lee et al., 1992, Ahuja and Murphy, 1996a). In 
contrast to the role of CXCL8, CXCL1 and CXCL6 in neutrophil recruitment, little is known 
about MIF-induced neutrophil recruitment. MIF was originally identified as a regulator for 
macrophage migration in vitro (David, 1966). However, many studies have reported 
expression in different human tumours, such as breast (Larsen et al., 2008), liver (Hira et al., 
2005), colorectal (Legendre et al., 0000) prostate (Meyer-Siegler et al., 2005), melanoma 
(Shimizu et al., 1999), oesophageal and recently increase level of MIF was detected in HNSCC 
patients and correlated with poor patient outcome and tumour progression (Dumitru et al., 
2011, Kindt et al., 2013a, Kindt et al., 2013b). Using qPCR, we confirmed that MIF was over-
expressed in a number of HNSCC cell lines suggesting that the data obtained with FaDu is 
common amongst all other HNSCC cells. Interestingly, HPV-negative cell lines generally 
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secreted more MIF than HPV-positive cell lines and this may be due to their aetiology 
(carcinogen-promoted mutations rather than viral mediated). This phenomenon has also 
been observed with chemokine secretion in the group’s laboratory (Sarmad Al-Sahaf, 
unpublished personal communication). This study went on to confirm that MIF is over-
expressed in HNSCC by measuring its expression in biopsies of human HNSCC and comparing 
this to normal mucosa. Interestingly, in normal oral mucosa weak MIF staining was localized 
in the basal/proliferating cells of mucosa and not in any of the upper differentiating cell, as 
reported by Cludts et al, where they showed low or absence of MIF expression in the basal 
cellular layer and weak stain was also detected in superficial layers of normal mucosa (CLUDTS 
et al., 2010).  It has been reported that MIF expression in the basal layer of human skin 
contributes to epidermal cell proliferation and differentiation (Shimizu et al., 1996), and this 
may account for why isolated normal oral keratinocytes displayed MIF expression in in vitro 
culture (it is the basal cells that are isolated and grown in culture). MIF expression was 
significantly increased in HNSCC tissues confirming that the in vitro cell line data is matched 
in vivo. MIF overexpression has also been reported in hypopharyngeal carcinoma (CLUDTS et 
al., 2010) and Laryngeal carcinoma (Kindt et al., 2013b) and this correlated positively with 
disease progression.   
 
Neutrophil migration toward FaDu conditioned media significantly increased when FaDu cells 
were incubated under hypoxia, suggesting that hypoxia induces the secretion of neutrophil 
chemoattractants from FaDu cells. Hypoxia, a common characteristic of locally advanced solid 
tumours, occurs due to the inability of oxygen to meet the cellular demand by the growing 
tumour mass (Vaupel and Mayer, 2007). In response to hypoxia, cellular adaptation is 
mediated by the transcription factor hypoxia-inducible factors HIF-1 and HIF-2. Hence, 
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activation of these transcription factors by tumour cells facilitates their progression by 
inducing proteomic and genomic changes that have a profound effect on tumour 
angiogenesis, anaerobic metabolism and other process that enable tumour cells to survive in 
a low oxygen concentration environment (Eales et al., 2016). Evidence shows that hypoxia 
can induce MIF secretion in breast cancers (Larsen et al., 2008), pancreatic adenocarcinoma 
(Winner et al., 2007) in both a HIF-dependent or independent manner. Although, MIF has 
been identified as a hypoxia inducible gene firstly in squamous cell carcinoma-derived cell line 
(FaDu) (Koong et al., 2000), but our gene expression data has not MIF upregulation in FaDu in 
response to hypoxia. However, other HNSCC cells (H357, SCC4, SCC72, SCC2 and SCC90) 
cultured under hypoxic conditions confirmed that MIF expression is induced by hypoxia. A 
recent study showed that knocking down hypoxia-inducible factors (HIF) -1α and HIF-2α I in 
HNSCC cells, significantly reduce the level of MIF, providing evidence that MIF is HIF 
dependant in vitro (Zhu et al., 2014). Surprisingly, silencing HIF did not affect the migration of 
CD11b+Gr-1+ myeloid cells to hypoxia treated HNSCC cells in vitro (Zhu et al., 2014). Hypoxia 
also induced expression of VEGF in all the cells tested and this is a well know pathway in most 
cancer types, including HNC (LIANG et al., 2008) and is the basis of tumour angiogenesis (Goel 
and Mercurio, 2013) . 
 
Small molecule antagonists of CXCR2, a CXCR4 antagonist and a MIF activity inhibitor were 
used to investigate the recruitment of neutrophils and monocytes into HNSCC tumour 
spheroids. Neutrophil recruitment into FaDu MCTS was significantly reduced in the presence 
of both CXCR2 inhibitors and in the presence of AMD3100, the CXCR4 inhibitor. 
Concentrations of inhibitors used have previously been shown to be non-toxic to neutrophils 
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in previous studies (Tazzyman et al., 2011, Bradley et al., 2009, Bot et al., 2014). Moreover, at 
a concentration determined to be non-toxic, the MIF inhibitor ISO-1, inhibited approximately 
77% of neutrophil infiltration into FaDu spheroids when compared to control. It has been 
showed previously that the CXCR2 small molecule inhibitor (AZ10397767) prevented 
neutrophil migration towards the CXCR2 specific ligands CXCL1-3 and CXCL5 but had no 
inhibitory effect towards CXCL8 (Tazzyman et al., 2011). These may explain the partial 
inhibition effect noticed using the CXCR2 antagonist in the experiment performed in this 
thesis and is in agreement with Hammond et al. whose findings showed that CXCL8 induces 
chemotaxis of neutrophils via both CXCR1 and CXCR2 (Hammond et al., 1995).  At first glance, 
this data suggest that neutrophils are recruited to FaDu MCTS via CXCR2 along a CXCL1/CXCL6 
axis. However, inhibition of CXCR4, a receptor that does not bind CXCL1, CXCL6 or CXCL8 also 
dramatically inhibited neutrophil recruitment, suggesting the role of another 
chemoattractant. Bernhagen et al (2006) found that MIF can bind to and activate signal 
transduction pathways via both CXCR2 and CXCR4 in monocyte and T-cells. We also found 
that recombinant MIF causes directed migration of neutrophils in a dose-dependent manner 
showing that MIF is chemotactic for neutrophils in vitro as reported by Bernhagen, who 
showed moderate chemotactic activity of neutrophils in response to MIF mainly exhibited 
through CXCR2 not CXCR1 (Bernhagen et al., 2007). 
 Since neutrophils do not express CD74 (Dumitru et al., 2011) it is likely that MIF acts via CXCR2 
and/or CXCR4 expressed by neutrophils. To support this ISO-1 was used, as it is the most 
characterized non-toxic inhibitor of MIF function. Many have reported that this compound is 
effective in blocking a MIF-dependent malignant phenotype (Meyer-Siegler et al., 2006). 
Therefore, the action of this inhibitor on neutrophil recruitment to FaDu MCTS was tested.  
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ISO-1 was found to be the most potent inhibitor of neutrophil recruitment. Since inhibitors to 
both CXCR2, CXCR4 and ISO-1 all block neutrophil recruitment these data suggest that MIF is 
the major neutrophil chemoattractant in HNSCC that is mediated most likely by both CXCR2 
and CXCR4. The evidence support our hypothesis is that, neutrophils isolated from MIF-/- 
mice showed a reduce migration index to cytokine-induced KC, homology to human CXCL1, 
known ligand for CXCR2 (Santos et al., 2011). On the other hand, our findings contrast to that 
of Dumitru et al. who showed that MIF neutrophil recruitment relied solely on CXCR2 
(Dumitru et al., 2011). Most literature proposes that the CXCR4 ligand CXCL12 is 
overexpressed and this has been widely detected in various tumours including HNSCC (Clatot 
et al., 2015). However, the cytokine array analysis did not detect expression of CXCL12 and so 
recruitment by this mechanism is unlikely, although further analysis is required to rule out 
this possibility.   
In contrast to neutrophils we found that monocyte (THP-1) recruitment into tumours was 
blocked by inhibitors to CXCR4 and ISO-1 whereas the CXCR2 inhibitors were much less 
effective.  This suggests that for monocytes, CXCR4 is the main receptor utilised and this is 
most likely driven by a MIF-mediated mechanism as FaDu MCTS did not express CXCL12 or 
CCL2 by cytokine array (generally known to be the main monocyte chemokine acting via CCR2).  
 
Taken together these data suggests that MIF is over-expressed in HNSCC and is the main 
driver of neutrophil recruitment to these tumours. However, this conclusion is based on in 
vitro functional experiments and so the next chapter will examine the potential role of MIF-
mediated neutrophil recruitment in an in vivo model. 
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Chapter 5: Effect of the MIF antagonist, ISO-1 and anti-Ly6G 
treatment on neutrophil infiltration and subsequent growth of 
FaDu xenograft tumours in vivo 
5.1. Introduction  
Data in chapter 4 showed that neutrophil recruitment to an HNSCC MCTS model was 
predominantly under the control of MIF, most likely acting via CXCR2 and CXCR4. A 
growing body of evidence has reported the therapeutic advantage of blocking MIF activity 
in oncology. Thus far, the main strategies involved in cancer studies include the use of 
small molecule inhibitors of MIF’s biological activity (He et al., 2009, Meyer-Siegler et al., 
2006, Kindt et al., 2013a) or destabilization of MIF via the heat shock chaperone complex 
(HSP90) (Schulz et al., 2012). Furthermore, inhibition of the receptor for MIF, CD74, 
decreased tumour cell proliferation and invasion in vitro (Govindan et al., 2013, Meyer-
Siegler et al., 2006). Indeed, anti-MIF therapeutic interventions are in clinical trials at the 
moment for solid tumours       
(https://clinicaltrials.gov/ct2/show/NCT01765790?term=MIF&rank=1). 
Anti-MIF antibodies have been developed by Baxter and recently investigated 
(Kerschbaumer et al., 2012). The authors showed that out of a panel of 74 antibodies 
screened, 14 were able to neutralize MIF activity in vitro while only three monoclonal 
antibodies (BaxG03, BaxB01, and BaxM159) reduced the cell growth and viability of the 
human prostate cancer cell line (PC3) by inhibiting activation of p44/42 mitogen-activated 
protein kinase (MAPK)/ ERK1/2. Administration of anti-MIF antibodies in a PC3-xenograft 
mouse model showed a significant reduction in tumour growth in a dose-dependent 
manner compered to isotype control antibody (Hussain et al., 2013).   
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Pharmacological inhibition of MIF using ISO-1, the most studied compound that binds to 
the catalytic site of MIF, has shown shrinkage in tumour size and reduced vascularization 
in xenograft experimental models of colorectal cancer (He et al., 2009) and Prostate 
cancer (Meyer-Siegler et al., 2006). A similar reduction in tumour growth was also 
achieved using anti-MIF antibodies in colorectal cancer (He et al., 2009).   
5.2. Aims 
The aim of this chapter was to explore the actions of the small molecule MIF inhibitor ISO-
1 as well as anti-Ly6G treatment on innate immune cell recruitment, growth and 
vascularity of FaDu xenografts in an in vivo CD-1 immunodeficient murine model of HNSCC. 
5.3. Methods 
5.3.1.  In vivo study Design  
A xenograft murine model was generated by injecting CD-1 nude mice subcutaneously with 
5×107 FaDu cells.  Tumours were allowed to develop for 3 days, at which point mice were 
randomly divided into treatment groups. Each group consisted of 5 tumour-bearing mice and 
the treatment schedule was as follows; control group were given Intraperitoneal (i.p.) 
injections of PBS, the neutrophil depleted group received 200 µg anti-Ly6G three times a week 
over a 3 week period while the ISO-1 treated group received 20 mg/kg ISO-1 twice weekly by 
the same route (He et al., 2009) (see section 2.2.10 for further details). Tumours were 
measured using measuring callipers and length, depth and width of the tumour were 
recorded. At the end of experiment, mice were injected with BrdU for 1 h, mice culled and 
the tumour and serum were collected for further analysis. Tumours were divided and FFPE 
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for IHC analysis (see section 2.2.7.5 and 2.2.7.6) or snap frozen for immunofluorescence 
analysis for presence of leukocyte populations (see section 2.2.8.2). 
5.3.2.  Tissue imaging and quantitative analysis   
For each tumour the entire tumour section was scanned using an image acquiring system 
(TissueFaxs200). Images were obtained with a 20X objective that automatically creates a high-
resolution digital file, which can be viewed using automated tissue analysis software 
HistoQuest (4.0.4.161). The HistoQuest software uses algorithms that allow cell detection 
based on nuclear segmentation and the intensity measurement of nuclear as well as 
membrane and cytoplasmic antigens. Analysis for this thesis focused on quantifying 
proliferating cells (BrdU+) and the microvessel density (MVD) in whole tumour sections. The 
area of necrosis was excluded from analysis and MVD was assessed using a modified “Hot-
spot” approach proposed by Weidner (Weidner, 1995). Whole tissue was examined and eight 
representative non-overlapping regions of interest (ROI) with high vascular density (HVD) and 
eight ROI with low vascular density (LVD) were selected (Fig. 5-1). The distribution of BrdU+ 
cells in relation to the vascular density of tumour (HVD vs LVD) was counted in each region.   
Each ROI had a fixed size of (0.03 mm2) and the mean number of BrdU + cells counted in each 
ROI was expressed as % of BrdU + cells / tumour tissue and between high and low vascular 
areas.  
The cut-off value to distinguish between positive (brown) and negative (blue) for nuclear 
detection of BrdU was determined manually based on the threshold selected on the IgG 
isotype control slide (threshold = 45) and then a threshold was selected for MVD was based 
on intensity of red (Vector red stain) threshold of CD31 immunostaining (threshold = 60).  
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Data from the quantitative analysis of immunostaining were expressed as following: 
  % cell proliferating = 
number of positive (brown)cells 
number of total cells 
 ×100 
% of MVD= 
Area of positive CD31 stain
total area of tumour 
×100 
  
Figure 5.1 Automated Image analysis system HistoQuest was used to analyse FaDu xenograft 
sections.  Tumour sections were scanned and area of tumour was measured (mm2) (black 
dotted line) area of necrosis was defined microscopically (green dotted line) and excluded from 
analysis. Proliferating activity of cells (BrdU+) was quantified on the whole tumour section and 
correlated to Microvessel density (MVD). A detailed analysis of BrdU + cells was investigated in 
8 region of interest (ROI) with HVD (red circles) and 8 ROI with LVD (blue circles). Each of ROI 
had a fixed size of 0.03 mm2. 
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5.4. Results 
5.4.1. Effects of ISO-1 and anti-Ly6G on tumour growth of FaDu xenograft 
tumours  
Mice were implanted with 5×107 FaDu cells to create subcutaneous tumours and were 
subsequently treated with ISO-1, anti-Ly6G or PBS as control to examine the role of neutrophil 
depletion of MIF inhibition on FaDu growth. The onset of a measurable tumour was observed 
at day 11, with tumour size of 49.3±6.9 mm3 for vehicle, 75± 18.4 mm3 for anti-Ly6G and 37.4 
± 16.7mm3 for ISO-1 treated mice.  At the next measurement at day 13, the tumours from 
vehicle-treated animals had increased by approximately 31 mm3 while the tumours from anti-
Ly6G neutrophil depleted mice only increased by 8 mm3 to around 45 mm3. However, tumour 
sizes in the ISO-1 treated mice had grown to approximately 62 mm3.  Because the tumour size 
was variable between individual tumours, the tumour size at each time point was calculated 
in proportion to initial tumour volume at day 11 (Fig. 5.2-A).   
All the tumours were found to be of equal size up until day 11 after which the growth of the 
tumour treatment groups started to diverge. Administration of vehicle control did not reduce 
or over promote tumour growth and these tumours grew at a consistent rate, and were 
significantly larger at the end of the experiment on day 21 than tumours at day 11 (p=0.0159). 
Treatment with anti-Ly6G appeared to reduce tumour growth from day 11 to day 21 
compared to PBS treated controls although this was not statistically significantly different 
(p=0.7606) (Fig.5.2-B). The anti-Ly6G tumours had increased growth from day 18 to day 21.  
However, inhibition of MIF using ISO-1 significantly (p<0.05) increased tumour volume 
between day 13 and day 18 compared to both PBS controls and anti-Ly6G treated tumours 
(Fig. 5.2-A). 
Measuring the tumour at the time of harvesting revealed that tumour-bearing mice treated 
with anti-Ly6G or ISO-1 were generally larger than tumours from untreated controls tumours 
with final tumour volume of 484±315mm3 for ISO-1 compared to 308±127 mm3 for anti-Ly6G 
treated tumours and 70±23 mm3 for PBS treated animals. However, the difference was not 
statistically significant between groups (Fig. 5.3).   
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Figure 5.2 Effect of anti-Ly6G and ISO-1 treatment on FaDu xenograft tumour growth. (A) 
Growth kinetics of FaDu tumour after treatment with i.p. injection of either vehicle (PBS), 
200 µg anti-Ly6G anti-Ly6G or 20mg/kg ISO-1. The tumour volume was measure every other 
day and tumour volume was calculated and represented as relative to initial tumour volume 
at day 11. Treatments with anti-Ly6G significantly reduce tumour volume in compare to ISO-
1 treated tumour at day 13, 15 and 18 (P=0.0286, 0.0460 and 0.0140 respectively) using 2-
way Anova. (B) Bar chart represents the difference in tumour size from initial developing of 
tumour (day 11) until the last dose of treatment (day 21). Two -way ANOVA test was used to 
compute the statistical significance and *= P<0.05 and ***= P<0.0001. Data are expressed as 
mean ± SEM (n=5). 
( A ) Vehicle control 
(PBS) 
 ( B ) Anti-Ly6G ( C ) ISO-1 
 
Figure 5.3 Growth of FaDu xenograft tumour in response to anti-Ly6G or ISO-1 treatment.  
CD-1 nude mice were inoculated with FaDu cells. Tumours were allowed to develop for 3 
days before mice received i.p. injection with either vehicle (PBS), anti-Ly6G or ISO-1 for 
three weeks. On day 22, mice were scarified and tumours were harvested and 
photographed (A, B, C). Scatter plot represented tumour volumes calculated from the 
dimensions of each individual xenografts mice at the end point (volume = length x depth x 
width). Data are expressed as range and black horizontal line represents the median (n=5). 
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Microscopic analysis of histological sections was carried out to further investigate the 
increase in tumour size in ISO-1 treated animals. The histopathology of FaDu xenograft 
stained sections revealed that tumours from control mice and anti-Ly6G mice appear as well 
circumscribed masses. In contrast, two out of five tumours excised from ISO-1 treated mice 
were less circumscribed masses with tumour infiltration into surrounding muscles (Fig. 5.4). 
 
 
 
 
 
 
Figure 5.4 Extent of tumour infiltration at the tumour margin when harvested. Histopathology of 
PBS control tumours (A), anti-LY6G (B) shows that tumours are well circumscribed, whereas in ISO-1 
treated mice (D) tumours were often found infiltrating into muscle tissue (red arrows).  
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The first objective of this examination was to assess the area of necrosis in each of treatment 
regimen. Tumour necrosis, a common feature of solid tumours, is usually a result of rapid 
tumour growth and inadequate blood supply. Areas of necrosis were identified, after 
consultation with an oral pathologist (Dr Keith Hunter), based on the morphology of 
fragmented cells, nuclear shrinkage and cellular debris (Fig. 5.5). Image analysis of the tumour 
area (as described in 5.3.2) from control and anti-Ly6G shows an average size of tumour of 
9.51mm2 and 9.12 mm2, respectively. In contrast, ISO-1 tumour measurements revealed large 
tumours with an average size of 16.72 mm2, with a large difference in size ranging between 
2.06 mm2 and 57.73 mm2. Control tumours displayed small foci of necrosis covering 18.9 ± 
9.7% mm2 (Fig. 5.5A), whereas anti-Ly6G tumours contained predominantly large necrotic 
areas of 31 ± 4.5% (Fig. 5.5B). Images from ISO-1 treated groups contained an area of 24.3 ± 
8.5% (Fig. 5.5C). Although the percentage area of necrosis was lower in control tumours than 
treated tumours, no statistical significance was detected between the groups (p = 0.4749 and 
0.8535 for anti-Ly6G and ISO-1, respectively). However, when necrosis is expressed relative 
to tumour area (Fig. 5.6-B), the results show that the large tumour size in ISO-1 treated group 
was as result of the presence of large area of necrosis (37%) with less tumour cells, compared 
to 15% necrosis in control tumours.     
 
.   
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Figure 5.5 Area of necrosis present in FaDu xenograft tumour growth. Histopathology of PBS 
control tumours (A, B), anti-Ly6G (C, D) and ISO-1 treated mice (E, F) shows the presence of 
necrosis (green dotted line). Necrosis was defined morphologically as change in tumour cells with 
nuclear shrinkage and cellular debris. The area of necrosis was measured using automated image 
analysis in whole tumour sections. At higher magnification images (B, D, F) neutrophils (black 
arrow) and other inflammatory cells could be identified by their distinctive nuclear morphology 
within the necrotic area. A,C,E scale bar = 500 µm,. B, D, F scale bar = 50 µm. 
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( A ) 
Figure 5.6 Image analysis of tumour necrosis present in FaDu xenograft tumours. (A) 
Presence of necrosis was assessed in whole tumour tissue and expressed as percentage 
relative of tumour area. One-way ANOVA showed no significance difference between 
control group or treated group (B) % Necrosis in proportion to the whole tumour area as 
measured by Image analysis. 
( B ) 
P B S a n t i - L y 6 G I S O - 1
0
5
1 0
1 5
2 0
2 5
3 0
3 5
R
e
la
t
iv
e
 a
r
e
a
 o
f
 n
e
c
r
o
s
is
/
 t
u
m
o
u
 (
m
m
2
)
 T u m o u r  a r e a
A r e a  o f  N e c r o s i s
173 
 
   
5.4.2. ISO-1 or anti-Ly6G alter the number of neutrophils in FaDu xenograft 
tumours  
To determine the importance of MIF in neutrophil recruitment that was observed in vitro and 
also in tumour progression, using the same FaDu tumour bearing mice were injected with 
ISO-1. Treatment with anti-Ly6G was used as a positive control for neutrophil depletion and 
was used alongside DMSO control treated mice.  At the end of experiment, tumours were 
removed, snap-frozen in OCT, sectioned and immunofluorescently stained for the murine 
neutrophil marker Ly6G, macrophage marker F4/80 and vascularization using CD31 (see 
section 2.2.8.2).  The intensity and area of fluorescence in mm3/microscopic field for each of 
the targeted cells was analysed using velocity software (section 2.2.8.3).  Image analysis (Fig. 
5.7) showed an 87% reduction (p=0.0013) in the number of murine neutrophils in FaDu 
xenograft tumours treated with anti-Ly6G when compared to vehicle control (PBS). Similarly, 
FaDu xenograft tumours treated with ISO-1 also displayed a significant (80%) reduction 
(p=0.0025) in the number of tumour-associated neutrophils with the area of fluorescence 
decreasing from average 42885.2 mm3/microscopic field with the control treated tumours to 
average 8896.1 mm3/microscopic field for the ISO-1 treated tumours and average 5594.37 
mm3/microscopic for anti-Ly6G (Fig. 5.7).    
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Figure 5.7 Image analysis of Ly6G+ neutrophils in anti-Ly6G and ISO-1 treated FaDu 
xenograft tumours. A) Representative images Ly6G staining (red, neutrophils) and DAPI 
(blue, nuclei) in tissue sections of xenograft tumours treated with DMSO control, anti-
Ly6G or ISO-1. Scale bar = 100 µm B) The number of Ly6G cells in z-stacks was measured 
based on intensity and area of fluorescence per microscopic field, and presented in bar 
chart as mean ± SEM (n=5).   One-way ANOVA test was used to compute the statistical 
significance **= p<0.001. 
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5.4.3.  Treatment of FaDu xenograft tumours with ISO-1 or anti-Ly6G affects 
macrophage recruitment.  
MIF has been reported to elicit human monocyte chemotaxis through CXCR2 (Bernhagen et 
al., 2007) and mice express a homologous of CXCR2 on monocytes (Cacalano et al., 1994). In 
addition, inhibition of MIF in an inflammatory disease model reduced infiltrated F4/80 
macrophages in diseased tissue (Leng et al., 2011). This evidence along with the data 
presented in chapter 4 suggests that treatment with ISO-1 or anti-Ly6G may alter macrophage 
recruitment into tumours. Therefore, the number of macrophages in ISO-1 and anti-Ly6G 
treated FaDu tumours were examined using the murine macrophage marker, F4/80 and 
compared to control tumours.  
Image analysis showed that the number of F40/80 positive cells in both anti-Ly6G and ISO-1 
treated tumour-bearing mice were lower than those observed in control mice (Fig. 5.8). 
Statistical analysis confirmed a significant reduction (p=0.0427, 40.2%) in the number of F4/80 
macrophages observed in FaDu xenograft tumours receiving anti-Ly6G compared to control 
tumours to 25870 mm3/microscopic field. Moreover, there was an even greater reduction in 
the number of F4/80 positive macrophages in ISO-1 treated FaDu tumours decreasing from 
43189mm3/microscopic field in control tumours to 6443.85 mm3/microscopic field in ISO-1 
treated tumours, equating to an 86% fold decrease in neutrophil numbers (p=0.0003).   
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Figure 5.8 Image analysis of F4/80 macrophages in anti-Ly6G and ISO-1 treated FaDu 
xenograft tumours. A) Representative images F4/80 staining (green, macrophages) and 
DAPI (blue, nuclei) in FaDu xenograft sections treated with DMSO control, anti-Ly6G or 
ISO-1. Scale bar = 100 µm. B) The number of   F4/80 cells in z-stacks was measured based 
on intensity and area of fluorescence per microscopic field, and presented in bar chart 
as mean ± SEM (n=5).  One-way ANOVA test was used to compute the statistical 
significance *= P<0.05, ***= P<0.0001. 
177 
 
5.4.4. Effects of neutrophil depletion and ISO-1 treatment on angiogenesis in 
FaDu xenograft tumours 
Accumulating evidence suggest that TAN play a role in the vascularization process in many 
types of tumours (Tazzyman et al., 2013) with one study showing an association between 
increased numbers of TAN detected in hepatocellular carcinoma (HCC) tissue and MVD. Zho 
et al showed that depletion of TAN using anti-Ly6G significantly attenuated the MVD in HCC 
based on immunostaining analysis of CD34-positive endothelial cells (Zhou et al., 2016). 
Therefore, the influence of TAN depletion by anti-Ly6G and inhibition of MIF in tumour 
vascularization was investigated in FaDu tumour sections using CD31, a murine endothelial 
cell marker.  Image analysis showed that there was no significant difference in CD31 density 
either in ISO-1 (11097.9 mm3/microscopic field) (P=0.1638) or anti-Ly6G (13026 
mm3/microscopic field) (p=0.2607) treated tumours compared to controls (20138.6 
mm3/microscopic field). These data exclude the possibility that the difference in tumour 
growth rate observed between control and treated tumours is due to an inhibitory effect on 
tumour angiogenesis by neutrophil or macrophage depletion.      
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Figure 5.9 Effect of anti-Ly6G and ISO-1 on the distribution of CD31 blood vessels in 
FaDu xenograft tumours. A) Representative immunostaining images of vascularized 
CD31+ areas (white, endothelial cell) and DAPI (blue, nuclei) in FaDu xenograft sections 
treated with DMSO, anti-Ly6G or ISO-1. Scale bar = 100 µm.  B) The number of CD31+ 
endothelial cells was measured based on intensity and area of fluorescence per 
microscopic field, and presented mean ± SEM (n=5). One-way ANOVA test was used to 
compute the statistical significance. 
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5.4.5. Effects of neutrophil depletion and ISO-1 treatment on tumour 
proliferation using BrdU  
TAN can release factors that are capable of stimulating tumour cell proliferation and depletion 
of neutrophils reduced the tumour growth and microvessel density in a melanoma and 
fibrosarcoma murine cancer model (Jablonska et al., 2010). In section 5.4.3 it was found that 
the number of neutrophils was significantly diminished in both anti-Ly6G and ISO-1 treated 
FaDu tumours. To test if this depletion affects tumour cell proliferation mice received BrdU, 
a thymidine analog which is incorporated into newly synthesised DNA, an hour prior to 
sacrifice and tumour removal. Proliferating cells were detected in tumour sections using anti-
BrdU (see section 5.3.2) and the number of BrdU+ cells counted using automated image 
analysis. The proliferation index was calculated by dividing the number of BrdU positively 
stained nuclei (Brown, Fig. 5.10) by the total number of cells detected in the same area of 
tumour (excluding areas of necrosis) and the value express as a percentage proliferating cell 
per image. 
 Microscopical analysis shows that BrdU+ cells were abundant in both the control and Ly6G 
depleted FaDu tumours with the BrdU staining co-localising to the nuclei of tumour cells. 
There was no significant difference (p=0.2758) in the abundance of proliferating cells 
between these two groups. In contrast, significantly (p=0.0155) fewer BrdU positive cells were 
detected in ISO-1 -treated cells (2.2%) compared to both control (8.7%) and Ly6G neutrophil 
depleted (11.9%) tumours (Fig. 5.11). Indeed, ISO-1 treated tumours displayed a 75-fold 
decrease in tumour cell proliferation compared to control and Ly6G display 35-fold increase 
in tumour cell proliferation compared to control (Fig. 5.11).  
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Figure 5.10 The proliferative status and vascularity of FaDu cells in control, Ly6G neutrophil 
depleted and ISO-1-treated xenograft murine models. Paraffin-embedded samples from 
tumour bearing mice were stained with anti-BrdU to measure the proliferative status of FaDu 
cells. A & B are representative images from vehicle control tumour, C & D are representative 
image from anti-Ly6G treated tumours and E & F are from ISO-1 treated tumours. Numbers 
of BrdU+ nuclei were counted in whole tumour sections. Scale bar A, C, E = 200 µm. Scale bar 
B, D, F = 50 µm. Black arrow indicated positive stain of BrdU in the nuclei of cells; red arrow 
indicates CD31 positive staining of blood vessels; green arrow shows a tumour cell 
undergoing mitosis. 
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5.4.6. Dual analysis of tumour vascularisation and proliferation  
Figure 5.11 Image analysis of the proliferative status in FaDu tumour xenografts. The 
number of BrdU positive nuclei (brown) were evaluated using automated image analysis in 
whole tumour tissue and expressed as % of BrdU + cells in the whole cell population. One-
way ANOVA test was used to compute the statistical significance of proliferating cells and 
this revealed no statistical difference in the % of BrdU+ cells between control and anti-Ly6G 
tumours. In contrast, the % of BrdU + cells in ISO-1 treated tumours were significantly 
reduced (*p<0.05) when compared to control.  Data are mean ± SEM. n=5/group. 
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Of note, BrdU + cells were observed to be accumulated in the tumour periphery or areas with 
HVD. Therefore, a detailed analysis of proliferating cells based on density of blood vessels 
distribution was carried out as described in section 5.3.3 (Fig 5.12 and Fig5.13). As can be seen 
in figure 5.14, BrdU+ accumulation was associated with areas of high vascular density (HVD) 
and a significant reduction (p=0.0005) in the number of BrdU + cells was observed in low 
vascular density (LVD) areas in comparison to those that were highly vascularised in control 
treated mice (1.52 cells and 13.47 cells respectively). Similarly, the number of proliferating 
cells in anti-Ly6G tumours significantly decreased from 14.42 cells in HVD areas to 2.43 cells 
in LVDs (p=0.0015). In ISO-1 treated, less proliferating cells was detected in general but more 
BrdU+ cells was observed around HVD with mean number of 5.3 cells, whereas no or very 
weak BrdU positive cells were detected in LVD.         
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Figure 5.12 Image analysis of BrdU in correlation to CD31 distribution in FaDu tumour 
xenografts. Dual stained sections were scanned using HistoQuest software that detected the 
intensity of both CD31 (white areas in overlay image B) and BrdU (brown) Scale bar = 50 µm. 
(C) High magnification image showing CD31 (red staining, red arrow) and BrdU (brown nuclear 
stain, black arrow), Scale bar = 100 µm. 
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( A )  LVD  
HVDD
D  
LVD  
HVD  
LVD  
HVD  
( C )  
( B )  
Figure 5.13. Image analysis of BrdU in FaDu tumour xenografts using the hot spot 
method.the intensity of BrdU+ (brown) in LVD (Aqua blue circle, left) and HVD (red circle, left) 
in control treted mice (A) anti-Ly6G (B) and ISO-1 treated tumour 
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Figure 5.14 Image analysis of BrdU in FaDu tumour xenografts using the hot spot method. 
Bar chart of BrdU+ cells in HVD and LVD areas of FaDu tumour, showing accumulation of 
proliferating cells in highly vascularize areas in comparison to avascular areas of tumors.  
The statistical significance of proliferation index between HVD vs LVD in each of treatment 
regimen was calculated by Students t-test. * = p<0.05, ** = p<0.005, *** = p<0.0001. Data 
are mean ± SEM of eight fields selected for each HVD and LVD area. 
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5.4.7. MIF expression in FaDu xenograft control and treated tumours  
MIF expression has been observed in vivo in tumours in this and other studies (Dumitru et al., 
2011), and has been shown to correlate with disease severity (Kindt et al., 2013). Therefore, 
the intensity of MIF immunostaining in control and treated tumours was evaluated using a 
modified Quick-score method (described in section 2.2.7.5) and scoring was independently 
reviewed by an oral pathologist (Dr Keith Hunter). Staining analysis showed expression of MIF 
primarily in the cell cytoplasm. Surprisingly, the detected level of MIF in the anti-Ly6G and 
ISO-1 treated mice was significantly higher than control mice (p=0.0045 and p=0.0005, 
respectively) (Fig. 5.15).  
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Figure 5.15 MIF protein expression levels in FaDu xenograft tumour sections. Paraffin-embedded 
sections from FaDu tumour bearing mice were stained with anti-human MIF antibody and the stain 
intensity was evaluated using a Quick-score method. The level of MIF detected in vehicle control 
(PBS) was lower than anti-Ly6G treated or ISO-1 treated mice model. One-way ANOVA test was 
used to compute the statistical significance of the scores variance of MIF cancer tissue with or 
without treatment. Scale bar = 500 µm. 
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5.4.8. MIF serum concentration in ISO-1, Ly6G-treated and control tumours   
Quantitative analysis of MIF released in to the serum of mice-bearing FaDu tumours as well 
as non-tumour-bearing mice was assessed by ELISA. Although the ELISA was developed with 
antibodies raised against human MIF, this cytokine was detected in mice with no tumours, 
albeit at low levels, suggesting some cross-reactivity to murine MIF. However, MIF levels were 
greatly increased in mice bearing human FaDu tumours showing that these tumours release 
MIF into the bloodstream (non-tumour bearing mice vs. control tumours, p=0.0001). High 
levels of MIF were also detected in the serum from both anti-Ly6G and ISO-1 treated tumour-
bearing mice. Interestingly, depletion of neutrophils using anti-Ly6G significantly reduced the 
levels of MIF in the serum of mice (p=0.0414) compared to controls (Fig. 5.15). In addition, 
ISO-1 treated tumour-bearing mice also displayed significantly reduced MIF levels in their 
serum compared to control tumours (p=0.0138, Fig. 5.15). However, there was no significant 
difference between the levels of MIF in the serum of ISO-1 and Ly6G-treated tumour-bearing 
mice.  
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Figure 5.15 MIF levels in tumour-bearing and non-tumour-bearing mice. ELISA analysis of MIF levels in 
the serum collected from non-tumour bearing or mice with treated or control FaDu xenograft. Non-
tumour-bearing mice showed low levels of MIF whereas the levels of MIF were significantly increased in 
all tumour-bearing mice. Administration of anti-Ly6G or ISO-1 significantly reduced the level of MIF in 
the serum compared to vehicle control tumours. Multiple comparisons One-way ANOVA test was used 
to compute the statistical significance for differences in MIF levels between normal and tumour-bearing 
mice (PBS, anti-Ly6G, ISO-1) or between untreated tumour bearing mice (PBS) and treated tumour-
bearing mice (anti-Ly6G, ISO-1). The histograms represent the mean ± SEM of MIF level from 5 mice for 
each treatment. *= p<0.05, **=p<0.005, ***= p<0.0001. 
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5.5. Discussion  
In this chapter it was demonstrated that administration of the small molecule inhibitor, ISO-
1, in FaDu tumour-bearing mice did not reduce the tumour growth when compared to control 
tumours. Instead the sizes of tumours were observed to increase after ISO-1 treatment. In 
contrast, targeting MIF either by using MIF inhibitor ISO-1 in xenograft colon or prostate 
cancer murine models (He et al., 2009, Meyer-Siegler et al., 2006) or using anti-MIF 
neutralizing antibody in a prostate xenograft model (Hussain et al., 2013) was shown to 
reduce tumour growth. Further histological analysis showed that although the tumour burden 
was greater, ISO-1 tumour-bearing mice contained larger areas of necrosis and less 
proliferating cells. This result is in line with an in vivo study that used humanized anti-MIF 
antibodies to treat a murine prostate cancer model, which showed a reduction in proliferating 
tumour cells using Ki67 immunostaining in dose-dependent manner (Husaan et al., 2013). 
Large areas of tumour were found to be necrotic (up to 37.5%) in the ISO-1 treated group 
compared to control tumours (15.5%). The reduction in number of proliferating cells 
associated with presence of large area of necrosis in ISO-1 section indicates a higher death 
rate in these tumours. This could be due to the direct effect of MIF on tumour cells or an 
indirect effect. It must be noted that the data presented in this thesis is a snapshot of events 
occurring at 21 days when the tumours were excised and analysed. However, time course 
data suggests that differences in tumour growth first occurred at 11 days, 7 days after 
treatment. It is possible that MIF inhibition affects events occurring in the tumours at day 11 
and 13 that have dissipated and so are not picked up by the analysis at day 21. Analysis of the 
early tumours would provide more insight into the reason for low proliferation with elevated 
necrosis but this was not possible in this study. Treatment of FaDu tumours with anti-Ly6G to 
deplete mice of neutrophils caused a marked reduction in tumour growth. A similar effect 
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was observed in a murine model of melanoma and fibrosarcoma (Jablonska et al., 2010), while 
neutrophil depletion did not influence tumour growth in a mammary tumour-bearing murine 
model (Coffelt et al., 2015). It has been demonstrated that the effect of neutrophil depletion 
on tumour growth is dependent on the stage of tumour development. Systemic depletion of 
neutrophils at an early stage of cancer development (Ly6G treatment started at the same 
time tumour cells were inoculated) had no effect on tumour growth. In contrast, when 
tumours were allowed to develop before neutrophil were depleted (as in the model described 
in this thesis), the authors observed a significant reduction in tumour growth in the murine 
model of Lewis lung cancer and mesothelioma (Mishalian et al., 2013). These data accord with 
the data presented in this thesis and suggest that neutrophils aid tumour progression once a 
tumour has been established.  
The FaDu tumour xenografts were evaluated microscopically and immunohistochemically for 
tumour necrosis, cell proliferation, vascularisation and presence of macrophages. In this study 
we observed that ISO-1 treatment induced a strong inhibitory effect on recruitment of innate 
inflammatory cells (neutrophils and macrophage). The inhibition was not 100% suggesting 
that other factors aid MIF in leukocyte recruitment. Data from the in vitro MCTS studies 
suggest that CXCL1, CXCL6 and CXCL8 may aid neutrophil recruitment in human tumours. 
Murine neutrophils express CXCR2 (the receptor for KC, the murine equivalent of CXCL1 – 
mice do not have the gene for CXCL8) and so are likely to be recruited via human CXCL1 
expressed by FaDu xenografts. It is possible that MIF and CXCL1 may act in concert because 
neutrophils from MIF-/- mice showed reduced migration toward KC (known as CXCL1 in 
human) in vitro (Santos et al., 2011), suggesting an interplay between the two molecules. 
Macrophages may also be recruited to tumours by chemoattractants independent of MIF, for 
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example by CCL2 a potent monocyte chemoattractant. In fact, CCL2 expression has been 
reported to be regulated by MIF in injured hepatocytes in an autocrine manner (Xie et al., 
2016). However, CCL2 was not detected in the conditioned medium for FaDu MCTS in the 
cytokine array data suggesting that this chemokine does not play a role in monocyte 
recruitment in HNSCC. However, there are several other monocyte chemoattractants (CCL7, 
CCL8, CCL13) that were not on the cytokine array that could be involved in the recruitment of 
monocytes to FaDu tumours and this possibility needs further investigation.   
One of the most important roles MIF has been observed to play in promoting tumour 
progression is stimulation of angiogenesis (He et al., 2006) and, although not statistically 
significant, tumours treated with ISO-1 and Ly6G displayed a marked and consistent reduction 
in CD31 staining (a marker of microvessel vessel density, which also expressed by endothelial 
cells lining lymphatic vessels). Knock-down of MIF in melanoma cells prior to implanting these 
cells in a syngeneic murine model showed up to a 40% reduction in CD31 staining density, 
without affecting tumour growth, in comparison to wild-type mice (Girard et al., 2012). A 
similar reduction in microvessel density, assessed by CD34, was observed in DU-145 xenograft 
tumours treated with ISO-1 (Meyer-Siegler et al., 2006), suggesting that MIF inhibition may 
affect tumour vascularisation either directly or indirectly by inhibition of leukocyte 
recruitment.    
Immunohistochemical analysis of MIF protein expression on FaDu xenografts tumour sections 
showed an increased level of MIF in ISO-1 and anti-Ly6G treated tumours compared to control 
tumours. This result could be explained by the fact that, diverse cell types store pre-formed 
MIF in their cytoplasm, ready to be released upon stimulation. Since MIF has been reported 
to act via autocrine and paracrine loops, the increased expression of MIF could be a feedback 
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mechanism to compensate for the loss of the MIF producing cells, neutrophils and 
macrophages (Daryadel et al., 2006, Calandra et al., 1994). It could also be that neutrophils 
and macrophages somehow regulate MIF production by tumour cells via paracrine signalling. 
Further experiments are required to determine if paracrine signalling mechanisms regulate 
MIF expression. In fact, blocking exogenous MIF by ISO-1 in glioblastoma multiforme cells 
enhanced mRNA expression not only of MIF but also its receptors CD74, CXCR2, and CXCR4 in 
vitro (Baron et al., 2011). 
The observation that MIF serum levels from FaDu xenograft tumour increase compared to 
non-tumour bearing mice show that MIF is released by the tumour into the circulation. 
Elevated levels of MIF in the circulation have been reported for many cancers, including, renal 
cancer (Du et al., 2013), HNSCC (Kindt et al., 2013b) and prostate cancer (Meyer-Siegler et al., 
2005). By contrast, the levels of protein detected in the serum of ISO-1 and anti-Ly6G treated 
mice were reduced compared to levels seen in control tumours.  This reduction in secreted 
MIF protein might be as a result of blocking the D-dopachrome active site of MIF (Lubetsky et 
al., 2002), whereas, the reduction of MIF serum levels observed in anti-Ly6G (and possibly 
ISO-1) treated mice may be due to the significant reduction in number of neutrophils in these 
tumours.  
The observation that MIF levels are increased in the tumours but decreased in the circulation 
of ISO-1 and Ly6G treated tumours may suggest that MIF is prevented from being released 
into the circulation.  It is possible that since MIF can be pre-stored intracellularly its presence 
is still detected in tumours using IHC but its secretion into the circulation is somehow reduced 
when neutrophils are absent or in the presence of ISO-1. It is possible that neutrophils 
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produce factors that regulate tumour cell secretion of MIF, although this needs to be 
examined experimentally.  
Administration of ISO-1 in a DU-145 prostate tumour model reduced tumour growth by 40% 
(Meyer-Siegler et al., 2006). Further investigation showed that inhibiting MIF in vitro could 
affect tumour growth directly by reducing the downstream signalling of ERK1/2 MAPK 
cascade (Meyer-Siegler et al., 2006).  In addition, a preliminary study using an irreversible MIF 
inhibitor (4-iodo-6-phenylpyrimidine (4-IPP), which is estimated to have 5-10 times more 
inhibitory potency than ISO-1, reduced migration of murine SCCVII squamous carcinoma cells 
in a Boyden chamber assay and proliferation in vitro (Kindt et al., 2013a), suggesting that 
exogenous MIF partially affects the proliferative capacity of tumour cells in vitro. MIF may 
also exert its effects indirectly by stimulating other cells. In fact, Dumitru et al (2011) showed 
increased proliferation and invasive properties of FaDu cells cultured as monolayers in the 
presence of FaDu-primed neutrophil conditioned medium. This effect was abolished when 
cells were co-culture with FaDu primed neutrophil conditioned medium in presence of ISO-1 
inhibitor (Dumitru et al., 2011). These data suggest that MIF activated neutrophils to secrete 
factors that affect tumour cell proliferation.           
Other possible reason for not observing an inhibitory effect generated by ISO-1 treatment in 
vivo might be dosing regimen.  The in vivo study in this thesis followed the same treatment 
regimen used in a colorectal cancer xenograft model (He et al., 2009), but ISO-1 
administration twice per week may be not enough to achieve sustained inhibition of MIF.  Of 
note, a 47% reduction in tumour growth was achieved by using MIF-/- mice (Girard et al., 
2012).  
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Chapter 6: The effect of cytokines and HNSCC-secreted factors on 
neutrophil phenotype 
6.1. Introduction  
The concept of neutrophil polarization into N1 (anti-tumour) or N2 (pro-tumour) 
phenotypes in response to molecules in the tumour microenvironment has been recently 
reported in two elegant studies using murine cancer models. In the first study, Fridlender 
et al, (2009) noted that upon inhibition of TGF-β in two murine cancer models (NSCLC and 
mesothelioma) neutrophils recruited to these tumours displayed what they characterised 
as an N1 phenotype. The most important features of the N1 anti-tumour phenotype are 
activation of cytotoxic T lymphocytes and improved ability to kill tumour cells, increased 
expression of pro-inflammatory cytokines such as TNF-α and their ability to stimulate the 
immune response with levels of immunosuppressive Arg-1 significantly reduced 
(Fridlender et al., 2009). In another study, when tumour-bearing Ifnβ1-/- mice received a 
low dose IFN-β therapy, neutrophils appeared to change their phenotype to one with an 
enhanced ability to cause tumour cell destruction (Andzinski et al., 2016); a trait of N1 
neutrophils. In addition, administration of adjuvant type I IFN treatment in melanoma 
patients resulted in reduced expression of CXCR1 and CXCR2, up-regulation of ICAM-1 and 
increased apoptosis of blood-derived neutrophils, other features that were deemed 
characteristic for anti-tumour N1 neutrophils (Andzinski et al., 2016). Further evidence 
confirmed the important role that type I INFs plays in polarization of TAN. Mice lacking 
endogenous INF-β acquire a TAN phenotype that express increased levels of pro-
angiogenic genes (VEGF, MMP9) as well as c-myc and STAT3 activation. Moreover, 
depletion of this type of neutrophil showed a therapeutic effect in reducing tumour 
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growth in both control and IFN-β–deficient mice (Jablonska et al., 2010). Such TAN have 
been described as displaying an N2 pro-tumour phenotype, and have immunosuppressive 
functions as well as increased secretion of chemokines CCL2, CCL5 and expression of 
chemokine receptor CXCR4 (Jablonska et al., 2010).  
The major challenge in studying TAN phenotype is the fact that the proposed phenotype 
and function of TAN has mainly been characterized in murine tumour models that may 
not directly relate to humans because of species-specific differences. Currently, there is 
only one study that describes the characteristic phenotype of TAN isolated from freshly 
removed lung tumour tissue when compared to neutrophils isolated from distant non-
malignant lung tissue (Eruslanov et al., 2014). Using flow cytometric analysis, the authors 
confirmed that human TAN show decreased expression of CXCR1, CXCR2, adhesion 
molecule CD62L (L-selectin) and increased expression of ICAM-1 (CD54), a previously 
reported neutrophil activation marker (Fortunati et al., 2009). In addition, analysis of CCR 
and CXCR chemokine receptor expression revealed increased levels of CXCR4, CXCR3, 
CCR7 and CCR5 on TAN whereas no expression was detected on peripheral blood 
neutrophils (Eruslanov et al., 2014).  Therefore, there appears to be differences in the 
phenotypic markers between human and murine N1 and N2 neutrophils. 
The influence of factors in the HNSCC microenvironment on the phenotype of TAN is 
unclear. There is evidence that the tumour-associated stroma, mainly CAF, within HNSCC 
induce elevated level of TGF-β in vitro and in vivo (Rosenthal et al., 2004), this study found 
high levels of MIF both in vitro and in vivo HNSCC tumours. Pilot study experiments 
described in this chapter test if stimulation with molecules found in the HNSCC 
environment are able to alter the phenotype of neutrophils in vitro.  
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6.2. Aims 
The aim of the work described in this chapter was to determine the phenotype of freshly 
isolated neutrophils upon stimulation with recombinant human MIF and HNSCC-derived 
factors and compare these phenotypes to those driven by INFγ (N1) or TGF-β (N2) 
phenotype. This entailed investigating changes in cell surface marker expression in 
response to each stimulus by flow cytometry. 
6.3. Methods 
6.3.1. Neutrophil isolation using MACSexpress 
Although the standard ficoll density gradient isolation method is a reliable and cost effective 
way to isolate neutrophils from blood, it is lengthy and prone to cause unwanted cell 
activation.  Thus, a different technique involving the use of antibody-coated micro-beads to 
deplete non-target cells from anti-coagulated whole blood within 30 minutes, yielding 
unstimulated neutrophils of high purity was used in the studies described here (the detailed 
method is described in section 2.2.2.2).   
 
 
 
 
6.3.2. Neutrophil polarization  
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To examine the neutrophil phenotype (N1 or N2 selected marker, Fig. 6.1), freshly isolated 
peripheral blood neutrophils from healthy donors were exposed to 100 ng/ml recombinant 
INF-γ to polarize neutrophils to an N1 phenotype, 25 ng/ml recombinant TGFβ to polarize 
neutrophils to an N2 phenotype, 100 ng/ml recombinant MIF or to conditioned medium from 
FaDu MCTS for 8 and 24 hours (see section 2.2.2.3).  
6.3.3. Multicolour flow cytometry  
At the end of incubation period neutrophils were washed with cold FACS buffer and stained 
according to the protocol in section 2.2.9.7. In summary, a cocktail of antibodies were 
selected according to antibody fluorochrome availability, receptor expression levels and 
classified into three groups for staining purposes; 1. CXCRs (CXCR1-FITC, CXCR2-PE, CXCR4-
PE-Cyanine-7), 2. adhesion molecules (CD62-L-FITC, ICAM-1-PE), 3. CCRs (CCR5-PE) and Fcγ 
receptor (CD64-FITC).  In addition, the neutrophil marker CD66b-APC and a LIVE/DEAD™ cell 
dye was used in each group so that viable CD66b-positive neutrophils could be gated for cell 
Figure 6.1 Schematic diagram for polarization of TAN in response to INF (N1 phenotype) or 
TGF-β (N2 phenotype) in mice and humans and characteristic alterations associated with 
both neutrophils phenotype.  
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surface expression analysis.  Compensation beads were run for each of the antibodies used 
to eliminate spill-over as a result of the use of multiple fluorochromes in this experiment and 
BD FACSDiva software was used for analysis (section 2.2.9.8). 
Neutrophils were gated based on expression of CD66b after excluding cell doublets and non-
viable cells. Expression of the selected N1 and N2 markers on the neutrophil population was 
examined after adjusting the gating using a fluorescence-minus one (FMO) control. 
Expression of cell surface markers on all tested neutrophils was measured using median 
fluorescence values and stimulations were performed and analysed on neutrophils obtained 
from each donor. Unfortunately, due to time constraints, the data presented here is not 
complete. Although experiments have been performed from neutrophils obtained from 3 
individuals, some of the analysis has only been performed for 2 individuals (further analysis 
is on going) whereas other experiments show data from 3 individuals (details are provided in 
the figure legends). In the following sections average median fluorescence values are in 
parentheses.  
6.4.  Results 
6.4.1. Neutrophil activation marker  
Un-treated peripheral blood neutrophils analysed directly after removal from the circulation 
(also called resting naïve cells) showed high expression of CXCR1 (3784), CXCR2 (2159) and 
CD62-L (474), low expression of ICAM-1 (266), CXCR4 (138), CCR5 (200) and CD64 (337) (Fig. 
6.2). In contrast, isolated neutrophils cultured at 37οC for 8 hours without stimulus (media 
only) displayed a reduced expression of CXCR1 (2062) CXCR2 (100) than freshly isolated 
neutrophils. There were no statistically significant differences in expression of CD62-L (250), 
CXCR4 (384), ICAM-1 (267), CCR5 (206) and CD64 (267) in freshly isolated compared to 8-hour 
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cultured neutrophils (Fig. 6.2-A). These cultured neutrophils showed a similar expression 
pattern to that described previously (Fortunati et al., 2009). Also, in order to characterise the 
change in expression of phenotype, the percentage of CD66b+neutrophils for each of selected 
marker was analysed and compered to naïve neutrophils (Fig. 6.2-B).   The results showed 
that 100% of naïve neutrophils expressed CXCR1, 96.4% expressed CXCR2, whilst little CXCR4 
expression was detected in naive neutrophils 0.76%. This result did not change after culturing 
neutrophils for 8 hours for CXCR1 and CXCR2 (99.6% & 82.1%, respectively) but a slight 
increase in number of CD66b+ expressing CXCR4 was observed (13.3%). However, less than 
half of the naïve neutrophil population expressed ICAM-1 (48.1%) and this was reduced after 
8 hours (5.4%). Similar to CD64, which was reduced form 24% in naïve neutrophils to 14.8% 
after an 8-hour incubation. While no difference in the number of CD66b+ for CD62L was 
detected in naïve or cultured neutrophils (27.4% and 24%, respectively) (fig 6.2-B)      
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Figure 6.2 Neutrophil phenotype after 8 hours in culture. (A)Expression of CXCR (CXCR1, 
CXCR2 and CXCR4) adhesion molecules (ICAM-1, CD62-L) CCR5 and Fc γ receptor 1 (CD64) 
between freshly isolated neutrophils and neutrophils cultured in serum-free media for 8 
hours then analysis by flow cytometry. Data are mean of MFI ± SD from 2 individuals. (B) 
Percentage of CD66b+ neutrophils positive for each of selected marker.    
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6.4.2. Phenotypic changes in polarized neutrophils  
Isolated neutrophils were incubated for 8 and 24 h with recombinant MIF and HNSCC 
conditioned medium collected from FaDu MCTS and compared to neutrophils treated with 
INF-γ to stimulate an N1-like phenotype, TGF-β to stimulate an N2-like phenotype or to those 
cultured in medium alone. As a result of the small sample size and variability between donors, 
no statistically significance difference could be detected between the tested groups. However, 
several observations were noted in the pilot study data that will be discussed in the following 
section. First observation notice was that gating with the neutrophil specific marker CD66b 
gave a single cell population for both treated and un-treated control cells when cells were 
incubated for 8 hours. However, at 24 h neutrophils were split into 2 populations, one 
expressing high levels of CD66b and one expressing low levels and this was observed for 
neutrophils in all conditions tested (Fig. 6.3).  
Figure 6.3 Flow cytometry analysis showing gating of neutrophils based on CD66 b in 
unstained cells (A), untreated cells (B), 8 hours TGF-β treated (C) and 24 hours TGF-β treated 
(D). Note the 2 populations of CD66b stained cells after 24 h.     
 
  ( A )   ( B )   ( C )   ( D ) 
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Alternatively, the modulation of surface marker expression in CD66b+ neutrophils after 8 
hours stimulation was expressed as % of cells positive for each marker (figure 6.4). No change 
in % of cells positive for CXCR1 was detected in any of treated groups after 8 hours. A slight 
reduction in % of CXCR2 was detected after INF-γ treatment (62.5%) followed by TGF-β (69%) 
and MIF (74.3%), while MCTS-CM showed same level of CXCR2 (81.8%) as control (82.1%). 
Massive increase in % of CD66b+ positive for CXCR4+ appeared after co-cultured with 
conditioned medium from FaDu MCTS (72.3% in compare to 13.3% media), while the use of 
single agent like TGF-β or MIF induce a slight increase (37.2% & 27.6%, respectively). Simalrly 
for percentage of CD6b+ positive for CD62L was increased upon MCTS-CM incubation (media 
24%) to 54.8% of cells and reduce upon TGF-β treatment (9.86%). However, ICAM-1 was 
detected only in 5.4% of CD66b+ neutrophils but INF-γ treatment increase the population of 
ICAM-1 up to 48.7% and up to 36.6% after MCTS-CM, while only slight increase in %ICAM-1 
was detected upon TGF-β or MIF (10%). As expected, treatment with INF-γ induce the 
percentage of CD64 positive cells from 14.8% to 38.7%, followed by MCTS-CM treatment 
(27.1%), while treatment with MIF (18.3%) and TGF-β (20.5%) show less predominant affect. 
Finally, although CCR5 have been suggested as a N2-TAN marker (Eruslanov et al., 2014), but 
only few cells was positive for CCR5 (2.53%) which only slightly up-regulte upon  TGF-β (4.2%) .     
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Generally, the expression of both CXCR1 (2185) and CXCR2 (1001) in the media control group 
was almost the same as in all the treated groups (MFI for CXCR1 2055, 2030, 2146, 1931, MFI 
for CXCR2 895.5, 1004, 861.5, 861.5 For TGF-β, INF-γ, MIF and conditioned medium (CM), 
respectively; Fig. 6.5 and fig 6.6). Treatment of neutrophils with INF-γ increased the 
expression of ICAM-1 (409) and CD64 (279) compared to untreated cells (ICAM-1 (274) and 
CD64 (267) respectively), whereas none of the treatments affected the expression of CD62L 
(Fig. 6.4). On the other hand, when incubated with the N2 stimulant TGF-β, neutrophils 
presented with increased expression of CXCR4 (703.5) compared to untreated control cells 
(384). Cells incubated with recombinant MIF displayed slightly increased expression of CXCR4 
(541), whereas conditioned medium from FaDu MCTS markedly increased the expression of 
neutrophil cell surface CXCR4 (1486). In addition, treatment with TGF-β also moderately 
increased the expression of CCR5 (248) compared to control (206) as did culture with INF-γ, 
recombinant MIF and conditioned medium (242, 252, 242, respectively). 
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Figure 6.4 Bar chart represent percentage of cells positive for selected marker in response 
to different stimuli after 8 hours  
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Figure 6.5 Modulation of neutrophil cell 
surface receptor expression in response to 
different stimuli.  A whisker plot showing 
median expression with interquartile range of 
CXCR receptor (CXCR1, CXCR2 and CXCR4) 
adhesion molecules (ICAM-1, CD62-L) CCR5 and 
Fcγ receptor 1 (CD64) in untreated cells (media) 
neutrophils cultured in TGF-β, INF-γ, MIF and 
CM for period of 8 hours then analysis by flow 
cytometry. Data for 2 or 3 individuals is shown. 
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Figure 6.6 Representative histogram overlay plot of neutrophil cell surface receptor 
expression in unstimulated neutrophils (naïve) or in response to different stimuli 
after 8 hours.  
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6.4.3. Neutrophil phenotype after 24 hours incubation  
 
Neutrophils incubated with same treatment regime were also analysed by flow cytometry 
after 24 hours. Unexpectedly, two populations were observed based on CD66b+ expression 
after 24 hours incubation on both control and treated neutrophils (Fig. 6.7-A). CD66b is an 
activation antigen that is specifically expressed on the cell surface of neutrophils and is also 
stored on the membrane of neutrophilic secondary granules that are released to the cell 
surface upon stimulation (Ducker and Skubitz, 1992). The number of CD66b+High and 
CD66b+low in each of the groups was analysed by gating each population. Untreated control 
neutrophils consisted of 65% CD66b+low and 32% CD66b+High (with 13% falling outside the 
gates). These levels were similar to neutrophils incubated with INF-γ (N1 phenotype) with 70% 
CD66b+low and 26% CD66b+High and neutrophils incubated with recombinant MIF (68% 
CD66b+low and 27% CD66b+High). In contrast, TGF-β stimulated (N2 phenotype) showed a 
decreased amount of CD66b+low neutrophils (40%) but increased numbers of CD66b+High 
neutrophils (59%). Similarly, neutrophils co-cultured in FaDu MCTS conditioned medium 
exhibited a similar pattern with 40% CD66b+low and 60% CD66b+High neutrophils (Fig. 6.7-B). 
Statistical analysis using one-way ANOVA highlights the major modulation of CD66b+ 
expression after 24 hours treatments. For example, TGF-β stimulated neutrophils significantly 
reduce the population of CD66b+low (P= 0.0180) and induce the population of   CD66b+High (P= 
0.0131). Treatment with FaDu MCTS conditioned medium also induce same pattern to TGF-β 
with significant diminish in expression of CD66b+low neutrophils population (P=0.0215) and 
significant increase expression of CD66b+High (P= 0.0214) in compare to untreated neutrophils 
control after 24hour ex vivo culture condition (Fig 6.8).    
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( A ) 
Figure 6.7 Response of neutrophils surface receptor after 24 h incubation.  (A) Flow 
cytometry contour plot showing two population of cells based on CD66b+ expression. (B) bar 
chart summarising the modulation in expression of CD66b+ cells in untreated cells (media) 
neutrophils cultured in TGF-β, INF-γ, MIF and CM for a period of 24 hours. Data are 
represented from 3 individuals as Mean ± SEM.  
( B ) 
M
e
d
ia
r
h
 T
G
F
- 
M
C
T
S
-C
M
r
h
 I
N
F
- 
r
h
 M
IF
0
2 0
4 0
6 0
8 0
1 0 0
%
 o
f 
C
D
6
6
b
+
C D 6 6 +
lo w
C D 6 6 +
H ig h
209 
 
 
C D 6 6 b +  
L o w   
C D 6 6 b +  
H ig h
 
0
2 0
4 0
6 0
8 0
1 0 0
%
 o
f 
C
D
6
6
b
+
M e d ia
rh  T G F -b
M C T S -C M
rh  IN F - g
rh  M IF
* *
* *
Figure 6.8 Statistical analysis comparing the change in CD66b+ expression in compared to 
untreated cell (media). One-way ANOVA was used to compute the modulation of CD66b+ 
expression after 24hours neutrophils cultured in TGF-β, INF-γ, MIF and CM for a period of 24 
hours. Data are represented from 3 individuals as Mean ± SEM. *P<0.05 
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Unfortunately, due to time constraints, a detailed analysis for each of the surface expression 
markers was only carried out on one donor sample.  The main observation was noticed by 
analysing the % of CXC4 positive cells is that after 24hours all neutrophils are CXCX4+ (83.8%) 
in compare to 13% of CD66b+ after 8 hours’ incubation, which could indicate that neutrophils 
are coming to the end of their life-span. In compare to media (83.8%), MCTS-CM (99.7%), TGF-
β (97.2%) followed by MIF (95.5%) are the factor induce expression of CXCR4% mainly.  While 
CXCR1+ CD66b+ induce from 6.73% in un-treated neutrophils up to 48.9% in response to TGF-
β, 43.8% in response to MIF, 31.4% in response to INF-γ and 16.2%  in response to MCTS-CM. 
While TGF-β increase CXCR2 + population (73.8%), MCTS-CM (54%) and INF-γ (36.9%) reduce 
the number of CD66b+ CXCR2 in compare to control (67.5%).  The CD66b+ cells that express 
adhesion molecules were low, where only CD62L detected in 1.21% of cells, ICAM-1 positive 
cells were increase mainly upon MCTS-CM stimulation (Fig 6.9).  As two population of CD66b+ 
was detected as showed in figure 6.7-A and from histogram plot in figure 6.10 the analysis of 
each of the selected receptor was carried out separately.  
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Figure 6.9 Bar chart represent percentage of cells positive for selected marker in response 
to different stimuli after 24 hours  
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Figure 6.10 Representative histogram overlay plot of neutrophil cell surface 
receptor expression in in response to different stimuli after 24 hours.  
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In general, neutrophils that were CD66bhi displayed increased expression of all the markers 
tested than CD66blow neutrophils irrespective of whether they were stimulated or not. Of 
note, TGF-β treatment induced increased expression of CXCR4 (7114) on CD66b+High and 
CD66b+low (5127) neutrophils when compared to control (media) cells (CD66b+High (4270) 
and CD66b+low (3597) respectively). Again, this increased CXCR4 and ICAM-1 expression was 
observed in neutrophils treated with conditioned medium from FaDu MCTS. The conditioned 
medium cells also showed decreased expression of CXCR1 and CXCR2 compared to controls. 
In contrast, treatment with INF-γ reduced the expression of CXCR4. Recombinant MIF did not 
alter the expression pattern of CXCR4 (CD66b+High (4965) and CD66b+low (4017) and levels 
of CCR5, CD64, CD62L were unchanged in all samples at this time point (fig.6.11).   
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Figure 6.11 Characterisation of neutrophils by flow cytometry after 24 hours. A bar chart 
comparing the expression of CXCR (CXCR1, CXCR2 and CXCR4), adhesion molecules (ICAM-1, 
CD62-L) CCR5 and Fc γ receptor 1 (CD64) in CD66b+High and CD66b+low in untreated cells (media) 
neutrophils cultured in TGF-β, INF-γ, MIF and conditioned medium (CM) for 24 hours. Data 
represented MFI of one donor. 
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6.5. Discussion  
There are currently only a few studies that have examined human neutrophil polarisation, 
often because of the difficulty in isolating unstimulated neutrophils from blood as well as from 
tumour tissue and the lack of well-characterised polarisation markers. Moreover, neutrophils 
are short-lived cells that do not survive well once isolated from the circulation or tissues. 
Indeed, cell surface expression of CXCR1, CXCR2 and CD62L decreased dramatically whereas 
CXCR4 increased upon 8-hour in vitro culture with medium alone compared to expression on 
freshly isolated neutrophils from the same donor. A previous study by Fortunati et al showed 
that cultured neutrophils acquired a phenotype characterized by decreased expression of 
CXCR1, CXCR2, CD62-L and up-regulation of ICAM-1 in time-dependent manner (Fortunati et 
al., 2009). The alteration in expression of CXCR4 is likely to be a natural response to cell 
survival signals as neutrophils in the circulation programmed for cell destruction in the bone 
marrow or spleen increase expression of CXCR4 and decrease expression of CXCR1 and CXCR2 
in order to migrate back to these tissues when their life-span is coming to an end (Martin et 
al., 2003). Therefore, it is likely that decreased CXCR1/2 and CD62L and increased CXCR4 
observed in culture are stress response signals signifying the desire for neutrophil termination.  
Neutrophils cultured for 8 hours in the presence or absence of stimulants were analysed by 
flow cytometry for differences in N1, N2 polarisation markers. According to the few studies 
examining neutrophil phenotypes, N1 neutrophils should display decreased CXCR1/2 and 
CD62L expression, and increased ICAM-1 expression (Andzinski et al., 2016). Using the N1 
stimulant INF-γ, overall we observed no change in CXCR1/2 or CD62-L expression but an 
increase in ICAM-1 expression compared to unstimulated neutrophils, so only one of the 
markers tested confirmed with previous data. Stimulation with MIF did not increase any of 
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the proposed N1 markers, however, incubation with FaDu MCTS conditioned medium did 
increase ICAM-1, suggesting at least some polarisation to an N1 phenotype if expression of 
these markers are believed to represent an N1 phenotype. Previously, Eruslanov et al (2014) 
characterized human TAN isolated from early stage lung cancer as CD66b+CD11b+CD15hi, here 
TAN were characterized by ICAM-1hi (in the previous study shown to be an N1 marker), CD62-
Llow, CXCR4hi, CCR5hi, CCR7hi, CXCR3hi (Eruslanov et al., 2014). At the mRNA level, high 
expression of CXCR4 as well as other cytokines (VEGF, arginase, CCL2, CCL5, MMP-9, C-MYC 
and STAT-3) has been detected in N2 TAN from murine tumours (Jablonska et al., 2010). 
Overall we found that after 8 hours human neutrophils stimulated with the N2 polarisation 
factor TGFβ a cytokine found to be over-expressed in HNSCC patients, (Rosenthal et al, 2004), 
displayed increased expression of CXCR4, with no change in the other markers analysed (CCR5, 
CCR7 and CXCR3 were not analysed in this study). Therefore, increases in some but not all 
suggested N2 markers were the same as observed in previous studies and it could be that 
increased expression in of CXCR4, are the most reliable markers for the human N2 phenotype. 
If this is the case then it could be argued that MIF and conditioned medium for FaDu MCTS in 
particular, skew neutrophils towards an N2 pro-tumour phenotype.   
After 24 hours it was noted that there were 2 populations of CD66b+ in both control and 
treated neutrophils whereas at 8 hours neutrophils showed as only a single population. 
Expression of cell surface CD66b has been shown to increase on activated, degranulating 
neutrophils (Ducker and Skubitz, 1992), suggesting that over time in culture some neutrophils 
become activated increasing their cell surface expression of CD66b. Interestingly, the ratio of 
high/low expressing neutrophils was similar for medium control, INFΥ and MIF-treatment 
with more CD66blow than CD66bhi cells. In contrast, treatment with the N2 cytokine TGFβ and 
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FaDu conditioned medium displayed elevated numbers of CD66bhi compared to CD66blow 
neutrophils. This suggests that TGFβ and FaDu conditioned medium may be able to further 
stimulate neutrophil degranulation and therefore their activation status increasing 
expression of CD66b. Expression of polarisation markers on both CD66blow and CD66bhi 
neutrophils was conducted for only one of the donor samples due to time constraints and so 
interpretation of this data must be taken lightly. The data showed that in nearly all cases 
CD66bhi neutrophils expressed more sell surface markers than CD66blow neutrophils and this 
may be linked with differences in their activation status. On the whole data at 24 hours 
matched those at 8 hours with TGFβ and conditioned medium from FaDu displaying increased 
expression of CXCR4 (and ICAM-1 for conditioned medium) suggesting polarisation to an N2 
phenotype. Treatment with MIF did not alter any polarisation markers at this time point.  
The use of specific cell surface markers to characterise neutrophil polarisation into N1 or N2 
phenotypes is controversial and at best can be described as in an early stage of development. 
Because only a few studies have been performed in this area there is currently no consensus 
as to which markers are N1 and which are N2. However, if the current paradigm is to be 
believed, the pilot data generated in this chapter tentatively suggest that the tumour 
microenvironment from HNSCC may polarise neutrophils to an N2 phenotype although this 
seems to be independent of MIF and may be due to TGFβ amongst other cytokines. Clearly, 
further experiments are required on more individuals to overcome individual-to-individual 
variability in cell surface expression of these markers and to gain a consensus of neutrophil 
polarisation. In addition, analysing the phenotype of neutrophils within HNSCC or even within 
specific areas of these tumours (necrotic, invasive front) and comparing these to the 
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neutrophil phenotype in non-diseased tissue would further clarify phenotypic markers and if 
these have any meaning in tumour progression or for diagnostic purposes.  
Unfortunately, this study was not able to investigate functional changes in neutrophil activity 
or cytokine secretion upon polarised as suggested in the literature (Fridlender et al., 2009 and 
Jablonska et al., 2010). Clearly, this is an emerging field and further extensive and detailed 
analysis of the change (or not) in polarised human TAN and their roles in tumour progression 
are required.  
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Chapter 7: General Discussion 
Several studies have linked the number of TAN in various types of cancer, including HNSCC, 
with poor patient prognosis, suggesting that the presence of neutrophils within tumours has 
an impact on tumour progression and outcome. However, only a few of these studies have 
evaluated TAN localization within cancer tissue. In chapter 3, the spatial distribution of TAN 
within HNSCC tissue of a small cohort of patients showed that TAN mainly accumulate in 
necrotic and stromal areas. The tumour stroma is the area that probably has the most cell 
diversity within the tumour microenvironment. It is composed of fibrous connective tissue 
and various types of non-cancerous cells that secrete factors, which continuously interact 
with the tumour cells. This process is often termed desmoplastic reaction (DR), which is 
characterized by a connective tissue densely packed with fibroblasts, inflammatory and 
endothelial cells. DR has been reported in HNSCC (Janot et al., 1996), but the contribution of 
neutrophils in the tumour stroma is poorly understood.  Most studies have focused on the 
communication between CAFs, the most predominant component of the stroma, and the 
adjacent tumour cells to provide evidence that this cell-cell interaction modulates tumour 
growth and facilitates HNSCC invasion (Rosenthal et al, 2004, Kawahiri et al 2009).  However, 
this study observed many neutrophils in the tumour stroma of HNSCC patient biopsies; an 
observation reported in hepatocellular carcinoma (HCC) (Kuang et al., 2011). In HCC the CD15+ 
neutrophils found in tumour stroma was associated with increased MMP-9 expression, a 
known regulator of the angiogenic switch.  An in vivo study has showed that co-culture of Gr-
1+CD11b+ neutrophils isolated from tumour-bearing mice promoted the activation of CAF and 
displayed enhanced survival and increased expression of cytokines, indicating the importance 
of cell communication between many cell types, including neutrophils within in the tumour 
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stroma. Furthermore, these interactions highlight the possibility of targeting tumour growth 
by disturbing the tumour stroma, indeed, treatment with the immunomodulatory drug 
dexamethasone reduced DR and attenuated tumour growth in a murine tumour model (Stairs 
et al., 2011). Collectively, these data support the notion that the presence of neutrophils in 
the tumour stroma is important in tumour progression and so further in vivo studies ideally 
using orthotropic HNSCC tumours along with Ly6G-depleted neutrophils and knock-out mice 
deficient in fibroblast-derived factors are required to substantiate these observations.  
TAN were found to accumulate in necrotic areas of HNSCC tumours. Necrotic tissue develops 
as a result of chronic stress due to the lack of oxygen within tissue. The presence of necrosis 
has been observed in HNSCC and patients with low levels of tumour necrosis were found to 
have a better prognosis and responded better to chemotherapy than patients with large areas 
of necrosis who tended to develop chemoresistant tumours (Kuhnt et al., 2005). Data in this 
thesis found that neutrophils were recruited in large numbers to areas of tumour necrosis. 
Although the mechanism of neutrophil recruitment to necrotic areas is largely unknown it is 
likely due to increased expression of hypoxia-regulated chemoattractants or factors released 
from necrotic tissue. This was substantiated to a degree by the finding that FaDu hypoxic 
conditioned medium was more chemotactic than that produced from cells cultured under 
normoxic conditions, and that MIF gene expression was up-regulated by hypoxia.  Zhu et al 
also observed accumulation of Gr-1+CD11b+ neutrophils around the necrotic zone in a 
xenograft HNSCC tumour model, and confirmed the increased migration of Gr-1+CD11b+ to 
hypoxic derived conditioned medium in vitro. Similar to our MCTS cytokine array analysis, the 
authors detected MIF, IL-6, sICAM-1, and PAI-1 release from HNSCC from under normoxic 
conditions with increased expression under hypoxia (Zhu et al., 2014). Knock-down of HIF-1α 
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and HIF-2α, the main regulatory mechanism for hypoxia in HNSSC cells, reduced the level of 
MIF but, in contrast to the data presented here, did not affect Gr-1+CD11b+ migration 
towards hypoxic condition medium in vitro, suggesting that other factors were responsible 
for the recruitment of neutrophils (Zhu et al., 2014). Other factors may also aid recruitment 
of neutrophils to necrotic areas such as HMGB1, a protein released by necrotic tissue (Scaffidi 
et al., 2002). HMGB1 specifically triggers neutrophil but not macrophage migration to necrotic 
tissue and this is independent of CXCR4 (Scaffidi et al., 2002).  Whereas migration of 
neutrophils lacking RAGE (receptor for advanced glycation end-products), the HMGB1 
receptor, was reduced  by 80% toward liver necrotic lysate compared to control neutrophils 
(Huebener et al., 2015). Further investigation using laser capture microdissection to isolate 
neutrophils from stroma and necrotic tissue of HNSCC patient tissue will help understand the 
molecular mechanism of recruitment and the cross-talk between TAN and cancer cells. It is 
likely that neutrophils accumulating in large numbers in HNSCC biopsies in this study do so by 
a combination of hypoxia regulated chemoattractants such as MIF and CXCL12 and the actions 
of HMGB1 within the necrotic debris. This study is limited by the number of patient samples 
analysed and inability to link neutrophil numbers and MIF expression in various areas of the 
tumour to patient outcome. Access to further patient samples and clinical data would have 
allowed a more in-depth statistical analysis and further investigation in this area is required.   
In chapter 4, MCTS generated from HNSCC carcinoma cells were utilized to investigate the 
complex phenomena of neutrophil recruitment and factors responsible for this process. The 
use of an in vitro 3D model to study the immune cell-tumour cell interaction provides an 
excellent alternative to conventional monolayer culture and experimental murine models 
where species differences occur. For example, neutrophils account for 50-70% of peripheral 
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blood leukocytes in humans, while they only make up 15-20% of peripheral blood leukocytes 
in mice (Haley, 2003). The key observation was that MCTS secrete multiple neutrophil 
chemoattractant factors, such as MIF, CXCL1 and CXCL8. MIF overexpression was detected in 
HNSCC patient biopsies and FaDu cells and has been reported previously by others (Kindt et 
al., 2013b, CLUDTS et al., 2010, Dumitru et al., 2011). Pre-incubation of neutrophils with a 
pharmacological inhibitor of CXCR4 and CXCR2 significantly inhibited neutrophil recruitment 
suggesting that ligands binding to these receptors (MIF, CXCL1, CXCL8, CXCL12) are important 
in this process. FaDu MCTS express little CXCL12 (array data) suggesting that factor is not 
crucial for neutrophil recruitment. Moreover, the MIF specific inhibitor ISO-1 caused a 
dramatic inhibition of neutrophil infiltration that was greater than blocking CXCR2 or CXCR4.  
This observation and the fact that neutrophils do not express the MIF receptor CD74 (Dumitru 
et al., 2011) strongly suggest that MIF is the main neutrophil chemoattractant and this is via 
a CXCR2/CXCR4 axis. Similar findings were observed when MIF expression was prevented in 
knock down studies using HNSCC cell lines Cal-27 and Tca8113.  When MIF expression was 
blocked, Gr-1+CD11b+ neutrophil recruitment was reduced from 10% to 4% (61% reduction) 
in a nude mouse xenograft model (Zhu et al., 2014). Using ISO-1 the data presented in this 
thesis showed reduced Ly6G neutrophil infiltration up to 80% in vivo and 87% in vitro MCTS 
FaDu model.  The difference between these studies could be due to the different HNSCC cell 
types employed. The involvement of CXCR4 in neutrophil chemotaxis has not reported before 
but migration of B lymphocyte towards MIF or CXCL12 was reduced significantly upon 
treatment of B cells with AMD3100 (Klasen et al., 2014). Interestingly, in vitro and in vivo data 
in this study showed that THP-1 monocyte recruitment to HNSCC might also by MIF-
dependent, or at least partially. Previous studies examining other tumour-derived factors 
have pointed to CCL2 and/or CXCL12 amongst other molecules as the main ligands that recruit 
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monocytes to tumours (Kitamura et al., 2015, Murdoch et al., 2004). This is the first report 
citing MIF as an important tumour-derived factor to recruit monocytes to HNSCC tumours. 
However, these data must be taken with caution as the THP-1 monocytic cell line was used in 
this study and there are several reports that THP-1 cells are not good models of peripheral 
blood monocytes (Heil et al., 2002) and so these data need to be repeated using human 
peripheral blood monocytes. Clearly, further investigations are required to confirm these 
findings but it does raise the possibility that MIF inhibition may reduce recruitment of both 
TAN and TAM.  
This hypothesis was further investigated in chapter 5 where depletion of neutrophils using 
anti-Ly6G caused a decrease in tumour volume compared to PBS controls. Similarly, Ly6G 
depletion of neutrophils caused a reduction in tumour growth in melanoma and 
fibroosarcoma in vivo tumour models (Jablonska et al., 2010) supporting the tumour-
facilitating role of TAN. Administration of ISO-1 in CD-1 mice bearing subcutaneous FaDu 
tumours caused a significant reduction in the number of TAN and TAM but increased the size 
of tumour. This result was unexpected as a reduction in tumour size upon ISO-1 treatment 
was previously reported in a murine model of colon and prostate cancer (He et al, 2009, 
Meyer-Siegler 2006). Histological examination showed large areas of necrosis in ISO-1 treated 
tumours when compared to PBS-treated controls and unexpectedly this observation was 
associated with a reduction in the number of proliferative (BrdU+) cells in ISO-1-treated 
compared to control tumours. These results were opposite to those found with neutrophil 
depletion using Ly6G and points to the involvement of MIF in other tumour processes as well 
as leukocyte recruitment. For example, the reduction of tumour cell proliferation could be a 
direct effect of blocking the actions of MIF on tumour cells and not as a result of neutrophil 
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depletion. Several in vitro studies have shown that MIF inhibition using ISO-1 in lung (A549) 
(Rendon et al., 2007) prostate (DU145) (Meyer-Siegler et al., 2006) and glioblastoma (LN229) 
(Schrader et al., 2009) affected the migration, proliferation and invasiveness of these cancer 
cells. Accordingly, blocking exogenous MIF may diminish the proliferation ability of HNSCC 
tumour cells. This is supported by evidence showing that blocking endogenous MIF using 
shRNA in HNSCC cells resulted in a significant inhibition of tumour cell proliferation and 
motility, suggesting that endogenous MIF acts in an autocrine feedback mechanism to 
promote cell division and migration (Kindt et al., 2013b). Therefore, it is possible that MIF acts 
to accelerate tumour growth in an autocrine fashion in early tumours leading to increased 
tumour growth, and increased hypoxia and necrosis but then tumour cell proliferation is 
inhibited by ISO-1 treatment leading to low tumour cell proliferation rates observed in later 
in vivo tumours. In other words, the effect of inhibiting MIF in other aspects of tumour biology 
in addition to the recruitment of leukocytes may significantly impact on tumour growth.  
Further investigations are required specifically looking at the early stage tumours to examine 
the precise role of MIF during HNSCC tumour progression. These studies could include the 
use of MIF knockout mice or MIF knock-out HNSCC cell lines, preferably implanted 
orthotopically as these will be more representative of tumours in humans.   
Although differences in vascularisation (CD31) were not found in this study between 
neutrophil-depleted and control tumours, there is much evidence to suggest that neutrophils 
can express pro-angiogenic factors and therefore have a significant impact tumour 
angiogenesis (Tazzyman et al, 2013). For example, CXCR4hi neutrophils are rapidly recruited 
to pancreatic islets that have been grafted into striated muscles. These CXCR4hi neutrophils 
produced 10 times more MMP-9 than neutrophils recruited to inflammatory stimuli with this 
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factor mediating islet revascularization (Christoffersson et al., 2012). A further investigation 
by same group using a different mouse model showed that hypoxia-induced secretion of 
VEGF-A identified distinct cell surface receptor expression on circulating pro-angiogenic 
neutrophils, such as VEGF receptor1 (VEGFR1), CXCR4 and integrin a4 subunit (CD49d) in both 
humans and mice (Massena et al., 2015). This observation may explain the increase in CXCR4 
expression that we reported upon neutrophil stimulation with TGF-ß and conditioned 
medium from FaDu MCTS. 
In chapter 6, the effect of MIF and HNSCC-derived molecules on TAN polarization ex vivo was 
examined by flow cytometry.  Neutrophils acquired an activated phenotype, characterized by 
decreased expression of CXCR1, CXCR2, CD62L and up-regulation of ICAM-1 in time-
dependent manner. Stimulation with the N2 polarisation factor TGFβ increased expression of 
CXCR4 and to a lesser extent CCR5. Prolonged culture of neutrophils for 24 hours resulted in 
two populations of CD66b+ neutrophils in both control and treated groups whereas at 8 hours 
only one population was observed. Although only based on three (and in some instances two) 
blood samples this study provides pilot data that healthy neutrophils can change their 
phenotype based on their cell surface marker expression when stimulated. However, since 
there are very few studies to analyse and validate neutrophil polarisation markers it is difficult 
to determine what exactly constitutes a N1 or N2 phenotype.  Expression of cell surface 
CD66b has been shown to increase on activated neutrophils (Ducker and Skubitz, 1992), 
suggesting that over time in culture all neutrophils become activated. This is a very 
preliminary study and neutrophil polarisation into N1 or N2 phenotypes is controversial as 
most of the evidence for TAN polarization comes from murine studies and these markers may 
not translate to a human setting. To date, only one study has attempted to characterise TAN 
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polarisation markers in neutrophils isolated from early stage lung cancer tissue. These cells 
were described as CD66b+CD11b+CD15hi and characterized by ICAM-1hi, CD62Llow, CXCR4hi, 
CCR5hi, CCR7hi, CXCR3hi (Eruslanov et al., 2014). This study is unable to confirm that TGFβ 
induces an N2 phenotype or that INFγ treatment induces an N1 anti-tumour phenotype and 
more studies from the field need to be published to validate and confirm these markers. 
However, for the first time, this study shows that neutrophils from healthy volunteers can be 
polarised, in particular by culturing them with HNSCC tumour-derived factors where elevated 
expression of CXCR4 was evident, pointing to an N2 phenotype. This is strong evidence that 
tumour factors as a whole can modulate the gene and protein expression of neutrophils; the 
implications of these changes require further examination.  
 
Overall the data provided in this thesis show that MIF is overexpressed in HNSCC tumours and 
this factor appears to be central for the recruitment of TAN and possibly TAM into HNSCC, 
and that this occurs by activation of CXCR2 and CXCR4. There is very good evidence that 
leukocyte (TAN and TAM) recruitment into HNSCC is closely linked with poor prognosis, and 
although not identified in this study, this appears to be due to pro-angiogenic factors that 
these cells secrete within the tumour microenvironment that aids tumour progression. 
Therefore, inhibiting the actions of MIF may be a potential adjunctive therapy aimed at 
increasing the survival rates of individuals presenting with HNSCC.  
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APPENDIX I 
Table 1. Detection of neutrophils in healthy and cancer tissue. A panel of ten normal and 
seventeen  HNSCC tumour tissue sections were screened for the presence of neutrophils 
using the neutrophil-specific marker CD66b. Abbreviations: M= Male, F=Female  
Case Age Gender Site Diagnosis 
1 55 M Tongue Normal 
2 72 F Buccal mucosa Normal 
3 69 F Buccal mucosa Normal 
4 59 F Buccal mucosa Normal 
5 58 F Buccal mucosa Normal 
6 33 F Buccal mucosa Normal 
7 57 M Buccal mucosa Normal 
8 56 F Buccal mucosa Normal 
9 36 F Labial mucosa Normal 
10 16 M Tongue Normal 
11 75 M Lower lip SCC mod diff 
12 74 M Tongue SCC mod diff 
13 77 F Tongue SCC mod diff 
14 57 M Tongue SCC mod diff 
15 73 F Lip SCC mod diff 
16 67 M Lip SCC mod diff 
17 76 F Floor of mouth SCC mod diff 
18 43 M Tongue SCC mod diff 
19 54 M Tongue SCC mod diff 
20 37 F Tongue SCC mod diff 
21 85 F Tongue SCC mod diff 
22 38 M Tongue SCC mod diff 
23 67 F Tongue SCC mod diff 
24 62 F Floor of mouth SCC mod diff 
25 57 M Tongue SCC mod diff 
26 76 M Tongue SCC mod diff 
27 72 M Tongue SCC mod diff 
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Case 
 
sex Site Age Stage Other 
node 
Grade Recurrence Follow up   (months) Survival A Presence of 
Necrosis 
1 F RMT 69 T1N1mi Yes well yes 9 DoD 433±211 Yes 
2 M RMT 66 T4N2b Yes UN no 24 DF 14±3.4 No 
3 F FOM 59 T2N2b Yes UN no 72 DF 32.75±5.9 No 
4 F AT 63 T4N1 NO well no 72 DF 0.041±0.041 No 
5 F PT 83 T2N2b Yes well no 24 DF 944±184.4 Yes 
6 M AT 65 T1N1 NO Mod 2nd P 48 DUR 3116±787 Yes 
7 M FOM ? T2N2b Yes UN UN UN UN 1240±519 Yes 
8 F AT 54 T1N1mi NO UN no 24 DF 0.6±0.4 No 
9 F HP 50 T1N2c NO POOR UN UN UN 1526±8.9 Yes 
10 M AT 50 T1N1 NO Mod no 60 DF 1831±392 Yes 
11 M FOM 65 T1N2c ? UN UN UN UN 2431±140 Yes 
12 M AT 71 T1N1 NO Mod no 96 DF 1076±382 Yes 
13 F FOM 54 T1N2c NO UN UN UN UN 38.5±16.6 No 
14 F FOM 76 T2N1 NO Well no 6 DUR 692±175 Yes 
15 M FOM 60 T4N1 NO UN no 60 DF 15.9±5.2 No 
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Table 2: Patient and tumour characteristics for MPO distrubtion study . Abbreviations: M= Male, F=Female, RMT=Retromolar trigone, 
FOM=Floor of mouth, AT=anterior tongue, PT= posterior tongue, HP= Hard palate, SP=soft palate, DoD= dead of disease, DF=disease free, 
DUR=dead unrelated cause, AWD=alive with disease
16 M FOM 53 T1N1mi NO UN yes 36 AWD 8.5±3.7 No 
17 M AT 49 T1N1mi NO UN no 96 DF 374±117 Yes 
18 M PT 57 T2N1 NO UN no 72 DF 1723±398 Yes 
19 M FOM 51 T1N2b Yes UN yes 84 DF 9.7±4.3 No 
20 F RMT 73 T1N1 Yes Well Yes 12 DF 1.6±0.88 No 
21 M FOM 37 T1N2b NO UN 2nd P 96 AWD 127±49.9 No 
22 M FOM 62 T1N1 NO UN no 144 DUR 394±76.8 Yes 
23 M FOM 59 T1N2b Yes Mod yes 84 DF 97.9±25.3 No 
24 M FOM 60 T4N1mi NO UN 2nd P 48 DUR 28.25±12 No 
25 M RMT 65 T3N1 NO UN UN UN UN 614±170 Yes 
26 M FOM 67 T4N1 NO Mod no 48 DF 555±87 Yes 
27 M SP UN T3N2b Yes UN UN UN UN 994±250 Yes 
28 M RMT 55 T4N2b Yes Mod no 72 DF 3.5±1.6 No 
29 F FOM 67 T4N1 Yes UN no 12 DUR 565±17.9          Yes 
30 M FOM 58 T2N1 NO Mod no 18 DUR 160±9 Mod 
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Figure 1  A human cytokines array coordinates for localizing the positive detected in 
the array  
  
 
 
255 
 
 
Table 1:  showing the cytokine/growth factor proteins detected in the array coordinates.  
 
 
 
